Official Protocol Title:
NCT number:
Document Date:
A Multi-Center, Open Label Study to Assess 
the Safety, Steady-State Pharmacokinetics 
and Pharmacodynamics of IMG-7289 in 
Patients with Myelofibrosis
[STUDY_ID_REMOVED]
23-June-2020
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
Imago BioSciences,  Inc.  Protocol IMG -7289- CTP -102  
IMG- 7289    23Jun 2020  
Page 2 of 97  
INVESTIGATOR SIGNATURE [CONTACT_44561]:  A Multi -Center, Open Label Study to Assess the Safety, 
Steady -State Pharmacokinetics and Pharmacodynamics of 
IMG- 7289 in Patients with Myelofibrosis  
Protocol No.:  IMG -7289 -CTP -102 
Version and Date Final:  Original Protocol:  01 November 2016  
Amendment 1:       25 January 2017  
Addendum 1:          13 July 2017  
Amendment 2:     01 September 2017  
US only  - Amendment 3:     01 December 2017  
Amendment 4:     19 December  2018  
[LOCATION_013] only  - Addendum 2:  31 January 2019  
[LOCATION_006] only  - Addendum  3:  19 February 2019  
Italy only  - Addendum 4:  04 July 2019  
Amendment 5:      02 September  2019  
Amendment 6:      23 June  2020 
Sponsor:  Imago BioSciences, Inc.  
[ADDRESS_469109] the study 
in compliance with: all local legal and regulatory requirements, good clinical practice as 
described in  the International Conference on Harmonization document “Guidance for 
Industry – E6 Good Clinical Practice:  Consolidated Guidance”; and the Declaration of 
Helsinki.  
 
_________________________________________________________________                               ____________________  
Investigator Signature                                                                                               [CONTACT_1782] 
 
________________ _________________________________________________                               ____________________ 
Investigator Name (Print)                                                                                                
[COMPANY_003]
[COMPANY_003]
Imago BioSciences,  Inc.  Protocol IMG -7289- CTP -[ADDRESS_469110] of Abbreviations  ............................................................................................................................... 8 
2 PROTOCOL SYNOPSIS  ...............................................................................................................................13  
3 INTRODUCTION  ............................................................................................................................................23  
3.1 Background on the Disease to be Treated  .......................................................................................23  
3.2 Background on the Drug Target  .........................................................................................................25  
3.3 Background on LSD1 in Myeloid Neoplasia and Myelofibrosis  .............................................26  
3.4 Background on IMG-7289  ...................................................................................................................27  
3.5 Potential Clinical Risks and Benefits when Treating with an LSD1 Inhibitor  ....................28  
3.6 IMG -7289 Dose Justification ..............................................................................................................30  
3.6.1  Rationale for and Safety of the Proposed IMG -7289 Starting Dose  .............................30  
3.6.2  Rationale for the IMG -7289 Dosing Schedule .....................................................................32  
4 HYPOTHESIS AND OBJECTIVES  .........................................................................................................32  
4.1 Hypothesis  .................................................................................................................................................32  
4.2 Objectives  ..................................................................................................................................................32  
[IP_ADDRESS]  Primary  ...................................................................................................................................  33 
[IP_ADDRESS]  Exploratoryɸ ......................................................................................................................... 33 
5 INVESTIGATIONAL PLAN .......................................................................................................................33 
5.1 Overview  ...................................................................................................................................................33  
5.1.1  Initial Treatment Period (ITP)  ...................................................................................................35  
5.1.2  Additional Treatment Period (ATP) for Qualifying Patients Only  ................................36  
6 STUDY POPULATION  ................................................................................................................................. 36 
6.1 Study Entry Criteria  ...............................................................................................................................36  
6.1.1  Inclusion Criteria  ...........................................................................................................................37  
6.1.2  Exclusion Criteria  ..........................................................................................................................38  
6.2 Patient Enrollment  .......... ........................................................................................................................39 
6.3 Patient Withdrawal  ................................................................................................................................. 39 
6.4 Replacement of Dropouts  .....................................................................................................................40  
6.5 Guidelines  ..................................................................................................................................................40 
6.6 Prohibited Medications  .........................................................................................................................40  
6.7 Patients Who Terminate Early or Discontinue Study Medication ...........................................40  
6.8 Treatment Failure  ....................................................................................................................................41  
7 STUDY TREATMENT  ..................................................................................................................................41  
7.1 Formulation, Labeling, Packaging and Storage  ............................................................................41  
7.1.1  Formulation  .....................................................................................................................................41  
7.1.2  Packaging and Labeling  ..............................................................................................................41 
Imago BioSciences,  Inc.  Protocol IMG -7289- CTP -102  
IMG- 7289    23Jun 2020  
Page 4 of 97 7.1.3  Storage  ..............................................................................................................................................41  
7.2 Dispensing, Administration, Dosage and Missed Doses  ............................................................42  
7.2.1  Dispensing  .......................................................................................................................................42  
7.2.2  Administration  ................................................................................................................................42 
7.2.3  Dosage:  Initial Treatment Period  ............................................................................................42 
[IP_ADDRESS]  Dosing of Amendment 5 Patients  .................................................................................. 43 
[IP_ADDRESS]  Dosing of Amendment 6 Patients  .................................................................................. 44 
[IP_ADDRESS]  Provisional Dose(s); Unacceptable Dose Limiting Toxicity is Demonstrated at 
the D s 45 
7.2.4  Dosage:  Additional Treatment Period  ...................................................................................46  
7.2.5  Missed Doses  ..................................................................................................................................46  
7.2.6  Interruption of Dosing  .................................................................................................................46  
8 DATA SAFETY MONITORING COMMITTEE (DSMC)/SAFETY ADVISORY BOARD 
(SAB) REVIEWS AND MANAGEMENT OF STUDY TOXICITIES, INCLUDING STOPPI[INVESTIGATOR_340977]...........................................................................................................................................................................46  
8.1 Data Safety Monitoring Committee (DSMC)/Safety Advisory Board Reviews  ................46  
8.2 Management of Study Toxicities  .......................................................................................................47  
8.2.1  Haematologic Toxicity  ................................................................................................................47  
8.2.2  Dose Limiting Toxicity (DLT)  ................................................................................................. 48 
8.2.3  Stoppi[INVESTIGATOR_1869]  ...............................................................................................................................48  
8.2.4  DLT at the Starting Dose (D s); IMG -7289 D s Reduction Rules  .....................................48  
9 STUDY ASSESSMENTS .............................................................................................................................49  
9.1 Informed Consent  ...................................................................................................................................50 
9.2 Screening Period, Including Baseline and Enrollment  ................................................................50  
9.2.1  Screening (Days -28 to Day -1)  ................................................................................................51 
9.2.2  Baseline Period (Days - 21 to Day -1) and Enrollment  ......................................................[ADDRESS_469111] Day of Screening Period (Day -1)  ..................................................................................52  
9.3 Initial Treatment Period (ITP)  ............................................................................................................52  
9.3.1  ITP D a
y 0 – Treatment Start  ......................................................................................................52  
[IP_ADDRESS]  ITP Pre -Dose Day 0  ........................................................................................................... 52 
[IP_ADDRESS]  ITP Dosing Day 0  ............................................................................................................... 53 
[IP_ADDRESS]  ITP Post -Dose Day 0  ......................................................................................................... 53 
9.3.2  ITP Weekly Visits - Days 7, 14, 21, 28, 35, 42, 49 and 56 (± 2 days)  .........................53  
[IP_ADDRESS]  ITP Days 7, 21, 35, 42 and 49 only ............................................................................... 54 
[IP_ADDRESS]  ITP Day 14 only  .................................................................................................................. 54 
[IP_ADDRESS]  ITP Day 28 only  .................................................................................................................. 54 
[IP_ADDRESS]  ITP Day 56 only  .................................................................................................................. 54 
Imago BioSciences,  Inc.  Protocol IMG -7289- CTP -102  
IMG- 7289    23Jun 2020  
Page 5 of 97 9.3.3  ITP Bi -Weekly Visits - Days 70, 84, 98 and 112 (± 2 days)  ...........................................54  
[IP_ADDRESS]  ITP Days 70 and 98 only  .................................................................................................. 55 
[IP_ADDRESS]  ITP Day 84 only  .................................................................................................................. 55 
[IP_ADDRESS]  ITP Day 112 only ................................................................................................................ 55 
9.3.4  ITP Monthly Visits - Days 140 and 168 (± 3 days)  ............................................................55  
[IP_ADDRESS]  ITP Day 140 only ................................................................................................................ 56 
[IP_ADDRESS]  ITP Day 168 only ................................................................................................................ 56 
9.4 Additional Treatment Period (ATP)  ................................................................................................ .57 
9.4.1  ATP Day 0 - Treatment ‘Re- start’  ...........................................................................................57  
[IP_ADDRESS]  Day 0  ....................................................................................................................................... 57 
9.4.2  ATP Days 28, 56, 84, 112, 140 and 168 (±4 days)  .............................................................58  
[IP_ADDRESS]  ATP Day 84 only  ................................................................................................................ 59 
[IP_ADDRESS]  ATP Day 140 only  .............................................................................................................. 59 
[IP_ADDRESS]  ATP Day 168 only  .............................................................................................................. 59 
9.5 Suspected Relapse  ..................................................................................................................................59  
9.6 Follow- Up Period Visits  .......................................................................................................................60  
9.6.1  End of Treatment  ...........................................................................................................................60  
9.6.2  Pre-End of Study Visit  .................................................................................................................60  
9.6.3  End of Study/Early Termination Visit  ....................................................................................61  
10 LABORATORY SAMPLING FOR SAFETY, PK AND PD ANALYSIS  ...................................61 
10.1  Laboratory Measures  .............................................................................................................................62  
10.1.1  Local Laboratory Measures ........................................................................................................62  
10.1.2  Central Laboratory Measures  ....................................................................................................63 
11 SAFETY  ..............................................................................................................................................................63  
11.1  Pregnancy  ..................................................................................................................................................63  
11.2  Adverse Events  .......... ..............................................................................................................................64  
11.2.1  Adverse Event Intensity  ..............................................................................................................65  
11.2.2  Adverse Event Relatedness  ........................................................................................................66  
11.2.3  Serious Adverse Events  ...............................................................................................................66  
11.2.4  Reporting Serious Adverse Events  ..........................................................................................67  
12 ANALYSIS AND STATISTICAL CONSIDERATIONS  ..................................................................68 
12.1  General Considerations  .........................................................................................................................68  
12.2  Power  ..........................................................................................................................................................68  
12.3  Treatment Assignment and Blinding  ................................................................................................68  
12.4  Study Endpoints  ......................................................................................................................................68  
12.4.1  Primary Endpoints .........................................................................................................................68  
12.4.2  Exploratory Endpoints  .................................................................................................................69  
Imago BioSciences,  Inc.  Protocol IMG -7289- CTP -102  
IMG- 7289    23Jun 2020  
Page 6 of 97 12.5  Safety and Tolerability Data  ................................................................................................................70  
12.6  Pharmacokinetics Data  ..........................................................................................................................71  
12.7  Pharmacodynamic Data  ........................................................................................................................71  
13 STUDY ADMINISTRATION .....................................................................................................................71 
13.1  Ethical Considerations  ...........................................................................................................................71  
13.2  Participation Information Sheet/Consent Form (PI[CONTACT_306741]) ............................................................[ADDRESS_469112] (IRB), Independent Ethics Committee (IEC) and Human 
Research Ethics Committee (HREC)  ..............................................................................................................[ADDRESS_469113] Dose Visits ..............................................................................82 
16.1.2  Schedule of Assessments: Initial Treatment Period  ...........................................................84  
16.1.3  Sched
ule of Assessments: Additional Treatment Period  ..................................................86  
16.2  The 2016 WHO Diagnostic Criteria for Primary Myelofibrosis (PMF)  ...............................[ADDRESS_469114] -Polycythaemia Vera 
Myelofibrosis (PPV -MF)  ...................................................................................................................................[ADDRESS_469115] -Essential Thrombocythaemia 
Myelofibrosis (PET -MF)  ....................................................................................................................................89  
16.5  Criteria for Grading Myelofibrosis (Arber et al. , 2016)* ...........................................................[ADDRESS_469116] Response Criteria for MF  ...........................................................90  
16.8  Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score  
(MPN -SAF TSS) – 24- Hour Recall  ................................................................................................................93  
Imago BioSciences,  Inc.  Protocol IMG -7289- CTP -102  
IMG- 7289    23Jun 2020  
Page 7 of 97 16.9  Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score  
(MPN -SAF TSS) – 7- Day Recall  ....................................................................................................................94  
16.10  Remote Data Review  .............................................................................................................................95  
16.10.1  Risk Assessment  ............................................................................................................................95 
16.10.2  Security Measures  .........................................................................................................................95  
16.10.3  Processes  ..........................................................................................................................................95  
[IP_ADDRESS]  Direct,  Controlled  Remote  Access to the Systems  Used  by [CONTACT_374733]/Source  Data.................................................................................... 96 
[IP_ADDRESS]  For Passive Access to Original  Docu ments/Original Data  via Live  Image  
Transmission  ............................................................................................................................................... 96 
[IP_ADDRESS]  Passing on Redacted Copi[INVESTIGATOR_374677]  ............................................................................................................................................... [ADDRESS_469117] of Abbreviations  
Abbreviation  Definition  
<, ≤, >, ≥  less than, less than or equal to, greater than, greater than or equal to  
± plus  
Ac acetylation  
ADL  activities of daily living  
AE adverse event  
ALP  alkaline phosphatase  
ALT  alanine aminotransferase  
AML  acute myeloid leukaemia  
aPTT  activated partial thromboplastin time  
AST  aspartate transaminase  
BCR -ABL  breakpoint cluster region -Abelson  
BUN  blood urea nitrogen  
°C degrees Centigrade  
CALR  calreticulin  
CBC  complete blood count  
CD cluster of differentiation  
CFR  Code of Federal Regulations  
cGMP  current Good Manufacturing Practices  
CI Clinical Improvement  
CL/F  apparent total clearance of drug after oral administration  
Clinical Benefit  not meeting progressive disease criteria as per Section 16.[ADDRESS_469118]  Co-repressor for RE1 -silencing transcription factor  
CR complete remission or response  
CXCL  chemokine (C -X-C Motif) ligand  
CXCR4  chemokine (C -X-C motif) receptor [ADDRESS_469119] computerized tomography  
CTCAE  Common Terminology Criteria for Adverse Events   
CV co-efficient of variation  
D Day 
DIC Disseminated Intravascular Coagulation  
DLT  dose limiting toxicity  
DNA  deoxyribonucleic acid  
DNMT  DNA -methyltransferase  
Imago BioSciences,  Inc.  Protocol IMG -7289- CTP -102  
IMG- 7289    23Jun 2020  
Page 9 of 97 Abbreviation  Definition  
Dpi [INVESTIGATOR_374678]; the estimate d dose of IMG -[ADDRESS_469120] visit  
Free base of 
IMG -7289  N-[(2S)-5-{[(1R,2S)-2-(4-fluorophenyl)cyclopropyl]amino} -1-(4-methylpi[INVESTIGATOR_9482] -
1-yl)-1-oxopentan -2-yl]-4-(1H-1,2,3- triazol -1-yl)benzamide, free base  
FSH  follicle stimulating hormone  
g or gm  Gram  
g/dL  gram per deciliter  
GCP  good clinical practice  
G-CSF gram colony stimulating factor  
GFI1  growth factor independent [ADDRESS_469121]  haematopoietic stem cell transplant  
IC inhibitory concentration  
ICH International Conference on Harmonization  
IEC Independent Ethics Committee  
IL Interleukin  
IMG -7289  N-[(2S)-5-{[(1 R,2S)-2-(4-fluorophenyl)cyclopropyl]amino }-1-(4-methylpi[INVESTIGATOR_9482] -
1-yl)-1-oxopentan -2-yl]-4-(1H-1,2,3- triazol -1-yl)benzamide, bis-tosylate salt ; 
bomedemstat  
indels  insertions and deletions  
INR International normaliz ed ratio  
IPF immature platelet fraction  
IRB Institutional Review Board  
IUD intrauterine device  
IWG -MRT  International Working Group  for Myelofibrosis Research and Treatment  
JAK Janus Kinases  
K Lysine  
KD knockdown  
KDM1A  lysine -specific demethylase [ADDRESS_469122] visit  
LSD1  lysine -specific demethylase 1  
LSDi  LSD1 inhibition or inhibitors  
MAO ; MAOI  monoamine oxidase (s); monoamine oxidase inhibitor(s)  
MCH  mean cell haemoglobin  
MCHC  mean cell haemoglobin concentration  
MCV  mean cell volume  
me; Me  methyl ; methylation  
Mg Milligram  
mg/kg  milligram per kilogram  
mg/kg/d  milligram per kilogram per day  
MedDRA  Medical Dictionary for Regulatory Activities  
MF Myelofibrosis  
Imago BioSciences,  Inc.  Protocol IMG -7289- CTP -102  
IMG- 7289    23Jun 2020  
Page 11 of 97 Abbreviation  Definition  
mL millilit re 
mL/min  millilit res/minute  
MPL  myeloproliferative leuk aemia  virus oncogene, thrombopoietin receptor  
MPN  myeloproliferative neoplasias or neoplasms  
MPP  multipotent progenitor  
MPN -SAF  TSS Myeloproliferative Neoplasm Symptom Assessment Form  Total Symptom Score  
MPV  mean platelet volume  
MRI  magnetic resonance imaging  
mRNA  messenger RNA  
Ms milliseconds  
MTD  maximally tolerated dose  
MYB  V-Myb Avian Myeloblastosis Viral Oncogene Homolog  
NCI National Cancer Institute  
ng·hr/mL  nanogram an hour per milliliter  
nM Nanomolar  
NOAEL  no-observed -adverse -effect -level  
NURD  nuclear remodeling and histone deacetylase  
OCT4  octamer -binding transcription factor [ADDRESS_469123] -essential thrombocyth aemia myelofibrosis  
PFS progression free survival  
Ph phosphorylation  
PI [INVESTIGATOR_678] (at each site responsible for patient care)  
PI[INVESTIGATOR_374679] /Consent Form  
PK Pharmacokinetics  
PKAP  Pharmacokinetic Analysis Plan  
PMF  primary myelofibrosis  
PPV -MF post -polycyth aemia vera myelofibrosis  
PR partial remission or response  
PT prothrombin time  
PV polycyth aemia vera  
QD once daily  
RBC  red blood cell  
RDW  red cell distribution width  
REST  RE-[ADDRESS_469124] -of-care  
SOX2  see SRY  
SRM  Study Reference Manual  
SRY  (sex determining region Y) -box 2; also known as SOX2  
STAT  Signal Transducer and Activator of Transcription  
Tmax time to maximum concentration  
TCP  Tranylcypromine  
TF transcription factor  
TNF  tumour  necrosis factor  
TPO  Thrombopoietin  
µL Microliter  
µM Micromolar  
Ub ubiquitination  
VAF  variant allele frequency  
Vz/F apparent volume of distribution during terminal phase after oral administration  
WBC  white blood cell  
WHO  World Health Organization  
WOCBP  wom en of child- bearing potential   
Imago BioSciences,  Inc.  Protocol IMG -7289- CTP -102  
IMG- 7289    23Jun 2020  
Page 13 of 97 2 PROTOCOL SYNOPSIS  
Protocol Title :  A Multi -Center, Open Label Study t o Assess t he Safety, Steady -State Pharmacokinetics 
and Pharmacodynamics o f IMG -7289 in Patients with Myelofibrosis 
Protocol No:   IMG- 7289 -CTP -102  
Investigator/Study Centers:   Approximately 25 sites in Australia , [LOCATION_013], Italy, [LOCATION_006] and US  with 
additional sites and countries as needed.  
Study Objectives:  
Hypothesis :  IMG- 7289 (bomedemstat) is a safe and tolerable orally available agent when 
administered to patients with myelofibrosis including primary myelofibrosis (PMF), post -
polycyth aemia vera myelofibrosis (PPV -MF), and post -essential thrombocyth aemia  myelofibrosis 
(PET -MF) ( collectively referred to as ‘MF’); inhibition of lysine -specific demethylase 1 (LSD1) by [CONTACT_374734] -
7289 will reduce spleen size in those with splenomegaly, improve haematopoiesis  and reduce 
constitutional symptoms associated with these disorders.  
Primary Objectives :  To eval uate in MF patients the effect of IMG -7289 on:  
• Safety and tolerability  
• Pharmacokinetics  (Phase 1/2a only)  
• Reduction in spleen volume        
Exploratory Objectivesɸ:  To evaluate in MF patients treated with IMG -7289:  
• The adequacy of the treatment regimen in producing a pharmacodynamic effect  
• Haematologic response*  
• Improvement in constitutional symptoms assessed using the Myeloproliferative Neoplasm 
Symptom Assessment F orm (MPN -SAF ; Phase 1/2a only ) and the MPN -SAF TSS (Total 
Symptom Score; Phase 2b)  
• Reduction in bone marrow fibrosis score  
• Relationship between dose and plasma trough concentrations over time (Phase 1/2a only)  
• The impact of therapy on disease burden as measured by [CONTACT_248261] -cell specific nucleic 
markers (DNA or RNA)**   
• The effect of treatment on cytokine profiles***  
• The relationship between genetic aberrations in malignant cells and pharmacodynamic 
response  
• To correlate conventional clinical responses with  exploratory assessments of response   
*Haematologic parameters , all of which may be assessed during treatment or after drug has been discontinued 
for a specified interval,  may comprise: complete blood count ( CBC) including platelets, red and white blood cell 
(RBC and WBC) and circulating blast cell counts; cellular composition of the bone marrow (% blasts) ; and, the 
induction of foetal haemoglobin .   
**Nucleic markers include RNA and/or DNA mutations detected by [CONTACT_374735].    
***Cytokine quantification.  
ɸSome or all may be analysed time and cost permitting.  
Investigational Drug:  The active drug substance is identified as IMG -7289  (bomedemstat) .   IMG -
7289 is an irreversible inhibitor of LSD1.
 
IMG- 7289 will be supplied as capsules  in multiple strengths.  These strengths, based on IMG -7289 
free base, i.e., the active substance, may include:   Capsule strengths 
CCI
CCI
Imago BioSciences,  Inc.  Protocol IMG -7289- CTP -102  
IMG- 7289    23Jun 2020  
Page 14 of 97 provided may change throughout the duration of the study.  Such details will be included via  updates 
to the Pharmacy Manual.  
Study Population:  Approximately  seventy -five (75) patients eighteen years of age or older with 
intermediate- 1, -2 or high risk PMF, PPV -MF, PET -MF (referred to collectively as ‘MF’) will be treated .   
Methodology:   This is a multi -center, open -label study evaluating the safety, tolerability, steady -state 
pharmacokinetics and pharmacodynamics of IMG -7289 administered orally once daily in patients 
with myelofibrosis (MF) .    
The therapeutic goal for the treatment of MF is to inhibit the activity of LSD1 in haematopoietic cells, 
particularly megakaryocytes, for only a fraction of the [ADDRESS_469125] received IMG -7289 to date in both 
IMG- 7289 -CTP -101 and - 102.  In the CTP -101 study, IMG -7289 was administered to patients with 
high -risk AML and MDS; the therapeutic thesis was to completely inhibit LSD1 in all haematopoietic 
cells, target ing both leukaemic stem cells and blasts, recognizing that patients would need clinical 
support for cytopenias.  The starting dose was 0.75 mg/kg/d and the effective dose, at which no safety signals were  observed, was deemed 6.0 mg/kg/d.  Though the great majority of the patients 
entered the study with Grade 3/4 thrombocytopenia, patients at all dose levels of IMG -7289 required 
platelet transfusions.  This sensitivity of thrombopoiesis to LSD1 inhibition in high -risk AML/MDS 
patients reflects the generally compromised nature of the bone marrow, including the reduction of megakaryocytes, in that disease.   
Taking this observation into account in association with the therapeutic goal for the treatment of myeloproliferative neoplasms - inhibiting LSD1 activity in haematopoietic cells for only a fraction  of 
the 24 -hour dosing cycle - and PK modeling, a starting dose (D
s) of 0.25 mg/kg/d was selected for the 
Phase 1/2a portion of this study.   
 
  A d ose-response curve was 
subsequently generated that provided a titration algorithm to adjust dose to achieve the modified target  platelet count of between 50 -75 k/µL (50-75 x 10
9/L), devised with a view to minimizing the 
probability of severe thrombocytopenia.   
 
 
 
 
 
  Acc
ordingly,  to enable patients to more quickly 
reach the optimum dose while still maintaining an adequate safety margin, a new IMG -7289 starting 
dose of 0.5 mg/kg  QD was  selected with protocol Amendme nt [ADDRESS_469126] patients  range s between 0.6 and 0.8 
mg/kg/d.  Thus, a new starting dose of 0.6 mg/kg/d has been chosen,  
  Starting therapy at a dose closer to the optimal 
dose should accelerate the proc ess of symptom and spleen volume reduction.   Additional detail for 
the rationale on the dose and dose schedule can be found in Section 3.[ADDRESS_469127]  
This study initiated as a Phase 1/2a study assessing the safety of the starting dose, an 85 day duration 
of treatment, and the pharmacokinetic and pharmacodynamic effects of IMG -7289, with transition to 
a Phase 2b study incorporating changes supported by t he Phas e 1/2a data .  This study consists of two 
treatment periods:  the Initial Treatment Period (ITP), followed by [CONTACT_374736] (ATP).  Patients are now enrolling  in the Phase 2b portion of the study, i n which patients are treated 
daily for 169  days  in the ITP .   The ATP  offers treatment to qualifying patients for an additional 169 
days.   
During the ITP, patients will return for study assessments weekly for 8 weeks  
 
 
  For the exceptional patient whose 
dose has not stabilized, weekly visits may continue at the PI’s discretion  (note: bi -weekly visits may 
also continue post Day 112) .   
  
 
 
 
 
  Such patients qualify for entry into the ATP, a 
transition which should occur without interruption in dosing.  Patients not deriving  clinical benefit , or 
who achiev e complete response (CR), partial response (PR) or clinical improvement (CI) and 
subsequently relapse ( Section 16.7) the equivalent of treatment failures, will disco ntinue IMG -7289 
and undergo End of Treatment (EoT), pre -End of Study (pre -EoS) and End of Study (EoS) visits . 
In the A TP, treatment may continue  for an additional [ADDRESS_469128] already achieved a stable dose, with bi -weekly visits no longer 
necessary.  Fo r the exceptional patient whose dose has not stabilized, bi -weekly visits may continue 
at the PI’s discretion.  On Day 168, patients will undergo the same procedures and assessments as in the ITP, including MRI or CT (if the patient is not a candidate for MRI), and bone marrow sampling.  
Prior to or at the  a ‘qualification’ 
CCI
CCI
CCI
CCI
CCI
Imago BioSciences,  Inc.  Protocol IMG -7289- CTP -102  
IMG- 7289    23Jun 2020  
Page 16 of 97 assessment will be made to determine whether the patient is continuing to derive clinical benefit . 
Such patients thereby [CONTACT_374737] -entry into the ATP, which is iterative; patients may continue to 
receive IMG -[ADDRESS_469129] dose.  Patients that do not enter the ATP, or discontinue early, will 
enter the follow -up period beginning with  an E oT.   
Patients will be followed closely throughout the study for both Adverse Events (AEs) and signs of toxicity by [CONTACT_374738].  Pharmacodynamic effects will be closely monitored by [CONTACT_374739], and requisite bone marrow aspi[INVESTIGATOR_99193]. T hroughout dosing, 
transfusions may be administered  if needed  in accordance with standard institutional guidelines.  
IMG- 7289 Dosing  
Through the use of dose titration, all patients will be dosed to the estimated dose of IMG -7289 needed 
in humans that provides sufficient exposure to inhibit normal ha ematopoiesis safely for a fraction  of 
the 24 -hour dosing cycle (designated the  Dpi).   
Initial Treatment P eriod (ITP) :   
Note:   Please refer to Section [IP_ADDRESS]  for p atients currently being treated under Amendment 5  
For patients commencing treatment under Amendment 6, treatment will begin on Day 0 at the new Ds 
of 0.6 mg/kg QD .  In association with this increased starting dose, the first up -titration is not 
permitted until Day 28.  Extending the time to first up -titration from Day 14 to Day 28 is supported by 
[CONTACT_374740] a stable platelet count is between 3 and 4 weeks; additionally, this approach minimizes the risk of severe thrombocytopenia for the few  patients  who 
may  requir e less than 0.6 mg/kg/ d.   
 
  
 
 
   
 
  
The p
latelet titration target expected to be associated with a clinically significant therapeutic effect is:   
• A platelet count of ≥ 50  to ≤ 75 k /µL (50 -75 x 109/L). 
Please refer to Section [IP_ADDRESS]  for additional information on the dosing of Amendment 6 patients.  
Additional Treatment Period (ATP):   Qualifying patients will ‘re -start’ IMG -7289 on ATP Day 0, with 
dose titration continuing as per  the Titration Rules in Table 3; there should be no interruption in 
dosing (i.e., Day 168 = Day 0 of new ATP).  A dditional dose -titration may occur in consultation with 
the Medical Monitor.   Note:   In [LOCATION_013], use of computerised tomography (CT) is not permitted for patients unable to 
undergo magnetic resonance imaging (MRI).  Only MRI is permitted for study purposes.  
CCI
Imago BioSciences,  Inc.  Protocol IMG -7289- CTP -102  
IMG- 7289    23Jun 2020  
Page 17 of 97 Study Duration:    
 
 the anticipated duration of partici pation in the  study is expected to be  
at least [ADDRESS_469130] visit (FPFV) to last patient- last visit (LPLV).   Additional 
treatment may be given, contingent on an assessment of patient benefit . 
Study Assessments :  The assessments outlin ed below are presented in detail by [CONTACT_182984]  
9, and in the Schedule of Assessments Sections 16.1 ). 
The Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN -SAF  TSS) 
will be used .  The 24 -HOUR RECALL  tool  (Appendix 16.8) will be completed daily for the [ADDRESS_469131] dose (Days - 6 to pre-dose Day 0) during  Baseline .  The 7 -DAY RECALL tool w ill be 
completed  weekly  from Day 7 through the EoS Visit  (Appe ndix 16.9).   Multiple questionnaires will 
need to be provided to patient for completion between visits as visit schedule decreases over time.  
Adverse events  (AEs)  will be assessed at every visit post  first IMG -7289 dose through the E oS visit.   
Physical Examination s (PE) , including vital signs:  a Full Physical Exam  will be performed at 
Screening .  Limited Physical Exams (LPE)  will be performed at all other clinic visits throughout the 
study.  LPEs include weight, a review of body systems to assess change from previous PE, and spleen 
measurement. The edge of the spleen shall be determined by [CONTACT_23302], measured in centimeters, 
using a soft ruler /tape , from the costal margin to the point of greatest splenic pro trusion.  The spleen 
should be measured in th e same manner at all visits.  
Urine or serum pregnancy testing  will be performed for  women  of child -bearing potential (WOCBP ; 
defined in Section 6.1 ) at Screening, Baseline (if separate from Screening visit), pre -dose Day 0, 
monthly (i.e., Days 28, 56, 84, 112, 140 and 168) throughout the study, upon suspi[INVESTIGATOR_331540], at 
the EoT, pre -EoS, and EoS/ET visits and if pregnancy is suspected while the patient remains on -study . 
Bone marrow aspi[INVESTIGATOR_337]* and biopsy  will be performed**:  
• At Baseline (no more than [ADDRESS_469132] IMG- 7289 dose).  
• At Day 168 (±7 days) .  
• Approximately ever y 6 months thereafter, at Day 168 (±7 days)  of the ATP , for as long as the 
patient  continues to qualify .  
• At EoT and ET (unless performed within the prior 5 weeks) , and u pon suspi[INVESTIGATOR_331540]  
(unless performed in the last 21 days or is scheduled in the next 7 days) .   
*Aspi[INVESTIGATOR_374680], but no later than the second pull, is required.  
**The total number of bone marrow evaluations required during the ITP  is 2 in ~[ADDRESS_469133] (if the patient is not a candidate for MRI) of the abdomen will be performed.   
• Pre-dose Day 0 (± 2 days)   
• At the Day 84 and Day 168  visit s (±7 days)  
• Approximately every 6 months  thereafter , at Day 168 (±7 days) of the ATP, for as long as the 
patient continues to qualify  Note:   In the [LOCATION_006], serious AEs (SAEs) will be recorded from time of consent through the EoS or 
until the Investigator and Imago BioSciences determine follow -up is no longer necessary.  
CCI
Imago BioSciences,  Inc.  Protocol IMG -7289- CTP -102  
IMG- 7289    23Jun 2020  
Page 18 of 97 • At EoT, ET, and upon suspi[INVESTIGATOR_331540]  (unless performed within the prior 5 weeks)  
Clinical laboratory measures :  The following laboratory measures will be performed at Screening, 
Baseline (if separate from Screening visit) , pre-dose Day 0, upon suspi[INVESTIGATOR_331540],  at the E oT, pre -
EoS, and E oS/ET  visits , and in accordance with the below: 
• Biochemistry  – monthly (i.e., Days 28, 56, 84, 112, 140 and 168) throughout the study    
• Haematology – every clinic visit throughout the study  
• Coagulation  – monthly (i.e., Days 28, 56, 84, 112, 140 and 168 ) throughout the study    
• Urinalysis – Day 84 and Day 168 throughout the study  
  Sam p le collection time -points are below. 
• Pre-dose Day 0, Day s 1 4, 28, 84 and 168, and each Day 168  visit  of the ATP, for as long as the 
patient continues to qualify  
• At EoT, and at ET (ET required only if the patient discontinues during the ITP ) 
Red Cell H aemoglobin F (HbF)  and %F cells  (Selected  sites only/ITP  only) :   
• Pre- dose Day 0, Day 84 and Day 168  
• At EoT and ET (both required only if the patient discontinues during the ITP ) 
*Any b one marrow aspi[INVESTIGATOR_374681].   
Bloo
d, bone marrow and/or their contents may be retained for future exploratory studies.   
Eligibility Criteria :   
Patients must meet all applicable Inclusion and none  of the Exclusion Criteria.  
Inclusion Criteria : 
1. Willing and able to sign the approved informed consent.  Note:   In [LOCATION_013], use of computerised tomography (CT) is not permitted for patients unable 
to undergo magnetic resonance imaging (MRI).  Only MRI is permitted for study purposes.  
CCI
CCI
CCI
Imago BioSciences,  Inc.  Protocol IMG -7289- CTP -102  
IMG- 7289    23Jun 2020  
Page 19 of 97 2. Age: 18 + years old at Screening.  
3. Diagnosis of either PMF  per World Health Organization ( WHO ) diagnostic criteria for 
myelo proliferative neoplasms (Section  16.2) , PPV -MF per the IWG -MRT (Section 16.3) , or PET -MF 
per the IWG -MRT (Section 16.4 ) and meet the following additional subtype specific criteria:  
a. Classified as high risk (3 prognostic factors) , intermediate risk -2 (2 prognostic factors)  or 
intermediate risk -1 (1 prognostic factor) . The prognostic factors, defined by [CONTACT_374741] (Cervantes, et al ., 2009) : 
i. Age > 65 years;  
ii. Presence of constitutional symptoms (weight loss, fever, night sweats);  
iii. Marked an aemia (Hgb < 10g/dL) *; 
iv. History  of leukocytosis [WBC > 25 x109/L (25,000/µL )]; 
v. Circulating blasts ≥ 1%.  
*A haemoglobin value < 10 g/dL must be demonstrated during Screening f or patients who are not 
transfusion dependent. Patients receiving regular transfusions of packed red blood cells will be 
considered to have haemoglobin < 10 g/dL for the purpose of evaluation of risk factors.  
4. Be refractory  or resistant to, inadequately controlled by [CONTACT_374742], or in the Investigator’s judgment, are not candidates for available approved therapy  
(note:  approved therapy includes ruxolitinib  and, in the US, fedratinib ). 
5. Eastern Cooperative Onco logy Group (ECOG) performance status score ≤2.  
6. Peripheral blast count ≤10 % prior to dosing  on Day 0 . 
7. Absolute neutrophil count ≥ 0.5 x 109/L (500 /µL)  prior to dosing on Day 0 .  
8. Platelet count ≥ 100  x 109/L (100  k/µL)  prior to dosing  on Day 0 . 
9. Life expectancy > [ADDRESS_469134] discontinued all  previous therapi[INVESTIGATOR_374682], any chemotherapeutic 
agents, immunosuppressive therapy (e.g., corticosteroids > 10 mg/day with the noted exception: 
use of corticosteroids for management of gout  is allowed; maintenance supplemental 
corticosteroid therapy such as prednisone ≤ 10 mg/day or corticosteroid equivalent is allowed), 
immune modulators (e.g., thalidomide), radiotherapy for at least 2 weeks prior, and interferon for 
4 weeks prior to study Day 0.  Low dose acetylsalicyclic acid is permitted.  Palliative radiation 
treatment to non -index or bone lesions performed < 2 weeks before treatment may be considered 
with Medical Monitor approval.  
11. Amenable to bone marrow evaluation, peripheral blood and  urine sampling during the study.  
12. Able to swallow capsules. 
13. Women of childbearing potential (WOCBP) and fertile men (see Section 6.1 ) must a gree to use an 
approved method of contraception  from Screening until 28 days * after last IMG -7289 dose.  
Methods of contraception include: estrogen and progestogen combined hormonal contraception 
which inhibits ovulation ; progestogen -only hormonal contraception associated with inhibition of 
ovulation ; intrauterine device (IUD) ; bilateral tubal occlusion ; vasec tomized partner in a 
monogamous sexual relationship  (vasectomy or tubal ligation at least six months prior to dosing) ; 
and, complete sexual abstinence (defined as refraining from heterosexual intercourse) .  Patients 
practicing abstinence must agree to use an approved method of contraception should they become sexually active during the study.   
*The risk of embryofetal toxicity is fully mitigated by 28 days which is >10 half -lives of the drug at the doses 
used in this study . Note:   In the [LOCATION_006], m ales with a pregnant partner must agree to use a condom to avoid 
exposure to the developi[INVESTIGATOR_82596].   
 
Imago BioSciences,  Inc.  Protocol IMG -7289- CTP -102  
IMG- 7289    23Jun 2020  
Page 20 of 97 Exclusion Criteria : 
1. Has undergon e major surgery ≤4 weeks prior to starting study drug or has not recovered from 
side effects of such surgery.   
2. Has undergone any surgical procedure within 2 weeks, excluding minor procedures ( e.g., skin 
biopsy or central venous catheter placement/removal) prior to starting study drug.  
3. History of splenectomy.  
4. History of or s cheduled haem atopoietic stem -cell transplant within 24 weeks of screening . 
5. Unresolved treatment related toxicities from prior therapi[INVESTIGATOR_014] (unless resolved to ≤ Grade 1). 
6. Current use of a prohibited medication (e.g.,  romiplostim) or expected to require any of these 
medications during treatment with the investigational drug.  
7. Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically 
related to IMG -7289 or LSD1 inhibitors (i.e., monoamine oxidase inhibitors; MAOIs) that 
contraindicates their participation.  
8. Current use of monoamine oxidase A and B inhibitors (MAOIs).  
9. Uncontrolled active  infection.  
10. A concurrent second active and non -stable malig nancy (patients with a concurrent second active 
but stable malignancy, such as non- melanoma skin cancers , are eligible).  
11. Evidence at the time of Screening of risk of bleeding, including any of the following:  
a. Activated partial thromboplastin time (aPTT) ≥ 1 .3 x the local upper limit of normal  
b. International normalized ratio (INR) ≥ 1.3 x the local upper limit of normal  
c. History of severe thrombocytopenia or platelet dysfunction unrelated to a myeloproliferative 
disorder or its treatment  
d. Known bleeding disorder  (e.g., dysfibrinogen aemia, factor IX deficiency, h aemophilia, 
Von  Willebrand's disease, Disseminated Intravascular Coagulation [DIC], fibrinogen 
deficiency, or other clotting factor deficiency)  
12. Evidence at the time of Screening of significant renal or hepatic insufficiency (unless due to haemolysis, or leuk aemic infiltration) as def ined by [CONTACT_374743]:  
a. Calculated glomerular filtration rate (GFR ; using the Cockcroft -Gault equation) <40 mL/min 
or serum creatinine > 1.5 x the lo cal upper limit of normal  
b. Aspartate transaminase ( AST ) or alanine aminotransferase  (ALT ) ≥2 x the local upper limit of 
normal  
13. Known human immunodeficiency virus (HIV) infection or known active Hepatitis B or  Hepatitis C 
virus infection  (testing will not be conducted as part of Screening procedures) . 
14. History of any illness/impairment of gastrointestinal ( GI) function that might interfere with drug 
absorption (e.g., chronic diarrhea), confound the study results or pose a n additional risk to the 
patient by [CONTACT_9286]; patients with gastric by[CONTACT_4897].  
15. Use of an investigational agent with in less than [ADDRESS_469135]  
7 half -lives of that agent,  whichever is the longer, pr ior to  study Day 0. 
16. Pregnant or lactating females ; females intending to become pregnant at any time during the 
study . For Italy ONLY, Exclusion 13 reads:  Active infection with hepatitis B virus (positive hepatitis B 
surface antigen ; note:  positive hepatitis B surface antibody and positive hepatitis B core 
antibody are not exclusionary provided disease is not active, which should be clearly 
documented in the patient’s medical history) or C virus (patients with positive hepatitis C 
antibody result would require confirmation of active disease with a positive hepatitis C 
polymerase chain reaction (PCR) test), seropositivity for human immunodeficiency virus (HIV).  
 
Imago BioSciences,  Inc.  Protocol IMG -7289- CTP -102  
IMG- 7289    23Jun 2020  
Page 21 of 97 GUIDELINES:  The se guidelines are for  use by [CONTACT_737], study staff and patient to safeguard 
patient safety while maintaining data integrity.  Please contact [CONTACT_374744].  
1. In general, supportive care (transfusions, administration of anti -fungals, etc.) should be 
maintained in accordance with institutional policy.  Additionally:  
a. It is advised that patients with a platelet count ≤ 10 x 109/L (10  k/µL) be transfused.  
2. Hydroxyurea may be used during the study in case of proliferation as follows:  
a. At the PIs discretion, i nitiate hydroxyurea treatment for white cell count ≥ 30 x 109/L 
(30,000/µL) and majority of cells appear to be immature cells (myelocytes/promyelocytes)  
b. Discontinue hydroxyurea treatment when white cell count is < 10 x 109/L (10,000/µL)  
3. Patien ts taking medications that have the potential to induce or inhibit CYP 3A4 or CYP 2D6 should be 
monitored closely for potential effects of co- administration; particular attention should be given to 
anti -infectives in the azole class.  
4. Cessation of IMG -7289 is invariably associated with a rebound in thrombopoiesis and platelet 
counts may easily exceed the baseline in any given patient.  When IMG -7289 is discontinued, the 
platelet count should be monitored closely  and the timing of the start of an a lternative therapy 
should take this into account . 
PROHIBITED MEDICATIONS/TREATMENTS :  Please consult the Medical Monitor with any 
questions pertaining to prohibited medications.  
1. All cytotoxic agents, with the exception of hydroxyurea  
2. All h aematopoietic growth factors: romiplostim, eltrombopag , granulocyte and granulocyte -
macrophage colony stimulating factor ( G-CSF and GM -CSF) and erythropoietin (EPO)  
3. Prednisone or prednisolone  > 10 mg/day (noted exception: use of corticosteroids for 
management of gout  is allowed)  and dexamethasone > 4 mg/day .  Maintenance supplemental 
corticosteroid therapy such as prednisone ≤ 10 mg/day or corticosteroid equivalent is allowed.  
4. Monoamine oxidas e A and B inhibitors  
5. Anticoagulant and nonsteroidal anti -inflammatory drug (NSAID; including aspi[INVESTIGATOR_248]) use are 
prohibited in patients when their platelet count is < 50 x 109/L (50  k/µL)  
Management of Study Toxicities :  Adverse event intensity will be evaluated using the National 
Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 3, 
published 14 June 2010.   Please refer to Section 8.2 for additional detail on management of study 
toxicities, including reduction of the starting dose based on DLT . 
Definitions : 
Haematologic Toxicity:  Haematologic  values outside of the normal reference range are inherent 
features of MPNs , and are expected effects  of many therapeutic attempt s to manage these diseases.  
The effects of IMG -7289 on normal myeloid haematopoiesis observed in non- clinical and clinical 
studies  are expected in humans; these are pharmacodynamic effect s of LSD1 inhibition by [CONTACT_374734] -7289, 
thus  not regarded as adverse.  These  events, with the exceptions below, will not be considered DLTs.   
Dose limiting toxicity (DLT):  A ny one of the following AEs that occurs through Day 7 of the Initial 
Treatment Period and is considered by [CONTACT_110515], probably or definitely related 
to IMG -7289:   
• Thrombocytopenia leading to clinically significant sequelae (i.e., a clinically sign ificant 
bleeding event* or the need for prophylactic transfusions);  
• A clinically significant bleeding event * in a patient with a platelet count >50  x 109/L (50 
k/µL) ;  
• Any Grade 4 or 5 non- haematologic  adverse event ;  
Imago BioSciences,  Inc.  Protocol IMG -7289- CTP -102  
IMG- 7289    23Jun 2020  
Page 22 of 97 • Any Grade 3 non-haematologic  adverse event with failure to recover to Grade 2 within 7 days 
of drug cessation, with the following exceptions:  
o ≥ Grade [ADDRESS_469136] medical care 
o ≥ Grade 3 aesthenia lasting less than 14 days  
• Any Grade 3  electrolyte abnormalit y unrelated to the underlying malignancy and persisting 
greater than  24 hours.  
*A clinically significant bleeding event is defined as an event  that is life -threatening, cannot be controlled 
and/o r results in haemodynamic instability.  
Patients who experience a DLT may have their dose adjusted downward if the Medical Monitor and 
Principal Investigator [INVESTIGATOR_374683] -7289.   
Please consult the Medical Monitor for IMG -[ADDRESS_469137] edition of the Investigator’s Brochure.    
Stoppi[INVESTIGATOR_1869]:  IMG -7289 will be discontinued in the event of the following:  
• Post DLT, the Medical Monitor and Principal Investigator [INVESTIGATOR_374684] -7289.  
• Post dose reduction due to DLT, the patient fails to demonstrate significant improvement within 21 days.  
CCI
Imago BioSciences,  Inc.  Protocol IMG -7289- CTP -102  
IMG- 7289    23Jun 2020  
Page 23 of 97 3 INTRODUCTION 
3.1 Background on the Disease to be Treated  
The BCR -ABL1 -negative myeloproliferative neoplas ms (MPNs) are a family of related neoplastic 
disorders of bone marrow .  The three main chronic BCR -ABL1 -negative MPNs are polycyt haem ia vera 
(PV), essential thrombocyt haem ia (ET) and primary myelofibrosis (PMF).  The cardinal clinical 
features of these disorders are increased red cell mass in PV, increased platelet count in ET, and bone 
marrow fibrosis in PMF.  The MPNs are clonal disorders arising most freq uently from acquired 
(somatic) mutations in a multipotent haem atopoietic stem/progenitor cell resulting in abnormal ities 
in red cell, granulocyte and platelet  production often in association with marrow fibrosis and 
extramedullary haem atopoiesis  and, in some cases evolution to acute myeloid leukaemia (AML ).   
Myelofibrosis is, per se , a clinical feature of many benign and malignant disorders (Popat et al ., 2006) .  
MF in the context of MPNs,  variably termed primary or secondary myelofibrosis, myelofibrosis with 
myeloid metaplasia, agnogenic myeloid metaplasia, or primary myelosclerosis, is a chronic inflammatory process in which excess collagen is deposited in bone marrow , impairing 
haem atopoiesis.   
The chronic MPNs are disorders of h aematopoie sis which share mutations that constitutively 
activate the physiologic signal transduction pathways responsible for myeloid h aematopoiesis.  The 
common pathogenic mechanism is activation of the Janus Kinase (JAK) and signal transducer and 
activators of transc ription (STAT) ; the JAK -STAT pathway is the signaling transduction pathway for 
the lineage- specific growth factors including thrombopoietin (TPO) and erythropoietin (EPO)  
(Abdel -Wahab and Levine, 2009; Stark and Darnell, 2012) .  MF patients have gain -of-function 
missense mutations in JAK2  (65%) and/or  the myeloproliferative leuk aemia virus oncogene, MPL 
(4%).  The more common alleles,  JAK2
V617F  and MPLW515L , result from G -to-T transversion mutations, 
the most common cause of which is oxidative damage to DNA.  Insertion and deletion (indels) mutations found in CALR  (23%)  are similarly gain -of-function mutations that result in activation of 
the JAK -STAT pathwa y (Rumi et al.,  2014; Nangalia et al ., 2013) .    
Many chromosomal and genetic abnormalities have also been identified in the MPNs .  Some, like 
deletions of chromosome 20q, may be antecedent cytogenetic abnormalities that predispose to mutations in JAK2 or are epi[INVESTIGATOR_374685] , that together determine the subsequent clinical course.  T he 
underlying mechanism s that generate the common pathogenic mutations , and the antecedent and 
subsequent mutations necessary to cause clinical disease and to shape the natural histor y remain a 
mystery .  In light of the unfruitful search for additional highly recurrent mutations with whole 
genome sequencing, t hese influences may be specific to the cell of origin in which the mutations 
arose, epi[INVESTIGATOR_374686], considering  the reportedly worse natural history of 
polycyth aemia in women compared to men (Spi[INVESTIGATOR_374687] ., 2014) . 
Some MPN  patients are asymptomatic at the time of diagnosis, and PV, ET and MF can be difficult to 
clinically distinguish.  Common presenting manifestations can include stroke, fatigue, weight loss, 
night sweats, fever, dyspnea, and abdominal discomfort owing to splenomegaly .  Leukocytosis, 
thrombocytosis and splenomegaly can be present.  M ajor complications arise from cytopenia s 
secondary to bone marrow failure, extramedullary haematopoiesis ( principally in the spleen and 
liver ), and evolution to AML .  Splenomegaly is for many patients the most distressing complication of 
Imago BioSciences,  Inc.  Protocol IMG -7289- CTP -102  
IMG- 7289    23Jun 2020  
Page 24 of 97 myelofibrosis leading to discomfort, inanition, splenic infarction, portal and pulmonary 
hypertension, and blood cell sequestration , while thrombosis is the dreaded complication of elevated 
red blood cell mass . 
Myelofibrosis associated with somatic mutations in haem atopoietic stem/progenitor cells is a 
progressi ve neoplastic disorder with a median lifespan of 5.5 years from the time of diagnosis, a 
shorter mean survival time compared to PV and ET (Hultcrantz et al.,  2015) .  Death most often results 
from the consequences of thrombocytopenia or neutropenia , haem orrhage or infection  (Malak et al.,  
2012) .  Complications exacerbating morbidity secondary to an aemia and extramedullary 
haem atopoiesis include portal hypertension  and heart failure .   
There are no specific treatments for the MPNs .   The JAK 1/2 inhibitor ruxolitinib is approved for the 
treatment of disease -related symptoms and splenomegaly in adult myelofibrosis (including PMF, 
PPV -MF and PET -MF) patients .  It is  effective at alleviating constitutional symptoms, normalizing 
blood counts  and red ucing spleen size in many patients.  Ruxolitinib does not appear to significantly 
alter the natural history of the disease but mortality in a three year period is reduced 50% in the high -risk patients.  Ruxolitinib is effective only during administ ration ; symptoms recur soon after 
treatment is stopped.  Fibrosis in the marrow is largely un affected  by [CONTACT_374745]; 
there is no short- term clinical impact on JAK2
V617F  allele frequencies, but treatment for more than 
three years may reduce the allele burden (Deininger et al ., 2015) .   
Other treatments principally manage symptoms.  An aemia associated with an erythropoietin (EPO) 
level <100 mU/m L may respond to EPO therapy but is associated with an increase in 
hepatosplenomegaly.   Prednisone can be e ffective for patients with evidence of active inflammation 
or autoimmune disease.  Allopurinol is used to treat h yperuric aemia.  Thalidomide at doses up to 
100 mg/day in combination with prednisone improv es anaemia and thrombocytopenia in 
approximately 60% of PMF patients and reduc es spleen size in approximately 20% but is not 
approved for this indication in many countries .  Low dose pegylated i nterferon- α2a early in the 
course of the disease reduce s splenomegaly and can produce molecular remissions but is associated 
with cytopenias and neurotoxocities but is not approved for this indication in many countries 
(Kiladjian et al ., 2008) .  Hydroxycarbamide has a low incidence of acute toxicity but also causes 
myeloid s uppression.  Low -dose alkylating agent s can reduce organo megaly, reverse marrow fibrosis  
and improve blood counts but only occasionally has  durable effects . 
No chemotherapeutic agent has averted MPN disease progression, myelofibrosis or thrombosis.  The only potentially curative treatment , haematopoietic stem cell transplantation (HSCT), has been  
employed more sparingly in the era of ruxolitinib though this trend is reversing as it becomes more 
widely appreciated that ruxolitinib is not curative nor does it  decrease the risk of leukaemic 
transformation .  The use of reduced intensity conditioning has reduced treatment -related mortality 
and enhanced overall survival at five -year s from  47%  with earlier regimens to 67% with one- year 
non- relapse mortality at 15-20% .  (Guardiola et al., 1999 ; Kroger et al ., 2009; Gupta, Hari and 
Hoff man,  2012). 
Imago BioSciences,  Inc.  Protocol IMG -7289- CTP -102  
IMG- 7289    23Jun 2020  
Page 25 of 97 3.2 Background on the Drug Target  
LSD1, also known as KDM1A, is an enzyme that removes mono - and dimethyl groups from histone 
(H) H3 at critical lysines (K), K4 and K9 (Shi et al. , 2004) .  Methylation of histone H3K4 and H3K9 is 
a post -translational modification associated with changes in the confirmation of chromatin  
(Bannister and Kouzarides, 2011 ; Beisel and Paro, 2011 ).  Chromatin is a collection of nuclear 
macromolecules consisting of DNA, protein scaffolding, enzymes enhancing transcription and 
synthesis of RNA (Kornberg, 1974) .  The DNA and its protein scaffold of histones form a complex 
called the nucleosome.   Each nucleosome is com posed of two copi[INVESTIGATOR_374688], H2A, H2B, H3 and H4, forming an octamer around which DNA is wrapped.  The rates of gene transcription are heavily influenced by [CONTACT_374746] (Bannister and Kouzarides, 2011; Beisel and 
Paro, 2011) . 
Epi[INVESTIGATOR_374689], the DNA bases such as cytosine or RNA, changes that do not alter the actual DNA sequence (Bird, 2002) .  Enzymes that modify these substrates by [CONTACT_374747][INVESTIGATOR_374690].  Histone and nucleic acid modifications provide binding sites for proteins and components of the transcriptional machinery that affect transcriptional gene silencing or activation  (Kouzarides, 2007) .  Histone modifications include acetylation (Ac), 
methylation (Me), phosphorylation (Ph) and ubiquitination (Ub).  By [CONTACT_374748], LSD1 is an epi[INVESTIGATOR_374691].  The primary therapeutic effects of LSD1 inhibition come from restoring the pattern of gene expression characteristic of differentiating 
myeloid progenitor cells.  
LSD1 is localized to specific sites in the genome through the agencies of proteins that bind DNA directly, generally transcription factors ( TFs) (Whyte  et al., 2012; Whyte  et al. , 2013) .  Many TFs, both 
activators such as V- Myb Avian Myeloblastosis Viral Oncogene Homolog (MYB) and steroid hormone 
receptors, as well as repressors such as growth factor independence 1 transcription repressor (GFI1)  
and RE -1 silencing transcription factor (REST), recruit LSD1 to specific genomic locations ( Metzger  
et al., 2005; Saleque et al., 2007; Lin et al., 2010) .  LSD1 is part of a larger protein complex, containing , 
e.g., Co -RE-1 silencing transcription factor (CoREST) or nucleosome remodeling and histone 
deacetylase (NuRD), which dictates the cell- and site -specific chromatin remode ling
 (Lee et al., 2005; 
Foster  et al. , 2010) .  These complexes may also include DNA methytransferase 1 (D NMT1 ) and 
histone deacetylases 1, 2 and 3 (HDAC1, 2, and 3) activities all of which contribute to maintaining or modifying the epi[INVESTIGATOR_374692] ( Shi et al. , 2005; Orkin and Hochedlinger, 2011) .  
Thus, an important property of LSD1 beyond its own enzymatic activity is its function as a scaffold for other pro teins and epi[INVESTIGATOR_374693] -recruited to genomic sites.   Likewise, LSD1 
bound to specific sites precludes the binding of other factors that may influence transcription.  
LSD1 is unique among the many histone demethylases in that it coordinates  flavin adenine 
dinucleotide (FAD) to oxidatively remove one or two methyl groups, in the process producing H
2O2 
and formaldehyde.   As such, FAD is an essential co -factor for LSD1 activity (Shi et al. , 2004).   The 
other 3 4 histone lysine demethylases, collectively termed the Jumonji demethylases , employ an iron -
dependent mechanism to remove methyl groups from histone lysines ( Klose  et al. , 2006) .  
Imago BioSciences,  Inc.  Protocol IMG -7289- CTP -102  
IMG- 7289    23Jun 2020  
Page 26 of 97 LSD1  is an essential gene; loss of LSD1 activity leads to early embryonic lethality (Wang  et al. , 2009; 
Foster  et al. , 2010) .  The protein is also needed for regulating the balance between self -renewal and 
proliferation (Wang  et al. , 2007 ).  A conditional in vivo  LSD1  knockdown (KD) using a doxycycline -
inducible short hairp in LSD1  (shLSD1 ) established LSD1 as a central regulator of haem atopoieti c 
stem cells (HSCs) and progenitor cells (Sprussel  et al. , 2012) . An inducible LSD1  KD resulted in 
profound but reversible thrombocytopenia, neutropenia and ana emia; monocyte numbers were 
increa sed.  LSD1  KD for 27 days led to an increase in circulating multipotent progenitors (MPPs) and 
HSCs with a concomitant down -regulation of chemokine (C -X-C motif) receptor 4 (CXCR4) without 
affecting the size of the quiescent long -term HSC pool (Sprussel  et al. , 2012) .   
LSD1 plays a key role in regulating the progression from pluripotency to terminal differentiation and 
balancing self- renewal and proliferation ( Adamo  et al. , 2011; Wang et al. , 2007; Whyte  et al. , 2012) .   
LSD1 is recruited to “high confidence” promoters and super -enhancers of genes essential for normal 
development by [CONTACT_941] “master” transcription factors octamer -binding transcription factor 4 (OCT4), 
SRY (sex determining r egion Y) -box 2  (SOX2), Nanog and the co -activator Mediator.  Though not 
essential for maintenance of the embryonic stem cell (ESC) state, as part of the NuRD complex, LSD1 
“decommissions” enhancers of genes maintain ing the pluripotency program allowing ES C to 
differentiate .  LSD1 is essential for the complete shutdown of the ESC gene expression program as 
cells transition to more differentiated cell states (Whyte  et al., 2012) .  The role LSD1 plays in ES C is 
phenomenologically similar to the essential role LSD1 plays during myeloid haem atopoiesis, in which 
enhancers active in HSCs generating a stem- cell gene expression signature [CONTACT_374804] 
“decommissioned”, allowing commitment of progenitors to specific myelo id lineages (Lara -Astiaso  et 
al., 2014) .  Enhancers essential for terminal myeloid differentiation in lineage -specific progenitor 
cells , the so -called de novo  enhancers, must be poised for activation by [CONTACT_374749] H3K4me1 
marks .  As progenitors commit to differentiation, LSD1 is down -regulated dramatically allowing de 
novo  enhancers  and promoters to be stably activated with progressive methyl or acetyl additions on 
H3K4 and H3K27, respectively ( Lara -Astiaso  et al. , 2014) .    
3.3 Background on LSD1 in Myeloid Neoplasia and Myelofibrosis  
Over-expression of LSD1  messenger RNA (mRNA) and excess LSD1 protein hav e been observed in 
many tumo ur types, including poorly -differentiated neuroblastoma, squamous cell carcinoma, 
Ewing’s sarcoma, AML, neuroendocrine carcinomas and epi[INVESTIGATOR_374694], prostate, 
bladder, small cell lung and colon cancers (Metzger et al. , 2005; Kahl et al. , 2006; Schulte et al. , 2009; 
Lim  et al., 2010) .  In MPN, LSD1 was over -expressed mainly in megakaryocytes and erythroid 
precursors and to a lesser degree in early myeloid cells (Niebel et al ., 2014) . Treatment of various  
tumo ur types in culture with LSD1 inhibitors (LSDi) has been reported to inhibit tumo ur growth, 
reduce their potential for migration and invasion, reduce clonogenic potential and eliminate cancer stem cells, induce markers of differentiation appropriate to the cell lineage, and induce apoptosis
 
(Somervaille and Cleary, 2006 ; Somervaille  et al. , 2009; Harris  et al. , 2012 ; Zhang  et al. , 2013 ).  In 
various models of mouse leukaem ia, treatment with LSD1 inhibitors induced monocytic markers of 
differentiation, reduced clonogenic potential of leukaem ia initiating cells (LICs), and induced cell 
death (Harris  et al. , 2012) .   
Imago BioSciences,  Inc.  Protocol IMG -7289- CTP -102  
IMG- 7289    23Jun 2020  
Page 27 of 97 LSD1 activity is present in a high proportion of malignant myeloid blasts  cells (Lin et al. , 2011 ;  
Rhodes  et al. , 2007; Wouters  et al. , 2009) .  LSD1 gene expression is among the highest in 
immunophenotypi[INVESTIGATOR_374695]/progenitor populations of myeloid neoplastic cells (Goardon  et al. , 
2011 ; Somervaille  et al. , 2009; Harris  et al. , 2012) .   
LSD1 may play a direct role in regulating pathogenic signaling from the activated JAK- STAT pathway.  
The JAK -STAT signa ling pathway is activated by [CONTACT_374750], JAK2  and CALR  
via the phosphorylation of STAT3 and STAT5, transcription factors that activate specific sets of genes 
with pleiotropic effects (Chen and Mullally, 2014) .  STAT3 activity as a transcription factor is 
modulated by  [CONTACT_374751] (K140) and is one of many reported substrate s for LSD1  (Yang 
et al ., 2010) .   
Proof -of-concept studies were pe rformed in well established , pre-clinical mouse models of PMF .  
Compared to mice treated with vehicle, LSD1 inhibition (LSDi) in transplanted mice markedly 
suppressed myeloproliferation reducing granulocyte and platelet counts, thus establishing  
therapeuti c eff icacy . Spleen weights  in treated animals showed a dose- proportional decrease .  
Histop athologic al analysis of bone marrow and spleen confirmed a marked reduction in 
myeloproliferation, as well as a reversal of extramedullary haem atopoiesis (EMH).  Most notably, 
there was near -complete resolution of  reticulin fibrosis in the bone marrow in the LSDi treatment 
arm .  This effect is not observed in this model when treating with ruxolitinib.  LSD1 inhibi tion had a 
significant impact on serum inflammatory  cytokine concentration s.  The anti -cytokine effects of 
JAK1/[ADDRESS_469138] compared to what was achieved with LSDi, as exemplified by  a very marked reduction in the plasma concentration of the Chemokine (C -X-C Motif) 
Ligand 5
 (CXCL5 ), a key participant in the pathologic inflammatory state  of MPN .   
LSD1 inhibition also reduced the mutant allele burden to a degree not  seen with JAK1/2 inhibitor 
therapy.  In mice treated with veh icle, 74.6 % of circulating cells were green fluorescent protein  cell-
positive (GFP+), while only 43 .2% of circulating cells were GFP+ in LSDi -treated mice.  Flow cytometry 
analysis of spleen and bone marrow  revealed reduced numbers of CD11b+/Gr1+ myeloid c ells and 
CD41+ megakaryocytes. The numbers of mutant GFP+ myeloid cells and megakaryocytes in these 
tissues were also significantly reduced by [CONTACT_374752].  This effect is not observed in this model 
when treating with ruxolitinib.  The decrease in platelet counts an d mutant clone burden, and the 
resolution of fibrosis after [ADDRESS_469139] LSD1 and human AML 
cells at concentrations of <5 nM.  Irreversible inhibitors of LSD1 include tranylcypromine (TCP) which has been used for the treatment of depression  for decades.  The targets of TCP therapy, 
however, include all FAD -dependent monoamine oxidases (MAO s) in addition to LSD1 .  TCP 
inactivates LSD1 in a manner identical to its action on MAO -A and MAO -B because these three 
enzymes share a similar oxidative chemistry.   
 
 
 
 
CCI
Imago BioSciences,  Inc.  Protocol IMG -7289- CTP -102  
IMG- 7289    23Jun 2020  
Page 28 of 97 3.5 Potential Clinical Risks and Benefits  when Treating with an LSD1 Inhibitor  
The treatment effects with an LSD1 inhibitor (LSDi) are anticipated t o be distinct  from  treatment 
with standard cytotoxic agents or with Janus Kinase (JAK) inhibitors.   LSD1 inhibition has specific 
effects on all myeloid lineages.  LSD1 activity is needed for the differentiation of progenitors to red 
cells, platelets and granulocytes.  .  Hence, LSD1 inhibition 
changes the composition in the marrow and the periphery of cells from these four lineages,  
 
 
  
 
 
The morphologic and clinical pathology changes may  not be familiar to clinicians and 
haematopathologists.    As such, there is potential for confusion in the interpretation of peripheral 
haematologic parameters and the morphology of bone marrow cells.  Outlined below are some of the 
anticipated clinical scenarios that might be observed in  MF patients  treated  with IMG- 7289 based on 
non- clinical and clinical studies conducted by [CONTACT_374753]1 : 
CCI
CCI
CCI
CCI
Imago BioSciences,  Inc.  Protocol IMG -7289- CTP -102  
IMG- 7289    23Jun 2020  
Page 29 of 97 Please refer to the Investigator’s Brochure, Section 6.3 for Reference Safety Information.  
CCI
Imago BioSciences,  Inc.  Protocol IMG -7289- CTP -102  
IMG- 7289    23Jun 2020  
Page 30 of 97 3.6 IMG -7289 Dose Justification  
A summary of the starting dose and dosing schedule  are provided below.  Further information , 
including additional relevant data, can be found in the Investigator’s Brochure. 
3.6.[ADDRESS_469140] of inhibiting LSD1  for a fraction of the dosing cycle (24 hours) .  Inhibition 
of LSD1 in vitro  and in non- clinical models of AML  (Harris et al ., 2012) induces monocytic 
differentiation  of malignant myeloid  cells , reduces their self -renewal potential, inhibits their growth 
and induces cell death.   In mouse models of MF, the percentage of mutant cell s is also reduced  
following treatment with IMG- 7289.   
LSD1 activity is essential for normal myeloid maturation ; loss o f >90% LSD1 activity in mice is 
associated with an arrest in the differentiation of myeloid progenitors and hence maturation of 
megakaryocytes, erythrocytes and granulocytes (Sprussel et al ., 2012) .  The production of 
monocytes , however, does not require L SD1 activity.  Consistent  with the respective lifespan of 
platelets, granulocytes and red cells, complete LSD1 inhibition leads to thrombocytopenia, 
neutropenia and anaemia with the reduced number of platelets being the first evident effect.  
Independent o f lifespan, for a given exposure, production of platelets appears more sensitive to the 
inhibition of LSD1 than is production of granulocytes or red cells.    
  Th
e starting dose was 0.75 mg/kg/d and the effective dose, at w hich no safety 
signals have been observed, was deemed to be 6.0 mg/kg/d.  Though the great majority of the 
patients entered the study with Grade 3/4 thrombocytopenia, patients at all dose levels of IMG- 7289 
required platelet transfusions.  This sensitivity  of thrombopoiesis to LSD1 inhibition in high -risk 
AML/MDS patients reflects the generally compromised nature of the bone marrow, including the reduction of megakaryocytes in that disease.
     
The therapeutic goal for the treatment of myeloproliferative ne oplasms  is to inhibit the activity of 
LSD1 in haematopoietic cells , particularly megakaryocytes, for only a fraction  of the [ADDRESS_469141] bone marrow fibrogenesis  
and symptoms .  Taking this thesis, the toxicology observations, and the PK studies into account, a 
starting dose (D s) of 0.25 mg/kg/d was selected for the Phase 1/2a portion of this study.  This dose 
was expected to be safe, but sub -therapeutic, that is, a dose insufficient to reduce the platelet count 
to the target range (NB: range was 100 -200  thousand (k) platelets per microliter (k/µL ; 100 x 109/L) 
in original protocol).  A dose -response curve was subsequently generated that provided a titration 
algorithm to adjust dose to achieve the modified target platelet count of between 50 -75 k/ µL  
(50-75 x 109/L), devised with a view to minimizing the probability of severe thrombocytopenia.  
Based on the patients treated up to that time , the dose sufficient to achieve a platelet count in the 
target range of 50 -75 k/ µL (50-75 x 109/L)  
 
  
a new IMG -7289 starting dose of 0.5 mg/kg QD was  selected  with Protocol Amendment [ADDRESS_469142] ranges 
between 0.6 and 0.8 mg/kg/d.  Thus, a new starting dose of 0.6 mg/kg/d has been chosen, one that is at least 75% of the estimated optimal dose for the majority of patients.  Starting therapy at a dose 
closer to the optimal dose should accelerate the process of symptom and spleen volume reduction.   
Dose escalation or  de-escalation may occur as per the rules detailed  in Section  7.2.3, contingent on 
study Day and based on the impact of LSDi on platelet, ANC and Hgb  count s.  Observations regarding 
dose- response have led to modifications of the titration schedule.  As additional patients have been 
treated, it has been noted that for a given daily dose , the time needed to reach a stable platelet count 
is between [ADDRESS_469143] up -titration from ITP Day 14 to ITP Day 28 also  
minimizes the risk of severe thrombocytopenia for the few patients who may require less than  
0.6 mg/kg/d.  In conjunction with the increased starting dose and the longer intervals between up -
titrations, the incremental dose titrations have been decreased.  By [CONTACT_17155] [ADDRESS_469144] of enhancing the clinical benefits.     
 
In summary, p er the dosing changes undertaken with this amendment,  in association with the 
increased starting dose of 0.6 mg/kg/d,  
 while down -titrations  can 
be made at any time in the best interest s of the patient.  Titration and re- challenge rules specific to 
ITP Days 7, [ADDRESS_469145] whether patient doses should be maintained 
or down -titrated (Table 2), with a second set of rules specific to ITP Day [ADDRESS_469146]  (Table 3). 
CCI
CCI
CCI
Imago BioSciences,  Inc.  Protocol IMG -7289- CTP -102  
IMG- 7289    23Jun 2020  
Page 32 of 97 3.6.2  Rationale for the  IMG -7289  Dosing Schedule  
The phenotypic effects of LSD1 inhibition are mediated  through changes in the gene expression 
patterns that are a consequence of transcriptional reprogramming that occurs in the absence of LSD1 
activity (Harris et al ., 2012) .  The  phenotypic consequences are cell -specific , include differentiation 
and, ultimately , cell death.  In the primary pharmacology studies with IMG -7289, these changes take 
place over a period of days to weeks ; in the assay for self- renewal potential (clonogenicity), these 
changes take days or weeks to observe.  Complete and sustained inhibition of LSD1 may be the best 
strategy to rapi[INVESTIGATOR_374696] ; however, in a less 
aggressive myeloid neoplasm such as myelofibrosis, that has characteristics more similar to a 
paraneoplastic condition, chronic treatment at doses that do not completely inhibit LSD1  is 
anticipated to be well tolerated while having a significant impact on disease.  At these doses in mouse 
MF models , the gradual loss of cells bearing the MPN mutation ( Jak2  or Mpl) is observe d over the 
course of LSD1 inhibition.   What emerges from these mouse studies is a strategy  that balances safety 
with clinical efficacy :  inhibit the enzyme for only a fraction  of the [ADDRESS_469147] been observed in either the AML/MDS 
or myelofibrosis studies with IMG -7289 at doses up to             
4 HYPOTHESIS AND OBJECTIVES  
4.1 Hypothesis  
IMG- 7289 is a safe and tolerable orally available agent when administered to patients with 
myelofibrosis including primary myelofibrosis (PMF), post -polycyth aemia  vera -myelofibrosis (PPV -
MF), and post -essential thrombocyth aemia -myelofibrosis (PET -MF) ( collectively referred to as ‘MF’); 
inhibition of lysine -specific demethylase 1 (LSD1) by [CONTACT_374734]- 7289 will reduce spleen size in those with 
splenomegaly, improve haematop oiesis  and reduce constitutional symptoms associated with these 
disorders. 
4.2 Objectives  
The following primary and exploratory objectives will be evaluated in patients with myelofibrosis  
including primary myelofibrosis (PMF), post -polycyth aemia vera- myelofibr osis (PPV- MF), and post -
essential thrombocyth aemia -myelofibrosis (PET- MF) ( collectively referred to as ‘MF’ ). 
CCI
CCI
Imago BioSciences,  Inc.  Protocol IMG -7289- CTP -102  
IMG- 7289    23Jun 2020  
Page 33 of 97 *Haematologic parameters , all of which may be assessed during treatment or after drug has been discontinued 
5 INVESTIGATIONAL PLAN 
5.1 Overview  
This is a multi -center, open -label study evaluating the safety, tolerability, steady -state 
pharmacokinetics an d pharmacodynamics of IMG -7289 administered orally once daily in patients 
with myelofibrosis (MF) .    
The therapeutic goal for the treatment of MF is to inhibit the activity of LSD1 in haematopoietic 
cells  for only a fraction  of the 24-hour dosing cycle , sufficient to reduce platelets to a safe level 
while inhibiting to the greatest extent possible the production , by [CONTACT_374754], of cytokines and 
growth factors that drive bone marrow fibrogenesis  and symptoms.  Considerations for a safe and 
thera peutic starting dose include d chronic toxicology studies, in conjunction with the clinical 
experience of the patients who have received IMG -7289 to date in both IMG -7289- CTP -101 and -
102.  In the CTP -101 study , IMG -7289 was administered to patients with hi gh-risk AML and MDS; 
the therapeutic thesis was to completely inhibit LSD1 in all haematopoietic cells, targeting both 
leuka emic stem cells and blasts, recognizing that patients would need clinical support for 
CCI
CCI
Imago BioSciences,  Inc.  Protocol IMG -7289- CTP -102  
IMG- 7289    23Jun 2020  
Page 34 of 97 cytopenias.  The starting dose was 0.75 mg/kg/d and the effective dose, at which no safety signals 
have been observed, was deemed 6.0 mg/kg/d.  Though the great majority of the patients entered the study with Grade 3/4  thrombocytopenia, patients at all dose levels of IMG -7289 required 
platelet transfu sions.  This sensitivity of thrombopoiesis to LSD1 inhibition in high -risk AML/MDS 
patients reflects the generally compromised nature of the bone marrow including the reduction of megakaryocytes, in that disease.   
Taking this observation into account in association with the therapeutic goal for the treatment of 
myeloproliferative neoplasms – inhibiting LSD1 activity in haematopoietic cells for only a fraction of 
the 24 -hour dosing cycle – and PK modeling, a starting  dose (D
s) of 0.25 mg/kg/d was selected for 
the Phase 1/2 a portion of this study.  This dose was expected to be safe, but sub -therapeutic, that is, 
a dose insufficient to reduce the platelet count to the target range (NB: range was 100 -200  thousand  
platelets per microliter (k/µL ; 100 -200 x 109/L) in original protocol). A dose -response curve was 
subsequently generated that provided a titration algorithm to adjust dose to achieve the modified  
target platelet count of between 50 -75 k/µL (50-75 x 109/L), devised with a view to minimizing the 
probability of severe thrombocytopenia.  
 
   Based on the patients 
treated up to that time , the dose sufficient to achieve a platelet count in the target range of  
50-75 k/ µL (50-75 x 109/L) was  expected to range from between 0.5 to 2.0 mg/kg.  The mean 
efficacious dose, that dose needed to achieve the target platelet count, was 0.81 mg/kg (range 0.5 to 1.9 mg/kg) ; the mean maximum dose administered was 0.86 mg/kg .  Accordingly, to enable patient s 
to more quickly reach the optimum dose while still maintaining  an adequate safety margin, a new 
IMG- 7289 starting dose of  0.5 mg/kg  QD was  selected  for protocol Amendment 4.  With the contin ued 
observation of additional patients treated, the estimated optimal dose for most ranges between 0.6 
and 0.8 mg/kg/d.  Thus, a new starting dose of 0.6 mg/kg/d has been chosen, one that is at least 75% of the estimated optimal dose for the majority of pa tients.  Starting therapy at a dose closer to the 
optimal dose should accelerate the process of symptom and spleen volume reduction.  Additional detail for the rationale on the dose and dose schedule can be found in Section 3.6 . 
To ensure patient safety, a Data Safety Monitoring Committee (DSMC) /Safety Advisory Board (SAB)  
will perform review s at least quarterly of safety parameters  and pharmacodynamic markers to draw 
conclusions around the safety and pharmacodynamic effect of IMG -7289.  Two sentinel patients were 
dosed sequentially at the original D
s of 0.25 mg/kg/d for 7 days and monitored twice -weekly before 
any additional patients were treated.  The DSMC/SAB  convene d within [ADDRESS_469148] -completion of 7 
days of treatment for each of the sentinel patients and determined it was  safe for:  
1. Each sentinel patient to continue dosing , and  
2. Additional patients to begin treatment with IMG -7289.   
Additionally, the DSMC /SAB  convened post -completion of 7 days of treatment of the required three 
patients at the new D s and determined : 
1. The safety of the new D s, and  
2. The ITP Day 3 (mid- week) visit could be re moved  from the visit schedule.  
CCI
Imago BioSciences,  Inc.  Protocol IMG -7289- CTP -102  
IMG- 7289    23Jun 2020  
Page 35 of 97 This study initiated as a Phase 1/2a study, assessing the safety of the starting dose, an 85 day duration 
of treatment, and the pharmacokinetic and pharmacodynamic effects of IMG -7289, with transition to 
a Phase 2b study including implementation of changes supported by [CONTACT_165894] 1/2a data.  This study 
consists of two treatment periods :  The Initial Treatment Perio d (ITP) , followed by  [CONTACT_374755] (ATP) .  Patients are now enrol ling in the Phase 2b portion of the study, i n which 
patients are treated daily for 169  days in the ITP .   In the ATP , which is iterative, treatment may 
continue  for an additional 169 days in those patients deriving clinical benefit  (defined as not meeting 
progressive disease criteria as per Section 16.7  and safely tolerating IMG -7289; this definition applies 
throughout the document and will not be repeated with each reference to clinical benefit) , as 
determined by [CONTACT_079].   
All patients will undergo follow -up period visits, including an End -of-Treatment (EoT) visit on the 
day of last dose  or as soon as possible thereafter , a pre -End -of-Study (EoS) visit approximately [ADDRESS_469149] dose, and an End -of-Study (EoS) visit approximately [ADDRESS_469150] dose.  Patients 
that do not enter the ATP, or discontinue early, will undergo follow -up, beginning with an E oT visit . 
Patients will be followed closely throughout the study for both Adverse Events (AEs) and signs of toxicity by [CONTACT_374756].  Pharmacodynamic effects will be closely monitored by [CONTACT_374757], and requisite bone marrow aspi[INVESTIGATOR_99193].  T hroughout dosing, 
transfusions may be administered  if needed  in accordance with standard institutional guidelines.  
5.1.1  Initial Treatment Period  (ITP)  
Through the use of dose titration, all patients will be dosed to the D
pi [INVESTIGATOR_374697]- 7289.  The D pi [INVESTIGATOR_374698] ≤ 2 mg/kg QD; however, this is not the upper limit for titration purposes as the dose 
needed to achieve a therapeutic effect will vary among patients and may change over time.  The  
platelet  titration target expected to be associated w ith a clinically significant  therapeutic effect is:   
• A platelet count of ≥ 50 to ≤ 75 k /µL ( 50-75 x 109/L)  
Additional details pertaining to dosing are located in Section  7.2.3 . 
During the ITP , patients will return to the clinic for study assessments weekly for 8 weeks (ITP Days  
7, 14, 21, 28, 35, 42, 49 and 56) , at least bi -weekly for 8 weeks  (ITP Days  70, 84, 98  and 112 ) and then 
monthly for 8 weeks (ITP Days  140 and 168) .  It is anticipated that by [CONTACT_10585] 8 (Day 56) patients will 
have achieved a stable dose, with weekly visits no longer necessary.  For the exceptional patient 
whose dose has not stabilized, weekly visits may continue at the PI’s discretion  (note: bi -weekly visits 
may also continue post Day 112) .  On Day s [ADDRESS_469151] 
(if the patient is not a candidate for MRI ).  On Day 168, bone marrow samp ling is also required.  Prior 
to or at the Day 168 visit, but ideally at the Day 140 visit  for logistical purposes, a ‘qualification’ 
assessment will be made to determine whether the patient  is deriving clinical benefit .  Such patients 
qualify for entry in to the ATP, a transition which should occur without interruption in dosing .  
Patients not deriving clinical benefit , or who achiev e CR, PR or CI and subsequently relapse ( Section 
16.7), the equivalent of treatment failures, will discontinue IMG -7289 and undergo all necessary 
follow up  visits.  
Imago BioSciences,  Inc.  Protocol IMG -7289- CTP -102  
IMG- 7289    23Jun 2020  
Page 36 of 97  
5.1.2  Additional Treatment Period (ATP) for Qualifying Patients Only  
For the purposes of clarity and efficiency, rather than continuing to present chronological days/  
weeks, visits are presented as ‘ ATP Day 0’, followed by, ‘ATP Days 28, 56, 84 ’, etc.  Qualifying patients 
will ‘re- start’ IMG -7289 on ATP Day 0, with dose titration  continuing as per the Titration Rules table 
(Section  [IP_ADDRESS]) ; there should be no interruption in dosing (Day 168 = Day 0 of the next ATP).   
Addi tional dose -titration may occur in consultation with the Medical Monitor.   
During the ATP , qualifying patients will return to the clinic monthly for study assessments ( ATP Days 
0, 28, 56, 84, 112, 140 and 168 ).  It is anticipated that patients continuing in the ATP will have already 
achieved a stable dose, with bi-weekly visits  no longer necessary.  For the exceptional patient whose 
dose has not stabilized, bi -weekly visits may continue at the PI’s discretion.   On Day 168, patient s will 
undergo the same procedures and assessments as per ITP Day 168, including  MRI or CT (if patient is 
not a candidate for MRI) , and bone marrow sampling .  Prior to or at the Day 168 visit, but ideally at 
the Day 140 visit for logistical purposes, a ‘qualification’ assessment will again be made to determine 
whether the patient is continu ing to derive clinical benefit, thereby [INVESTIGATOR_1312]- qualify ing for continued 
treatment  in the ATP.  The ATP is iterative and  may repeat  (ATP1, ATP2, etc.) , witho ut interruption 
in dosing,  as long as the patient continues to qualify.  
Patients not deriving clinical benefit , or who achiev e CR, PR or CI and subsequently relapse ( Section 
16.7), the equivalent of treatment failures,  will discontinue IMG -7289 and undergo EoT, pre- EoS and 
EoS visits.      
6 STUDY POPULATION 
6.1 Study Entry Criteria  
For purposes of eligibility, the following  definitions apply:  
• A woman is considered of childbearing potential (WOCBP), i.e. fertile, following menarche 
and until becoming post -menopausal unless permanently sterile. Permanent sterilisation 
methods include hysterectomy, bilateral salpi[INVESTIGATOR_92796] b ilateral oophorectomy.  
• A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a post- menopausal state in women n ot using hormonal 
contraception or hormonal replacement therapy. However, in the absence of 12 months of amenorrh oea, a single FSH measurement is insufficient.  
• A man is considered fertile after puberty unless permanently sterile by [CONTACT_31657].
 Note:   In [LOCATION_013], use of computerised tomography (CT) is not permitted for patients unable to 
undergo magnetic resonance imaging (MRI).  Only MRI is permitted for study purposes . Note:   In [LOCATION_013], use of computerised tomography (CT) is not permitted for patients unable to 
undergo magnetic resonance imaging (MRI).  Only MRI is permitted for study purposes.  
Imago BioSciences,  Inc.  Protocol IMG -7289- CTP -102  
IMG- 7289    23Jun 2020  
Page 37 of 97 • Abstinence is defined as refraining from heterosexual intercourse .  True abstinence, when this is 
in line with the preferred and usual lifestyle of the subject  is permitted . Periodic abstinence (e.g., 
calendar, ovulation, symptothermal, post -ovulation methods), declaration of abstinence for the 
duration of exposure to IMP, and withdrawal are not acceptable methods of contraception.  
6.1.[ADDRESS_469152] meet all o f the applicable criteria to be eligible for enrollment in this study:  
1. Willing and able to sign the approved informed consent.  
2. Age: 18 + years old at Screening.  
3. Diagnosis of either PMF  per World Health Organization ( WHO ) diagnostic criteria for 
myeloprolife rative neoplasms (Section  16.2) , PPV -MF per the IWG -MRT (Section 16.3 ), or PET -
MF per the IWG -MRT (Section 16.4 ) and meet the following additional subtype specific criteria:  
a. Classified as high risk (3 prognostic factors) , intermediate risk -2 (2 prognostic factors)  or 
intermediate risk -1 (1 prognosti c factor). The prognostic factors, defined by [CONTACT_374758] (Cervantes, et al ., 2009) : 
i. Age > 65 years;  
ii. Presence of constitutional symptoms (weight loss, fever, night sweats);  
iii. Marked an aemia (Hgb < 10g/dL) *; 
iv. History  of leukocytosis [ WBC > 25 x109/L (25,000/µL )]; 
v. Circulating blasts ≥ 1%.  
*A haemoglobin  value < 10 g/dL must be demonstrated during Screening for patients who are not 
transfusion dependent. Patients receiving regular transfusions of packed red blood cells will be 
considered to have haemoglobin < 10 g/dL for the purpose of evaluation of risk factors.  
4. Be refractory  or resistant to, inadequately controlled by [CONTACT_374759], or in the Investigator’s judgment, are not candidates for available approved therapy  
(note:  approved therapy includes ruxolitinib  and, in the US, fedratinib ). 
5. Eastern Cooperative Oncology Group (ECOG) performance status score ≤2.  
6. Peripheral blast count ≤10 % prior to dosing  on Day 0 . 
7. Absolute neutrophil count ≥ 0.5 x 109/L (500 /µL)  prior to dosing on Day 0 . 
8. Platelet count ≥ 100  x 109/L (100  k/µL)  prior to dosing  on Day 0 . 
9. Life expectancy > [ADDRESS_469153] discontinued all previous therapi[INVESTIGATOR_374682], any chemotherapeutic 
agents, immunosuppressive therapy (e.g., corticosteroids > 10 mg/day with the noted exception: 
use of corticosteroids for management of gout is allowed; maintenance supplemental 
corticosteroid therapy such as prednisone ≤ 10 mg/day or corticosteroid equivalent is allowed), immune modulators (e.g., thalidomide), radiotherapy for at least 2 weeks prior, and interferon 
for 4 weeks prior to study Day 0.  Low dose acetylsalicyclic acid is permitted.  Palliative radiation 
treatment to non -index or bone lesions performed < 2 weeks before treatment may be considered 
with Medical Monitor approval.  
11. Amenable to bone marrow evaluation, peripheral blood and urine sampling during the study.  
12. Able to swallow capsules. 
Imago BioSciences,  Inc.  Protocol IMG -7289- CTP -102  
IMG- 7289    23Jun 2020  
Page 38 of 97 13. Women of childbearing potential (WOCBP) and fertile men (see Section 6.1) must a gree to use an 
approved method of contraception from Screening until 28 days * after last IMG- 7289 dose.  
Methods of contraception include: estrogen and progestogen combined  hormonal 
contraception which inhibits ovulation;  progestogen -only hormonal contraception 
associated with inhibition of ovulation ; intrauterine device (IUD) ; bilateral tubal occlusion ; 
vasectomized partner in a monogamous sexual relationship  (vasectomy or tubal ligation at 
least six months prior to dosing) ; and, complete sexual abstinence ( defined as refraining from 
heterosexual intercourse ).  Patients practicing abstinence must agree to use an approved method 
of contraception should they become sexually active during the study.  
 * The risk of embryofetal toxicity is fully mitigated by 28 days which is >10 half -lives  of the drug at the doses 
used in this study . 
6.1.2  Exclusion Criteria  
Patients will be excluded from the study if they meet any of the following criteria:  
1. Has undergone major surgery ≤4 weeks prior to starting study drug or has not recovered from 
side effects of such surgery.   
2. Has undergone any surgical procedure within 2 w eeks, excluding minor procedures (e. g., skin 
biopsy or central venous catheter placement/removal) prior to starting study drug.  
3. History of splenectomy.  
4. History of or s cheduled haem atopoietic stem -cell transplant within 24 weeks of screening . 
5. Unresolved treatment related toxicities from prior therapi[INVESTIGATOR_014] (unless resolved to ≤ Grade 1).  
6. Current use of a prohibited medication (e.g.,  romiplostim) or expected to require any of these 
medications during treatment with the  investigational drug.  
7. Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically 
related to IMG -7289 or LSD1 inhibitors (i.e., monoamine oxidase inhibitors; MAOIs) that 
contraindicates their participation.  
8. Current use of monoamine oxidase A and B inhibitors (MAOIs).  
9. Uncontrolled active  infection.  
10. A concurrent second active and non -stable malignancy (patients with a concurrent second active 
but stable malignancy, such as non- melanoma skin cancers , are eligible).  
11. Evidence at the time of Screening of risk of bleeding, including any of the following:  
a. Activated partial thromboplastin time (aPTT) ≥ 1.3 x the local upper limit of normal  
b. International normalized ratio (INR) ≥ 1.3 x the local upper limit of normal  
c. History of severe thro mbocytopenia or platelet dysfunction unrelated to a 
myeloproliferative disorder or its treatment  
d. Known bleeding disorder (e.g., dysfibrinogen aemia, factor IX deficiency, h aemophilia, 
Von  Willebrand's disease, Disseminated Intravascular Coagulation [DIC], fibrinogen 
deficiency, or other clotting factor deficiency)  Note:   In the [LOCATION_006], m ales with a pregnant partner must agree to use a condom to avoid exposure 
to the developi[INVESTIGATOR_82596].   
 
Imago BioSciences,  Inc.  Protocol IMG -7289- CTP -102  
IMG- 7289    23Jun 2020  
Page 39 of 97 12. Evidence at the time of Screening of significant renal or hepatic insufficiency (unless due to 
haemolysis, or leuk aemic infiltration) as def ined by [CONTACT_374743]:  
a. Calcu lated glomerular filtration rate (GFR ; using the Cockcroft -Gault equation ) <40  mL/min  
or serum creatinine > 1.5 x the local upper limit of normal  
b. Aspartate transaminase ( AST ) or alanine aminotransferase  (ALT ) ≥2 x the local upper limit 
of normal  
13. Known human immunodeficiency virus (HIV) infection or known active Hepatitis B or  Hepatitis 
C virus infection  (testing will not be conducted as part of Screening procedures) . 
14. History of any illness/impairment of gastrointestinal ( GI) function that might interfere with drug 
absorption (e.g., chronic diarrhea), confound the study results or pose a n additional risk to the 
patient by [CONTACT_9286]; patients with gastric by[CONTACT_4897].  
15. Use of an investigational agent with in less than [ADDRESS_469154]  
7 half -lives of that agent,  whichever is the longer, pr ior to the study Day 0. 
16. Females who are p regnant or breastfeeding or  plan  to become pregnant or breastfeed at any time 
during the study . 
6.2 Patient Enrollment  
A sufficient number of patients who fulfil the inclusion /exclusion criteria documented in Section 6.1 
will be screened to ensure approximately 75  patients are enrolled and treated in this study.    
6.3 Patient  Withdrawal  
In accordance with the Declaration of Helsinki, Good Clinical Practice (GCP), and International 
Conference on Harmonization (ICH) Guidelines and applicable regulations governing human subject 
protection, a subject has the right to withdraw from  the study at any time for any reason.  Subjects 
may also be removed from the study by [CONTACT_343884].   The reason for withdrawal, if given, will be provided to the Sponsor  and documented i n the eCRF .  Patients will be requested to 
return for  follow- up beginning with an End of Treatment visit as per  Section  9.6.1. 
The Sponsor or Investigator may remove p atients from the study for various  reasons, including:  
• Taking another investigational medicinal agent during their involvement in the study  
• Major violation of, or deviation from, study protocol procedures which, in the judgment of the 
Medical Mon itor, could adversely affect the patient or the integrity of the study including missing 
an extended duration of IMG -7289 doses or other evidence  of major non -compliance;  
• Withdrawal from the study is, in the Investigator’s judgment, in the patient’s best interest;  
• Experiencing a Dose Limiting Toxicity (DLT), as per S ection  8.2.2. For Italy ONLY, Exclusion 13 reads:  Active infection with hepatitis B virus (positive hepatitis B 
surface antigen ; note:  positive hepatitis B surface antibody and positive hepatitis B core 
antibody are not exclusionary provided disease is not active, which should be clearly 
documented in the patient’s medical history) or C virus (patients with positive hepatitis C antibody result would require confirmation of active disease with a positive hepatitis C 
polymerase chain reaction (PCR) test), seropositivity for human immunodeficiency virus (HIV).  
 
Imago BioSciences,  Inc.  Protocol IMG -7289- CTP -102  
IMG- 7289    23Jun 2020  
Page 40 of 97 6.4 Replacement of D ropouts  
A minimum of patients are required to  complete the entirety of the Initial Tre atment Period  
(including MRI/CT ).  Non-completers  may or may not be replaced as determined by [CONTACT_6802] /SAB. 
6.[ADDRESS_469155] the Medical Monitor with 
questions  or with planned/known divergences from these guidelines . 
1. In general, supportive care (transfusions, administration of anti -fungals, etc.) should be 
maintained in accord ance with institutional policy.   Additionally: 
a. It is advised that patients with a platelet count ≤ 10 x 109/L (10 k /µL) be transfused.  
2. Hydroxyurea may be used during the study in case of proliferation as follows:  
a. At the PI’s discretion, initiate hydroxyurea treatment for white cell count ≥ 30 x 109/L 
(30,000/µL) and majority of cells appear to be immature cells (myelocytes/  promyelocytes)  
b. Discontinue hydroxyurea treatment when white cell count is < 10 x 109/L (10,000/µL)  
3. Patients taking medication s that have the potential to induce or inhibit CYP 3A4 or CYP 2D6 should 
be monitored closely for potential effects of co -administration; particular attention should be 
given to anti -infectives in the azole class.  
4. Cessation of IMG -7289 is invariably associat ed with a  rebound in thrombopoiesis and the platelet 
count can easily exceed the baseline value in any given patient.   When IMG -7289 is discontinued, 
the platelet count should be monitored closely and the timing of the start of an alternative 
therapy shou ld take this into account.  
6.6 Prohibited Medications  
Please consult the Medical Monitor with any questions pertaining to prohibited medications.  
1. All cytotoxic agents, with the exception of hydroxyurea  
2. All h aematopoietic growth factors : romiplostim, eltrombopag, granulocyte  and granulocyte -
macrophage colony stimulating factor ( G-CSF and GM -CSF) and erythropoietin (EPO)  
3. Prednisone and prednisolone  > 10 mg/day (noted exception : use of corticosteroids for 
management of gout  is allowed)  and dexamethasone > 4 mg/day .  Maintenance supplemental 
corticosteroid therapy such as prednisone ≤ 10 mg/day or corticosteroid equivalent is allowed.  
4. Monoamine oxidase A and B inhibitors  
5. Anticoagulant and nonsteroidal anti- inflammatory drug (NSAID; includin g aspi[INVESTIGATOR_248]) use are 
prohibited in patients when their platelet count is < 50 x 109/L (50  k/µL)  
6.7 Patients Who Terminate Early or Discontinue Study Medication  
All patients who terminate the study early, or who discontinue IMG- 7289 will be requested to return 
for follow -up visits, beginning with an End of Treatment visit  as detailed in Section 9.6.1 .  If a patient 
refuses to enter follow -up, then an Early Termination visit should be performed as detailed in Section Note:   In [LOCATION_013], use of computerised tomography (CT) is not permitted for patients unable to 
undergo magnetic resonance imaging (MRI).  Only MRI is permitted for study purposes.  
CCI
Imago BioSciences,  Inc.  Protocol IMG -7289- CTP -102  
IMG- 7289    23Jun 2020  
Page 41 of 97 9.6.3.  Patients who discontinue IMG- 7289 due to a DLT will be asked to undergo the  EoT, Pre -EoS 
and EoS visits . 
6.8 Treatment Failure  
MF patients not deriving  clinical benefit  (defined as not meeting progressive disease criteria as per 
Section 16.7 and safely tolerating IMG -7289), or who achiev e complete response (CR), partial 
response (PR) or clinical improvement (CI) and subsequently relapse (Section 16.7), the equivalent 
of treatment failures, will discontinue IMG -[ADDRESS_469156] is IMG -7289,   
 
 
  Details  on capsules, including strengths , colours  and 
size s, can be found  in the Pharmacy Manual.   
The capsules will be manufactured in accordance with Annex  13 and principles of cGMP at:  
Xcelience  LLC 
[ADDRESS_469157]  
Tampa, FL [ZIP_CODE]  [LOCATION_003]   
 
Changes to  this section will be included via  updates to the Pharmacy Manual and notification to sites, 
as appropriate .   
7.1.2  Packaging and Labeling  
IMG- 7289 will be supplied to the site  pharmacy department by [CONTACT_374760] (or designee) in 
bottles containing capsules in accordance with all applicable regulatory requirements.  
Labels will also be in accordance with all applicable regulatory requirements for the labeling of active 
pharmaceutical ingredients and with Annex  13 of GMP.  Labels  will contain the drug name, protocol 
number, lot number, expi[INVESTIGATOR_11313], storage conditions , name [CONTACT_374805] a caution that the 
drug is for clinical trials use only.  
7.1.3  Storage  
The recommended long -term storage conditions for IMG- 7289 is for the storage temperature not to 
exceed 25 °C. IMG -[ADDRESS_469158] maintenance  
(Section 14.5) .  The Investigator must provide a prescription form every time drug is dispensed , 
including (but not limited to) the identification of the patient to whom drug is to be dispensed, the 
patient’s weight, the requested dose in mg and the Investigator (or designee’s) signature.   
7.2.[ADDRESS_469159] ration of  IMG- 7289 on any day that it is taken in the clinic.   
With the exception of ITP  Day 0, it is not required that IMG- 7289  be taken in the clinic; this wil l be 
determined based on the patient’s regular daily dosing time.  When applicable, the date and time of 
each administration in the clinic will be recorded in the source notes.  
IMG- 7289 dosing will be based on the patient’s ITP  Day 0 weight.  If during the  study the patient’s 
weight differs from ITP Day 0  by [CONTACT_726] 10%, the amount of IMG -7289 dispensed should be 
corrected per the dose chart provided.  I n cases where using the ITP Day 0 weight  is impractical for 
dispensing, a weight taken as close to ITP Day 0 as possible (e.g., Screening /Baseline) may be used ; 
weight at a current visit may also occasionally need to be used.  T he source data must  clear ly 
document the  weight used . 
Patients shoul d be instructed to:  
• Take their IMG -7289 once daily,  
• Swallow their IMG -7289 capsules whole, with a glass of water  
• Take IMG -7289 o n an empty stomach (f ast for 1 hour prior to and 30 minutes  after dose)    
Patients may have clear liquids prior to their dose, and following study drug administration . 
7.2.3  Dosage:  Initial Treatment Period  
In the ITP , all patients will be treated daily, for 169  days .  Dosi ng will begin on Day 0 at a starting dose 
of IMG- 7289 free base contingent on the protocol version the patient enrolled under.  Details on the 
selection of and rationale for the starting dose and dosing schedule can be found in Section 3.6 . 
Through the use of dose titration, all patients will be dosed to the IMG- 7289 Dpi; the dose needed to 
safely inhibit normal h aematopoiesis for a fraction  of the dosing cycle .  At every visit , a haematology  
assessment  will be performed for use in associatio n with  the Titration and Re -challenge Rules which 
are based on an evaluation of platelet, absolute neutrophil (ANC) and haem oglobin  (Hgb) counts  in 
comp arison with results from the prior visit .  Please refer to Section [IP_ADDRESS]  for patients currently 
being treated under Amendment 5 , and Section [IP_ADDRESS]  for Amendment 6 details. 
CCI
Imago BioSciences,  Inc.  Protocol IMG -7289- CTP -102  
IMG- 7289    23Jun 2020  
Page 43 of 97 The D pi [INVESTIGATOR_374699] ≤2 mg/kg QD; however, this is not the upper limit for titration purposes 
as the dose needed to achieve a therapeutic effect will vary among patients and may change over 
time.  The platelet titration target expected to be associated wi th a clinically significant therapeutic 
effect is:   
• A platelet count of ≥ 5 0 to ≤ 75  k/µL (5 0-75 x 109/L)  
Please consult the medical monitor regarding d ose modifications of IMG -7289 should an adverse 
event (AE) requiring a dose reduction occur, and  also for the management of clinically significant 
changes in platelets, neutrophil counts, or other haematologic parameters.  
CCI
Imago BioSciences,  Inc.  Protocol IMG -7289- CTP -102  
IMG- 7289    23Jun 2020  
Page 44 of 97 
CCI
 
Page 45 of 9
7 purposes and to 
enable re-challenge to commence as soon as counts re turn to the required level, if safe to do so. 
CCI
CCI
CCI
Imago BioSciences,  Inc.  Protocol IMG -7289- CTP -102  
IMG- 7289    23Jun 2020  
Page 46 of 97 7.2.4  Dosage:  Additional Treatment Period  
For all patients  entering a new Additional Treatment Period , dose titration will be  per the Titration 
Rules in Table 3.  Additional dose -titration may occur in consultation with the Medical Monitor.    
7.2.5  Missed Doses  
Patients who do not take their IMG -7289 dose at the usual required time should take it immediately 
upon noting that it was not taken; the patient should not take the dose more than 12 hours after the 
usual dosing time.  If a patient misses a dose, they should not take two doses the following day, but should notify their study coordinator and continue with their normal daily dose the following day.  
For a dosing hiatus due to an SAE, please consult the Medical Monitor for guidance on re -start of 
dosing.   Patients who miss an extended duration of IMG -7289 doses or exhibit  serial non -
compliance with treat ment may be removed from the study at the discretion of the S ponsor.  
7.2.6  Interruption of Dosing  
Patients requiring a Dose Hold according to the Titration and Rechallenge Rules, or due to an (S)AE, 
should be monitored at least weekly for safety purposes and to enable re- challenge to commence as 
soon as counts return to the required level, if it safe  to do so. During these visits, patients are 
required to undergo complete b lood counts only.  
8 DATA SAFETY MONITORING COMMITTEE (DSMC) /SAFETY  ADVISORY 
BOARD (SAB) REVIEWS AND MANAGEMENT OF STUDY TOXICITIES , 
INCLUDING STOPPI[INVESTIGATOR_16442]  
8.1 Data Safety Monitoring Committee (DSMC) /Safety Advi sory Board  Reviews  
Safety will be monitored throug hout the study in accordance with a Data Safety Monitoring Plan 
(DSMP) /Safety Advisory Board Plan (SABP)  by a DSMC /SAB constituted by , at a minimum:  the Imago 
BioSciences Principal Medical Monitor, the Coordinating/ Lead Principal Investigator [INVESTIGATOR_374700] , an AML clinical trials specialist  with extensive clinical experience .  The 
DSMC /SAB will provid e recommendations regarding the conduct of the study and guidance to 
Investigators to ensure the safety and well- being of all participating patients.  To do so, t he 
DSMC /SAB will perform review s at least quarterly of safety parameters  and pharmacody namic 
markers, to draw conclusions around the safety and pharmacodynamic effect of IMG -7289.  DSMC 
responsibilities will remain in effect until the study has ended.  
The DSMC /SAB will also review patient dose titrations and may recommend adjustments .  At th e 
original D s, data from the first  sentinel patient  was  reviewed by [CONTACT_6802] /SAB  prior to dosing the 
next sentinel patient.  The DSMC /SAB convene d within [ADDRESS_469160] -completion of 7 days of treatment 
for each of the sentinel patients at the original D s and determined it was  safe for:  
1. Each sentinel patient to continue dosing , and  
2. Additional patients to begin treatment with IMG -7289.   
Additionally, the DSMC /SAB  convened post -completion o f 7 days of treatment of the required three 
patients at the new D s and determined : 
1. The safety of the new D s, and  
2. The ITP Day 3 (mid- week) visit could be re moved  from the visit schedule.  
Imago BioSciences,  Inc.  Protocol IMG -7289- CTP -102  
IMG- 7289    23Jun 2020  
Page 47 of 97 8.2 Management of Study Toxicities  
Adverse event intensity will be evaluated using the National Cancer Institute (NCI) Common 
Terminology Criteria for Adverse Events (CTCAE) version 4.[ADDRESS_469161] available edition of the 
Investigator’s Brochure.   
8.2.1  Haematologic Toxicity  
Haematologic values outside of the normal reference range are inherent features of MPNs , and are 
expected effects  of many therapeutic attempt s to manage these diseases.   
Both genetic knockdown (KD) of LSD1 mRNA and pharmacologic inhibition of LSD1 show that the 
loss of LSD1 activity arrests the production of mature red cells, platelets and granulocytes while over -
producing monocytes (Sprussel  et al. , 2012; Kerenyi  et al. , 2013 ).  Production of cells of lymphoid 
lineage, B and T cells is unimpaired indicating that LSD1 has very cell -specific functions and its 
inhibition also has very specific effects.  LSD1 inhibition in malignant myeloid cells causes the induction of monocytic differentiation markers, as well as a reduction of self -renewal potential of 
neoplastic cells, all of which eventually result in apoptosis of treated cells.  Thus, the an aemia, 
thrombocytopenia, neutropenia and monocytosis attending LSD1 inhibition, as observed in animals treated with IMG -7289, reflect primary pharmacodynamic effects.  The kinetics of an aemia, 
thrombocytopenia, and neutropenia following complete LSD1 inhibition are a function of the lifespan  
of the individually affected cell types.  Over the course of LSD1 inhibition, platelet and neutrophil counts are the most affected, reflecting their short me an lifespan s of approximately seven  and twelve 
days , respectively .  Recovery of peripheral counts is reversible, rapid, and temporarily overshoots 
baseline haematologic values.  At lower doses, the effects on ha ematopoiesis are much less 
pronounced suggest ing that a modicum of residual LSD1 activity is sufficient to support blood cell 
formation.  Thus, both the duration of LSD1 inhibition as well as the degree of inhibition are critical to the pharmacodynamic effects on myeloid lineages.  
The intended dosing  plan for MF patients is predicated on the observation that inhibition of LSD1 has 
a therapeutic effect when LSD1 is inhibited for a fraction of the [ADDRESS_469162] practices in the routine 
management of  malignant myeloid diseases.  
Imago BioSciences,  Inc.  Protocol IMG -7289- CTP -102  
IMG- 7289    23Jun 2020  
Page 48 of 97 The effects of IMG -7289 on normal myeloid haematopoiesis observed in non- clinical and clinical 
studies are expected  in humans;  thes e are pharmacodynamic effect s of LSD1 inhibition by [CONTACT_374734] -7289, 
thus  not regarded as adverse .  These events, with the exceptions  below,  will not be considered DLTs.   
8.2.[ADDRESS_469163]
oppi[INVESTIGATOR_374701]- 7289 will be discontinued in the event of the following: 
• Post DLT, the Medical Monitor and Principal Investigator [INVESTIGATOR_374684] -7289.  
• Post dose reduction due to DLT, the patient fails to demonstrate significant improvement within 21 days.  
• Post temporary interruption of IMG -7289 due to platelet counts below 25 x 10
9/L (25 k /µL) , the 
patient's platelet cou nts don’t return to > 5 0 x 109/L (5 0 k/µL)  within 21 days.  
Patients who discontinue IMG -7289 will enter follow -up assessments beginning with E oT visit.  
CCI
CCI
 9 STUDY ASSESSMENTS   
This section provides comprehensive detail on the visits and assessments required;  this section 
should serve as the main guidance for use during study visits .  The Schedule of Assessments (Section 
16.1) contains these details in schematic form, and is provided for use in a support ive/ reference  
capacity only .  In an effort to maintain clarity while facilitating a modicum of brevity, the ‘ Terms’ in  
Table 4 below  will be utilized in this section  to encompass the broader ‘ Protocol Meaning’ as stated.  
Table 4:  List of Protocol Terms and Meanings  
 Term  Protocol Meaning  
Limited  Physical Exam, 
including Vital Signs  • Spleen measurement - The edge of the spleen shall be 
determined by [CONTACT_23302], measured in centimeters, using a soft 
ruler /tape , from the costal margin to the point of greatest 
splenic protrusion.  The spleen should be measured in the same 
manner at all visits. 
• Vital signs , after patient has s at semi -supi[INVESTIGATOR_2525] ~3 minutes, of:  
o Heart rate  
o Respi[INVESTIGATOR_697]  
o Temperature  
o Systo lic/diastolic blood pressure  
• Weight , measured (in kg)  
• Review of body systems for changes from previous visit  
Full Local Lab Assessment  Assessment consisting of the following test  panels  to be performed 
locally  (see Section 10.1.1  for specifi c analytes required) : 
• Haematology with manual differential  
• Coagulation  
• Biochemistry  
• Urine or serum pregnancy test for women of child bearing 
poten tial ( WOCBP); results to be reviewed prior to dosing , if 
applicable  
Collect  MPN -SAF  TSS 
 MPN- SAF TSS is to be completed by [CONTACT_374761].  The [ADDRESS_469164] dose (Days - 6 
to pre -dose Day 0) during Baseline.  The 7 -DAY RECALL tool  will be 
completed weekly from Day 7 through the EoS Visit.  Ideally, the 7-DAY RECALL version will be completed on the same tim e and day 
each week for consistency.  On visit days, the MPN -SAF TSS  should 
be completed prior to the  study visit, and if the patient arrives 
without a completed MPN -SAF  TSS, then it will  be completed during 
the visit and collected  prior to the patient de parting.   Importantly, 
multiple MPN- SAF TSS forms will need to be provided to the patient 
for completion between visits as visit frequency decreases to less 
than weekly.   Date of completion should be documented on each  
MPN -SAF  TSS completed .  
CCI
CCI
Imago BioSciences,  Inc.  Protocol IMG -7289- CTP -102  
IMG- 7289    23Jun 2020  
Page 50 of 97  Term  Protocol Meaning  
Bone Marrow Sampling  • Aspi[INVESTIGATOR_337] (sample taken  from first pull, whenever possible, and 
no later than the second) and biopsy collected as per site 
standard procedure.   
• A central laborato ry will perform morphology review , 
myelofibrosis grading  and genomic analysis (See Section 10.1.2 ).   
• Note:   Any results available from site routine work -up, including 
morphology, cytogenetics, other genetic interrogations will be 
collected for study purposes either via the eCRF or through 
collection of local reports . 
Dosing Instructions  • Instruct patients to refer to their Dosing Card every da y, for 
details on IMG- 7289 dosing and what to do if a dose is missed  
• Take their IMG -7289 in accordance with Section 7.2.2  
• Handle any missed IMG -7289 doses as per Section 7.2.5  
• Bring all medication to every clinic visit, including empty bottles  
Administer  
IMG -[ADDRESS_469165] time of 
dosing . 
Adverse Events and Concomitant Medications  Use non -directive questions (i.e., “How are you feeling”)  to query 
patient re: any AEs that may have occurred .  Also , inquire about  
medication changes  since the last visit . 
 Note:  If at any time additional clinical evaluation outside of the visit schedule is deemed necessary 
by [CONTACT_737], then unscheduled visits should  occur  as appropriate. 
9.[ADDRESS_469166] provide written informed consent before undergoing any study -related procedures.  
The Principal Investigator  (PI) , or designee, will explain to the patient the aims of the study, the 
risks and benefits involved and that their participation is voluntary.  Each patient will acknowledge 
receipt of this information and that they wish to participate  in the study by [CONTACT_374762] e of the PI , or designee, who will also sign 
and date the Participant Information Sheet/  Consent Form  (PI[CONTACT_306741]) . Time, date, name [CONTACT_374806] [CONTACT_374763].  
9.2 Screening Period , Including Baseline  and Enrollment  
The Screening period  is comprised by [CONTACT_374764] ; in this circumstance, the visit must be completed  within 21 days before Day 0.   If the patient 
screen fails, document the reason( s) in the source data and on the Screening & Enrollment log.  
Adverse events (AEs)  will be assessed at every visit.  E vents occurring p re-first IMG -7289 dose will 
be recorded as Medical History; those occurring post first IMG -7289 dose through the EoS visit  will 
be recorded as AEs .   
Note:   In the [LOCATION_006], serious AEs (SAEs) will be recorded from time of consent through the EoS or 
until the Investigator and Imago BioSciences determine that follow -up is no longer necessary.  
Imago BioSciences,  Inc.  Protocol IMG -7289- CTP -102  
IMG- 7289    23Jun 2020  
Page 51 of 97 9.2.1  Screening (Days -28 to Day -1) 
• Review of all I nclusion and E xclusion Criteria 
• Complete medical /medication  history including:  
o 2016 WHO criteria for PMF  (Section 16.2), or IWG -MRT recommended criteria for  
PPV -MF (Section 16.3) or PET -MF (Section 16.4) .  
o Risk determination, using the IWG prognostic factors  
o Calculate ECOG performa nce status  (Section 16.6) 
o History of all treatments  for their current disease (including clinical course with 
ruxolitinib and/or other MF therapy) or any previous oncologic conditions ; including 
chemical, surgical and/or radiotherapeutic  
o All concomitant medication, in addition to any used in the 15  days prior to Screening  
o Transfusion history, including:  each RBC transfusion  received with approximate volume 
and total units  transfused over the 6 month period  prior to Screening  
Note:   while on -study, any blood product transfusion  received (RBC, platelets , etc.), with 
approximate volumes, and total units transfused will also be documented.  
• Full PE, including Vital Signs  – review of all body systems as indicated by [CONTACT_23804]/symptoms  
• Height (without shoes)  
• Full Local Laboratory Assessment  
• Urinalysis  
Note :  If Screening/Baseline are not  occurring on the same day, then please refer to Section 9.2.2 .  If 
Screening/Baseline are occurring on the same day, then the following are required at Screening:  
• Germline sample (s) for Central Laboratory genomic analysis  
• Blood sample s for Central L aboratory genomic analysis * 
• Bone Marrow Sampling*  
• Schedule MRI or CT (if patient is not a candidate for MRI) for pre -dose Day 0 ± 2 days  
• Provide patient with multiple copi[INVESTIGATOR_374702] -SAF TSS 24-HOUR RECALL  tool and instruct 
patient to complete the questionnaire daily for 7 consecutive days beginning on Day - 6 and 
ending pre -dose Day 0.    
*If possible, bone marrow and blood sampling for genomic analysis should be performed on the same day.  
9.2.2  Baseline Period (Days -21 to Day - 1) and Enrollment  
If Screening and Baseline visits are conducted  on separate days, then the following are required at 
the Baseline visit :  
• Limited PE, including vital signs  
• Full Local Laboratory Assessment  
• Urinalysis Note:   In Italy, HIV, HBsAg , HBsAb, HBcAb  and HCV testing  must also be performed.  
Imago BioSciences,  Inc.  Protocol IMG -7289- CTP -102  
IMG- 7289    23Jun 2020  
Page 52 of 97 • Germline sample(s) for Central Laboratory genomic analysis  
• Blood sample s for Central L aboratory genomic analysis* 
• Provide patient with multiple copi[INVESTIGATOR_374702] -SAF TSS 24-HOUR RECALL  tool and instruct 
patient to complete the questionnaire daily for 7 consecutive days  beginning on Day -6 and 
ending pre -dose  Day 0  
• Bone Marrow Sampling*  
• Schedule MRI or CT (if patient is not a candidate for M RI) for pre -dose Day 0 (± 2 days)  
*If possible, bone marrow and blood sampling for genomic analysis should be performed on the same day.  
9.2.3  Enrollment  
For eligibility purposes, the following should be reviewed and/or confirmed:  
• History of recent surgical procedures  
• Recent use of investigational drugs  
• Laboratory results , including historical laboratory values, will be assessed by [CONTACT_79929] (PI) before enrol lment.  Any deviation in laboratory values that are confirmed on  
re-examination to be clinically significant by [CONTACT_978] [INVESTIGATOR_374703]. 
Once Screening/B aseline procedures have been performed and  it is confirmed that  the patient can 
be enrolled, p atients will be enrolled in accordance with  procedures detailed in  the Study Reference 
Manual.    
If the patient screen fails during this time , document the reason( s) in the patient’s source data and 
on the Screening & Enrollment log.  
9.2.[ADDRESS_469167] Day of Screening Period (Day - 1)  
On Day - [ADDRESS_469168]  the patient and remind the m to: 
• Report to the clinic the following day  at the ag reed time  
• Not eat for at least 1 hour prior to dosing as  IMG- 7289 is to be taken on an empty stomach  
9.3 Initial Treatment Period (ITP)  
Procedures are presented below for each visit by [CONTACT_374765]- dose, at dosing, and 
post -dose (as applicable).  
9.3.1  ITP Day 0 – Treatment  Start     
[IP_ADDRESS]  ITP Pre-Dose Day 0 
• Update medical/medication  history with any changes  since Screening  
• Limited PE, including Vital Signs  Note:   In [LOCATION_013], use of computerised tomography (CT) is not permitted for patients unable to 
undergo magnetic resonance imaging (MRI).  Only MRI is permitted for study purposes.  
Imago BioSciences,  Inc.  Protocol IMG -7289- CTP -102  
IMG- 7289    23Jun 2020  
Page 53 of 97 • Collect the completed copi[INVESTIGATOR_374702] -SAF  TSS, and provide patient with the MPN -SAF TSS  
7-DAY RECALL  tool  for completion prior to arriving for, or at their Day 7 visit  
• Full Local Laboratory Assessment  
• Urinalysis 
• Perform abdominal MRI (or CT if the patient is not a candidate for MRI)  within a ±2 day window  
• Dispense doses sufficient until  the next visit  and provide Dosing Instructions  
• Ensure patient continues to meet eligibility criteria  prior to dosing  
[IP_ADDRESS]  ITP Dosing Day 0  
• Administer Study Drug  
[IP_ADDRESS]  ITP Post -Dos e Day 0  
• Patients should remain in clinic for at least [ADDRESS_469169] dose   
• Query for Adverse Events , using non -directive questions (i.e., “How are you feeling”)   
• Schedule  Day 7 clinic visit  
9.3.2  ITP Weekly Visits - Days 7, 14, 21, 28, 35, 42, 49 and  56 (± 2 days)  
• Limited PE , including Vital Signs  
• Adverse Events and C oncomitant Medication s 
• Collect MPN -SAF  TSS and provide the MPN -SAF TSS 7-DAY RECALL  tool to patient for completion 
prior to arriving for, or at the next visit  
• Pre-dose: Perform haematology assess ment  and determine if dose titration is required  in 
accordance with:  
o Amendment  6 patients:   Refer to Section [IP_ADDRESS] , and utilize:  
 Table 2 for Days 7, 14 and 21  
 Table [ADDRESS_469170]    
o Continuing Am endment  5* patients:  Refer to Section [IP_ADDRESS], and utilize:  
 Table 1 
• Pre-dose : Perform drug accountability  and collect study medication   
• Dispense doses sufficient until  the next visit  and provide Dosing Instructions  
• Schedule next clinic visit  
*Amendm ent [ADDRESS_469171] complete the Initial Treatment Period and transition to Amendment 6 titration 
and re -challenge rules upon commencing the Additional Treatment Period.  Note:   In [LOCATION_013], use of computerised tomography (CT) is not permitted for patients unable to  
undergo magnetic resonance imaging (MRI).  Only MRI is permitted for study purposes.  
CCI
Imago BioSciences,  Inc.  Protocol IMG -7289- CTP -102  
IMG- 7289    23Jun 2020  
Page 54 of 97 [IP_ADDRESS]  ITP Days 7, 21, 35, 42 and 49 only  
• Pre-dose : Blood sample for haematology  
[IP_ADDRESS]  ITP Day  14 only  
• Pre-dose : Blood sample for haematology  
• Pre-dose : Blood sample for Central Laboratory c ytokine analysis  
[IP_ADDRESS]  ITP Day 28 only  
• Pre-dose : Full Local Laboratory Assessment  
• Pre-dose : Blood sample for Central Laboratory c ytokine analysis  
[IP_ADDRESS]  ITP Day 56 only  
• Pre-dose :  Full Local Laboratory Assessment  
• Provide extra cop ies of the MPN -SAF TSS 7-DAY RECALL  tool to patient sufficient until the next 
visit ( for completion during the ‘off’ week , Day 6 3 and prior to arriving for, or at the Day 70 visit ) 
9.3.3  ITP Bi-Weekly Visits  - Day s 70, 84 , 98 and 112  (± 2 day s) 
Note:   It is anticipated that by [CONTACT_10585] [ADDRESS_469172] achieved a stable dose, with weekly visits  
no longer necessary.  For the exceptional patient whose dose has not stabilized, weekly visits may 
continue at the PI’s discretion.   For such patients, the following is required at each weekly visit:  
• Pre-dose : Blood sample for haematology  
• Pre-dose: Perform haematology assessment and determine if dose titration is required in 
accordance with:  
o Amendment 6  patients:   Refer to Section [IP_ADDRESS] , and utilize:  
 Table 3    
o Continuing Amendment 5* patients:  Refer to Section [IP_ADDRESS], and utilize:  
 Table 1 
All other patients will undergo the following at bi -weekly visits:  
• Limited PE, including Vital Signs  
• Adverse Events and C oncomitant Medication s 
• Collect MPN -SAF  TSS and provide extra copi[INVESTIGATOR_374702] -SAF TSS 7- DAY RECALL  tool to patient 
sufficient until the next visit ( for completion during each ‘off’ week , i.e., Days 7 7, 91 and 105 and 
prior to arriving for, or at the next visit ) 
• Pre-dose : Perform haematology assess ment  and determine if dose titration is required  in 
accordance with:  
o Amendment 6 patients:   Refer to Section [IP_ADDRESS] , and utilize:  
 Table 3 
o Continuing Amendment 5* patients:  Refer to Section [IP_ADDRESS], and utilize:  
 Table 1 
Imago BioSciences,  Inc.  Protocol IMG -7289- CTP -102  
IMG- 7289    23Jun 2020  
Page 55 of 97 • Perform drug accountability  and collect study medication  
• Dispense doses sufficient until  the next visit  and provide Dosing Instructions  
• Schedule next clinic visit  
*Amendment [ADDRESS_469173] complete the Initial Treatment Period and transition to Amendment 6 titration 
and re -challenge rules upon commencing the Additional Treatment Period.  
[IP_ADDRESS]  ITP Day s 70 and 98 only  
• Pre-dose : Blood sample for haematology  
[IP_ADDRESS]  ITP Day 84  only  
• Pre-dose : Full Local Laboratory Assessment  
• Pre-dose : Urinalysis  
• Pre-dose : Blood sample for Central Laboratory genomics  (all sites) , cytokine  (all sites) , HbF and 
%F cell  (US sites only) analysis   
• Perform abdominal MRI (or CT if patient is not a candidate for MRI (±7 days))  
[IP_ADDRESS]  ITP Day 112 only  
• Pre-dose : Full Local Laboratory Assessment  
• Provide extra copi[INVESTIGATOR_374702] -SAF TSS 7-DAY RECALL  tool to patient sufficient until the ne xt 
visit ( for completion during each  ‘off’ week , i.e., Days 1 19, 126 and 13 3 and prior to arriving for, 
or at the next visit).  
9.3.4  ITP Monthly Visits  - Days 140 and 168 (± 3 days)  
Note:   It is anticipated that by [CONTACT_10585] [ADDRESS_469174] achieved a stable dose, with bi -weekly 
visits no longer necessary.  For the exceptional patient  whose dose has not stabilized, bi -weekly visits 
may continue at the PI’s discretion.   For such patients, the following is required at each  
bi-weekly visit:  
• Pre-dose : Blood sample for haematology  
• Pre-dose : Perform haematology assessment and determine if d ose titration is required  in 
accordance with:  
o Amendment 6 patients:   Refer to Section [IP_ADDRESS] , and utilize:  
 Table 3  
o Continuing Amendment 5* patients:  Refer to Section [IP_ADDRESS], and utilize:  
 Table 1  Note:   In [LOCATION_013], use of computerised tomography (CT) is not permitted for patients unable to 
undergo magnetic resonance imaging (MRI).  Only MRI is permitted for study purposes.  
Imago BioSciences,  Inc.  Protocol IMG -7289- CTP -102  
IMG- 7289    23Jun 2020  
Page 56 of 97 All other patients will undergo the following at monthly visits:  
• Limited PE, including Vital Signs  
• Adverse Events and Concomitant Medications  
• Collect MPN -SAF  TSS and provide extra copi[INVESTIGATOR_374702] -SAF TSS 7- DAY RECALL  tool to patient 
sufficient until the next visit ( for completion during e ach “off” week , i.e., Days 147, 154 and 161  
and prior to arriving for, or at the next visit)   
• Pre-dose : Full Local Laboratory Assessment  
• Pre-dose : Perform haematology  assessment and determine if dose titration is required  
(necessary at Day 168 only if patient is continuing to ATP)  in accordance with:  
o Amendment 6 patients:   Refer to Section [IP_ADDRESS] , and utilize:  
 Table 3  
o Continuing Amendment 5* patients:  Refer to Section [IP_ADDRESS], and utilize:  
 Table 1  
• Perform drug accountability  and collect study medication  
• Dispense doses sufficient until the next visit  and provide Dosing Instructions (necessary at Day 
168 only if patient is continuing to ATP)  
• Schedule next clinic visit  
*Amendment [ADDRESS_469175] complete the Initial Treatment Period and transition to Amendment 6 titration 
and re -challenge rules upon commenci ng the Additional Treatment Period.  
[IP_ADDRESS]  ITP Day 140 only  
• Provide extra copi[INVESTIGATOR_374702] -SAF TSS 7-DAY RECALL  tool to patient to patient sufficient until 
the next visit (for completion during each  ‘off’ week , i.e., Days 147, 15 4 and 161 and prior to 
arriving for, or at the next visit)  
• Qualification:   Assess whether the patient is eligible for the ATP .  If it is determined that the 
patient is deriving clinical benefit  (defined as not meeting progressive disease criteria as per 
Section 16.7 and safely tolerating IMG -7289), then the patient qualifies for and may enter the ATP 
upon completion of the Day 168 visit .  This qualification assessment is initiated at Day  140 for 
logistical purposes and may be reversed at the Day 168 visit in consideration of patient status at 
the time.  
[IP_ADDRESS]  ITP Day 168 only  
• Urinalysis 
• Pre-dose:  Blood sample for Central Laboratory genomics  (all sites) , cytokine  (all sites) , HbF and 
%F cell ( US sites only) analysis  
• Perform abdominal MRI (or CT if patient is not a candidate for MRI (±7 days))  
Note:   In [LOCATION_013], use of computerised tomography (CT) is not permitted for patients unable to 
undergo magnetic resonance imaging (MRI).  Only MRI is permitted for study purposes.  
Imago BioSciences,  Inc.  Protocol IMG -7289- CTP -102  
IMG- 7289    23Jun 2020  
Page 57 of 97 • Bone Marrow Sampling ( ±7 days to ensure  availability of results for qualification assessment  if 
required by [CONTACT_737] ) 
• Qualification:   Confirm applicability of earlier determination regarding patient eligibility for 
continued treatment in the ATP, contingent on whether the patient is deriving clinical benefit.  If 
the patient is entering the ATP , please proceed to Section 9.4  below.  If the patient is not entering 
the Additional Treatment Period , please proceed to Section 9.6  below.  
9.4 Additional Treatment Period (ATP)  
Those  patients deriving clinical benefit  (defined as not meeting progressive disease criteria as per 
Section 16.7 and safely tolerating IMG -7289; this definition applies throughout the document and 
will not be repeated with each reference to clinical benefit)  that enter the Additional Treatment 
Period will ‘re- start’ IMG- 7289.  For the purposes of clarity and efficiency, rather than continuing to 
present chronological days/weeks, visits are presented as ‘ ATP Day 0’, followed by, ‘ATP Days  28, 56, 
84,’ etc.   
The visits and procedures contained herein may repeat as long as the patient continues to qualify for additional treatment.  Continued treatment in the ATP should occur without interruption in dosing; Day [ADDRESS_469176] re- consented to Amendment 6, please note that 
when commencing their next ATP the Amendment 6 dose titration rules ( Table 3) will be followed; 
until such transition, the Amendment 5 dose titration rules ( Table 1) will be followed .  
Procedures are presented below for each visit by [CONTACT_374765]- dose, at dosing, and 
post -dose (as applicable).  
9.4.1  ATP Day 0 - Treatment ‘Re-start ’ 
[IP_ADDRESS]  Day 0   
All assessments should ideally be performed pre -dose; however, with the exception of the 
haematology blood test and determination of the need for a dose titration, the assessments may be performed post -dose if needed.  
The below assessments do not need to be repeat ed if  performed on the same or calendar day prior.    
• Verify patient meets the criteria for additional treatment  
• Limited PE, including Vital Signs  
• Adverse Events and Concomitant M edication  
• Collect MPN -SAF  TSS and provide extra copi[INVESTIGATOR_374702] -SAF TSS 7- DAY RECALL  tool to patient  
sufficient until the next visit ( for completion during each ‘off’ week , i.e., Days 7, 14 and 21 and 
prior to arriving for, or at the next visit ) 
• Pre-dose : Full Local Laboratory Assessment  
• Urinalysis 
• Pre-dose : Perform haematology assessment and determine if dose  titration is required according 
to Table 3 in Section [IP_ADDRESS]*     
Imago BioSciences,  Inc.  Protocol IMG -7289- CTP -102  
IMG- 7289    23Jun 2020  
Page 58 of 97 • Dispense doses sufficient until the next visit  and provide Dosing Instructions  
• Administer Study Drug, if appropriate, based on patient’s routine dosing time  
• Schedule next  clinic visit  
*Amendment 5  patients starting a new ATP Day 0 after re -consenting to Protocol Am endment  6 will be treated 
under Amendment 6 titration and re -challenge rules . 
9.4.2  ATP Days 28, 56 , 84, 112, 140  and 168  (±4 days)  
Note:   It is anticipated that patients continuing in the ATP will have already achieved a stable dose, 
with bi-weekly visits  no longer necessary.  For the exceptional patient whose dose has not stabilized, 
bi-weekly visits may continue  at the PI’s discretion.  Fo r such patients, the following is required at 
each bi -weekly visit:  
• Pre-dose :  Blood sample for haematology  
• Pre-dose:  Perform haematology assessment and determine if dose titration is required in 
accordance with:  
o Amendment 6 patients:   Refer to Section [IP_ADDRESS] , and utilize:  
 Table 3    
o Continuing Amendment 5* patients:  Refer to Section [IP_ADDRESS], and utilize:  
 Table 1  
 
All other patients will undergo the following at monthly visits.  
• Limited PE, including Vital Signs  
• Adverse Events and C oncomitant Medication s 
• Collect MPN -SAF  TSS and provide extra copi[INVESTIGATOR_374702] -SAF TSS 7- DAY RECALL  tool to patient 
sufficient until the next visit ( for completion during each ‘off’ week , i.e., Days 3 5, 42, 49, etc. and 
prior to arriving for, or at the next visit)  
• Pre-dose : Full Local Laboratory Assessment  
• Pre-dose: Perform haematology assessment  and determine if dose titration is required  
(necessary at Day 168 only if patient is continuing in ATP)  in accordance with:  
o Amendment 6 patients:   Refer to Section [IP_ADDRESS] , and utilize:  
 Table 3    
o Continuing Amendment 5* patients:  Refer to Section [IP_ADDRESS], and utilize:  
 Table 1  
• Perform drug accountability and collect study medication  
• Dispense doses sufficient until the next visit  and provide Dosing Instructions  (necessary at Day 
168 only if patient is co ntinuing in ATP)  
• Schedule next clinic visit  
*Amendment [ADDRESS_469177] complete the Treatment Period they are currently being treated under in 
accordance with the Amendment 5 titration and re -challenge rules and will transition to  the Amendment 6 
rules upon commencing a new Additional Treatment Period.  
Imago BioSciences,  Inc.  Protocol IMG -7289- CTP -102  
IMG- 7289    23Jun 2020  
Page 59 of 97 [IP_ADDRESS]  ATP Day 84 only  
• Urinalysis 
[IP_ADDRESS]  ATP Day 140 only  
• Assess whether the patient continue s to be eligible for the ATP.  If it is determined that the patient 
is deriving clinical benefit (defined as not meeting progressive disease criteria as per Section 16.7  
and safely tolerating IMG -7289), then the pat ient qualifies for and may re -enter the ATP upon 
completion of the Day 168 visit.  This qualification assessment is initiated at Day 140 for logistical 
purposes and may be reversed at the Day 168 visit in consideration of patient status at that time.  
[IP_ADDRESS]  ATP Day 168 only  
• Urinalysis 
• Blood sample for Central Laboratory genomics and cytokine analysis  
• Perform abdominal MRI  (or CT if patient is not a candidate for MRI ( ±7 days )).       
• Bone Marrow Sampling ( ±7 days to ensure  availability of results for qualification assessment  if 
required by [CONTACT_737]) unless performed in the prior 5 weeks  
• Qualification:   Confirm applicability of earlier determination regarding  patient eligibility  for 
continued treatment in the ATP, contingent on whether  the patient is deriving clinical benefit .  If 
the patient is re -entering the ATP, please revert back to Section 9.4 for the ATP visit schedule  and 
associated procedures and assessments; otherwise, please proceed to Section 9.[ADDRESS_469178] 
remission , then a Suspected Relapse visit should be performed with the following assessments:  
• Limited PE, including Vital Signs  
• Adverse Events and C oncomitant Medication s 
• Collect MPN -SAF  TSS 7-DAY RECALL  tool  
• Full Local Laboratory Assessment  
• Urinalysis 
• Blood sample s for Central L aboratory genomic analysis*  
• Perform abdominal MRI or CT (if patient is not a candidate for MRI) within ±7 day s of visit,  
unless performed in the prior 5 weeks  
• Bone Marrow Sampling * (unless performed in the last  21 days or is scheduled in next 7  days)  
*If possible, bone marrow and blood sampling for genomic analysis should be performed on the same day.  Note:   In [LOCATION_013], use of computerised tomography (CT) is not permitted for patients unable to 
undergo magnetic resonan ce imaging (MRI).  Only MRI is permitted for study purposes.  
Note:   In [LOCATION_013], use of computerised tomography (CT) is not permitted for patients unable to 
undergo magnetic resonance imaging (MRI).  Only MRI is permitted for study purposes.  
Imago BioSciences,  Inc.  Protocol IMG -7289- CTP -[ADDRESS_469179] dose  
or as soon as possible thereafter.    
Patients should return to the clinic for the following assessments:  
• Limited PE, including Vital Signs  
• Adverse Events and C oncomitant Medication s 
• Collect MPN -SAF  TSS and provide copi[INVESTIGATOR_1093] 7- DAY RECALL  tool to patient for completion 
each week prior to Pre -EoS Visit  
• Full Local Laboratory Assessment  
• Urinalysis 
• Collect blood sample for Central Laboratory genomics  (all sites) *, cytokine  (all sites),  HbF** and 
%F cell** ( US sites only) analysis  
• Bone Marrow Sampling* (only if not performed in the previous 5 weeks)  
 Perform abdominal MRI or CT (if patient is not a candidate for MRI) within  ±7 days  of visit, 
unless performed in the prior 5 weeks  
• Ensure all study medication has been returned and accounted for  (if applicable)  
• Schedule the pre -End of Study visit [ADDRESS_469180] dose  
*If possibl e, bone marrow and blood sampling for genomic analysis should be performed on the same day.  
**Only required if E nd of  Treatment  occurs during ITP.  
9.6.2  Pre-End of Study  Visit  
The pre -Eos visit sho uld be  conducted  14 days ( ±3 days) post  last dose.  
Patients should return to the clinic for the following assessments:  
• Limited PE, including Vital Signs  
• Adverse Events and C oncomitant Medications  
• Collect MPN -SAF  TSS and provide copi[INVESTIGATOR_374702] -SAF TSS 7-DAY RECALL  tool to patient for 
completion each week prior to EoS visit  
• Full Local Laboratory Assessment   
• Urinalysis 
• Ensure all study medication has been returned and accounted for  (if applicable)  Note:   In Italy, HIV, HBsAg , HBsAb, HBcAb  and HCV testing  must also be performed.  
Note:   In [LOCATION_013], use of computerised tomography (CT) is not permitted for patients unable to 
undergo magnetic resonance imaging (MRI).  Only MRI is permitted for study purposes.  
Imago BioSciences,  Inc.  Protocol IMG -7289- CTP -102  
IMG- 7289    23Jun 2020  
Page 61 of 97 • Schedule the End of Study visit in 14  days’ time  
9.6.3  End of Study /Early Termination  Visit  
Early Termination:  patients  should be seen in clinic as soon as possible after stoppi[INVESTIGATOR_374704] -up period . 
End of Study:  patients should be seen in clinic 28  days (±  2 days) after the last dose of study drug.  
The following assessments are required at End of Study/Early Termination visit : 
• Limited PE, including Vital Signs  
• Adverse Events and C oncomitant Medication s 
• Collect MPN -SAF  TSS 7-DAY RECALL  tool  
• Full Local Laboratory Assessment  
• Urinalysis 
• Blood sample s for Central L aboratory genomic analysis*  
• Ensure all study medication has been returned and accounted for  (if applicable)  
At Early Termination only : 
• Collect blood sample for Central Laboratory cytokine  (all sites) **, HbF** and %F cell** ( US sites 
only) analysis  
• Bone Marrow Sampling* (only if not performed in the previous 5 weeks)  
• Perform abdominal MRI or CT (if patient is not a candidate for MRI) within ±7 days  of visit, 
unless performed in the prior 5 weeks  
*If possible, bone marrow and blood sampling for  genomic analysis should be performed on the same day.  
**Only required if Early Termination occurs during ITP.  
10 LABORATORY SAMPLING FOR SAFETY, PK AND PD ANALYSIS  
Blood, bone marrow and/or  their contents may be retained for future exploratory studies.  
The amount of blood collected from each patient will vary based on collection of drug concentration 
samples contingent on upward dose titrations determined by [CONTACT_374766].  The average of the blood volume s, which var ies by [CONTACT_374767] n, is provided below for each cohort.  
Initial Treatment Period : Approximately  425 -455 mL blood contingent on whether HbF and %F cells  
are to be analyzed, over 32 weeks .  Approximately 4-6 mL of bone marrow aspi[INVESTIGATOR_374705] 2-4 cm 
of trephine bone marrow biopsy will be collected  over ~ 32 weeks .  
Note:  The above blood volume, and bone marrow sampling time -points and volume, includes all 
Screening assessments and each study visit up to and including the E oS visit .  Not include d, how ever, 
are any additional procedures required if a patient qualifies for the Additional Treatment Period .   
See Section 10.[ADDRESS_469181].    Note:   In [LOCATION_013], use of computerised tomography (CT) is not permitted for patients unable to 
undergo magnetic resonance imaging (MRI).  Only MRI is permitted for study purposes.  
Imago BioSciences,  Inc.  Protocol IMG -7289- CTP -102  
IMG- 7289    23Jun 2020  
Page 62 of 97 10.1 Laboratory Measures  
Details on the laboratory assessments performed throughout the study are provided below by 
[CONTACT_374768] (i.e., biochemistry, haematology, etc.).  Details on the specific laboratory 
assessments required at each visit are located in Section [ADDRESS_469182] is required, at a minimum, the following clinical laboratory 
determinations (or their equivalent) will be performed.   Exceptions are noted by [CONTACT_356012] (*) to reflect 
that the particular analyte will only be analysed  if the test is available at the particular institution .   
10.1.1  Local Laboratory Measures  
Biochemistry : C-reactive protein, calculated creatinine clearance* ( by [CONTACT_3158] -Gault method)  
and/ or serum creatin ine*, uric acid, urea * or blood urea nitrogen (BUN) *, albumin, protein, total 
bilirubin, conjugated (direct) bilirubin *, unconjugated (indirect) bilirubin *, gamma 
glutamyltransferase (GGT), alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate transaminase (AST), lactate dehydrogenase (LDH).     
Urine  or Serum  Pregnancy Test : For WOCBP, either a urine or serum pregnancy test  will be utilized  
according to institution standard procedure .   For either method, the result must be confirmed prior 
to next scheduled dose of IMG -7289.   
Urinalysis : Leucocyte  esterase , nitrites, urobilinogen, protein, pH, blood, specific gravity, keton es, 
bilirubin  and glucose.  
Bone marrow  sampling:  At each sample time -point both an aspi[INVESTIGATOR_374706] , 
to be obtained as per site standard procedure. Evaluation will be performed centrally  (see Section 
10.1.2 ); however, any locally available  cytogenetic  or genetic interrogations  performed on samples 
obtained at the same time -point as study samples,  will also be reported in the eCRF  or collected via 
local lab reports .   
Sample Processing : Imago BioSciences will not provide either  a laboratory manual or study supplies 
for the collection and handling of samples to be analysed locally .  Local laboratory  standard 
procedures should be followed at each site.  Note:   In Italy, Additional Tests:   HIV test, HBsAg, HBsAb, HBcAb, HCV are required at Screening 
and End of Treatment.  Test results will not be entered into the clinical database; eligibility 
will be confirmed for patients via the question “ Does the patient satisfy all inclusion and 
exclusion criteria?” on the Inclusion/ Exclusion (IE) eCRF.  Individual inclusion/exclusion 
criteria will be source document verified.  
CCI
Imago BioSciences,  Inc.  Protocol IMG -7289- CTP -102  
IMG- 7289    23Jun 2020  
Page 63 of 97 Blood sample volume: the volume of blood  needed to perform all local lab measurements varies by 
[CONTACT_374769] 15 mL.  
10.1.2  Central Laboratory Measures  
11 SAFETY  
The Investigator is responsible for monitoring the safety of patients enro lled i n this study.   
Once an Investigator determines a patient is a treatment failure (see Section 6.8) or if the patient is 
withdrawn from treatment ea rly due to a Dose Limiting Toxicity , the patient should discontinue 
study treatment and undergo follow up period visits  beginning with E oT (see  Section 9.6.1).   
11.[ADDRESS_469183] IMG -7289 dose.  Female 
patients will be instructed to notify the Investigator immediately if they become  pregnant; male 
patients will be instructed to notify the Investigator immediat ely if they discover that their sexual 
partner is pregnant.  Pregnancy data during the study will be reported in an expedited manner using 
the Pregnancy Report Form and following the SAE reporting process (see Section 11.2.4).  I t will be 
necessary to collect detailed information on the course of any pregnancy occurring in a patient on 
study , including pregnancies in the partners of male patients, ass uming consent to do so is provided .  
If the outcome and/or a complication of the pregnancy meets serious criteria (i.e., miscarriage or congenital anomaly/birth defect), then it should be reported as an SAE using the SAE Report Form.  
Pregnant patients will discontinue study medication for the duration of the pregnancy.  The 
pregnancy will be followed by [CONTACT_374770] (SRM) .   
It is not known  whether IMG -[ADDRESS_469184] effects of prior IMG- 7289 exposure on fetal development are also unknown.     
All patients will be encouraged to discuss contraception and pregnancy concerns with their physician in advance of becoming pregnant.  Full disclosure of a patient’s participation in this study to their general practitioner  is strongly recommended.  
11.[ADDRESS_469185] dose of IMG -7289 through to the End of Study Visit 
(scheduled at [ADDRESS_469186] IMG -7289 dose).  Adverse event recording will continue for patients 
who discontinue study treatment early but remain in follow -up, until their E nd of Treatment, Pre-
End of Study and End of Study Visits  have been completed.  
Note: Any medical event which occurs from the time of Informed Consent but prior to dosing with IMG- [ADDRESS_469187] still be documented in the patient’s medical notes and will be recorded on the 
appropriate medical history e CRF pages.  
Adverse events will be rec orded on designated e CRF pages. Each AE is to be characterised (i .e., 
verbatim term) and information provided regarding its seriousness, start and stop dates, intensity, outcome, and causal relationship with the study drug .  
An AE is any undesirable physic al, psychological or behavioral effect experienced by a patient during 
participation in an investigational study, in conjunction with the use of the drug or biologic, whether or not product -related.  This includes any untoward signs or symptoms experienced  by [CONTACT_374771] -7289 until completion of the study.  Note:   In the [LOCATION_006], serious AEs (SAEs) will be recorded from time of consent through the EoS or 
until the Investigator and Imago BioSciences determine that follow -up is no longer necessary.  
Imago BioSciences,  Inc.  Protocol IMG -7289- CTP -102  
IMG- 7289    23Jun 2020  
Page 65 of 97 Adverse events may include, but are not limited to:  
• Subjective or objective symptoms spontaneously offered by [CONTACT_5363]/or 
observed by [CONTACT_204418]  
• Findings at physical examinations  
• Laboratory abnormalities of clinical significance  
Progression of underlying malignancy is not reported as an AE if it is consistent with the suspected 
progression of the underlying cancer. Cli nical symptoms of progression may be reported as AEs if the 
symptom cannot be determined as exclusively due to the progression of the underlying malignancy or does not fit the expected pattern of progression for the disease under study. If there is any uncertainty about an AE being due to only the disease under study, it should be reported as an AE.  
It is important Investigators record accurate AE terms in the e CRFs.  Wherever possible, a specific 
disease or syndrome rather than individual associated signs, symptoms or laboratory parameter will 
be identified by [CONTACT_374772] e CRF.  However, if an observed or reported sign, 
symptom or laboratory parameter is not considered a component of a specific disease or syndrome by [CONTACT_12244] r, or is atypi[INVESTIGATOR_2855], it should be recorded as a separate AE i n the e CRF.  
Disease signs, symptoms, and/or laboratory abnormalities already existing prior to the use of the investigational product are not  considered AEs after treatment unless  they reoccur after the patient 
has recovered from the preexisting condition or in the opi[INVESTIGATOR_204377] a clinically significant exacerbation in intensity or frequency.   
Clinical significance is defined as any variation in signs, symptoms, or testing that has medical relevance and may result in an alteration in medical care.  The Investigator will continue to monitor the patient until the assessment returns to Baseline or until the Investigator determines that follow -
up is no longer medically necessary.  
11.2.1  Adverse Event Intensity  
Adverse event intensity will be evaluated using the National Cancer Institute (NCI) Common 
Terminology Criteria for Adverse Events (CTCAE) version 4.[ADDRESS_469188] igator will be required to assess the intensity of the adverse 
drug/biologic experience using the following categories and associated guidelines:   
Grade  Guideline  
1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention 
not indicated  
2 Moderate; minimal, local or noninvasive intervention indicated; limiting age -appropriate 
instrumental ADL*  
3 Severe or medically significant but not immediately life -threatening; hospi[INVESTIGATOR_8942]; disabling; limiting self -care ADL**  
4 Life-threatening consequences; urgent intervention indicated  
5 Death related to AE  
Note 1: A semi- colon indicates ‘or’ within the description of the grade.  
Note 2: Activities of Daily Living (ADL)  
*Instrumental ADL refer to preparing meals, shoppi[INVESTIGATOR_3112], using the telephone, managing 
money, etc.  
**Self -care ADL refer to bathing, dressing and undressing, feeding self, using the toilet, taking 
medications, and not bedrid den.  
Imago BioSciences,  Inc.  Protocol IMG -7289- CTP -102  
IMG- 7289    23Jun 2020  
Page 66 of 97 11.2.2  Adverse Event Relatedness  
The Investigator will make a judgment regarding whether or not, in his/her opi[INVESTIGATOR_1649], the AE was 
related to study drug.  The Investigator will also evaluate any changes in laboratory values, make a 
determination as to whether the change is clinically significant , and whether or not the change(s) 
were related to study drug.  However, even if the Investigator feels there is no relationship to the study drug, the AE or clinically significant laboratory abnormality MUST  be recorded i n the e CRF.  
Below are guidelines for relationship assessment:  
• Unrelated: There was no relationship of the adverse event to the use of the drug or 
biologic. This may include, but is not limited, to the adverse experience being an expected 
outcome of a previously existing or concurrent disease, concomitant medication or procedure the subject experienced during their treatment  period.  
• Remote/Unlikely: Adverse events which are judged probably not related to the drug or 
biologic.  
• Possible: There was no clear relationship of the adverse event to the use of the drug or 
biologic; however, one cannot definitively conclude that ther e was no relationship.  
• Probable: While a clear relationship to the drug or biologic cannot be established, the event is associated with an expected adverse event (per the current Investigator 
Brochure or DSMC  findings) or there is no other medical conditio n or intervention which 
would explain the occurrence of such an experience.  
• Definite: The relationship of the use of the drug or biologic to the experience is considered definitively established.  
If a causal relationship is considered probable, possible, or definite by [CONTACT_226112] 
(dependent on the regional reporting requirements), the AE is considered to be “related” for 
purposes of regulatory reporting. If a causal relationship is considered remote/unlikely or unrelated, the AE is conside red “unrelated” for purposes of regulatory reporting.   
11.2.[ADDRESS_469189] dose  through the End of 
Study Visit (scheduled for approximately [ADDRESS_469190] IMG- 7289  dose) or until the Investigator 
and Imag o BioSciences determine that follow -up is no longer necessary.  Serious adverse events that 
are suspected to be drug related will be reported even if they occur when the patient is no longer on the study.   
An SAE is any AE that results in any of the follo wing outcomes:  
Death¥ 
Life- threatening experience . Any adverse event that places the patient, in the view of the reporter, 
at immediate risk of death from the adverse event as it occurred, i .e., does not include an adverse 
event that had it occurred in a more severe form, might have caused death.  
Required or prolonged inpatient hospi[INVESTIGATOR_11956]¥. The adverse event resulted in an initial 
inpatient hospi[INVESTIGATOR_374707]. If a patient is 
hospi[INVESTIGATOR_374708], a period of normal hospi[INVESTIGATOR_374709]:   In the [LOCATION_006], serious AEs (SAEs) will be recorded from time of consent through the EoS or  
until the Investigator and Imago BioSciences  determine that follow -up is no longer necessary.  
Imago BioSciences,  Inc.  Protocol IMG -7289- CTP -102  
IMG- 7289    23Jun 2020  
Page 67 of 97 outlined in the protocol or by [CONTACT_374773]. Hospi[INVESTIGATOR_374710].  
Persistent or significant disability/i ncapacity . An adverse event that resulted in a substantial 
disruption of a person’s ability to conduct normal life functions.  
Congenital Anomaly. The exposure of the patient to the drug or biologic during pregnancy that is 
judged to have resulted in the co ngenital anomaly/birth defect.  
Important medical events . Adverse events that may not result in death, be life -threatening, or 
require hospi[INVESTIGATOR_56233] a serious adverse event when, based upon appropriate 
medical judgment, may jeopardise the patient or subject and may require medical or surgical intervention to prevent one  of the outcomes listed above. Important medical events or interventions 
may be considered an SAE based upon medical judgment  of the Investigator.   
¥Note:   Hospi[INVESTIGATOR_374711].  An SAE with an outcome of death solely due to progression of the underlying 
malignancy does not need to be reported as an SAE.  
11.2.4  Reporting Serious Adverse  Events  
SAEs will be reported promptly , using the SAE Report Form, once the Investigator determines that 
the event meets the protocol definition of an SAE.  The Investigator or design ee will report the SAE 
within 24 hours of his/her becoming aware of thes e events  regardless of relationship of the 
SAE to the use of study drug , in accordance with the instructions in the Study Reference Manual. 
The Investigator will always provide an assessment of relatedness at the time of the initial report as 
described in Section 11.2.2.   The SAE Report will always be completed as thoroughly as possible with 
all available details of the event within the designated tim e frames. Copi[INVESTIGATOR_204380], 
autopsy reports, and other documents may be requested.   
If the Investigator does not have all information regarding an SAE, he/she will not wait to receive 
additional information before reporting the SAE . The SAE Report will be updated when additional 
information is received within 24 hours of receipt of such information . 
Important:   For fatal and life -threatening events, the Sponsor’s Medical Responsible Person should 
be contact[CONTACT_15608].  A death occurring during the study or information related to such 
occurrence that comes to the attention of the Investigator during the study must be reported immediately to the Sponsor.   Contact [CONTACT_374774] , with a detailed SAE 
reporting procedure to be included in the Study Reference Manual (SRM), before any patients are 
consented . 
Table 5:  Serious Adverse Event Reporting Contact [CONTACT_374775],  Inc.  Protocol IMG -7289- CTP -[ADDRESS_469191] (IRB), Independent Ethics Committee (IEC) and Human 
Research Ethics Committee (HREC) , as applicable, must be notified in writing of any SAEs that require 
expedited reporting to Regulatory Authorities.  Depending upon regional req uirements, it is the 
responsibility of either the Investigator or Imago BioSciences to notify the IRB/IEC/ HREC .  All SAEs 
meeting expedited reporting requirements  will be reported to appropriate regulatory agencies by 
[CONTACT_374776] .  
12 ANALYSIS AND STATISTICAL CONSIDERATIONS  
12.1 General Considerations  
Detailed methodology for summary and statistical analyses of the data collec ted in this trial will be 
documented in a Statistical Analysis Plan (SAP).  Additionally, a Pharmacokinetic Analysis Plan (PKAP) will be prepared.  These documents may modify the plans outlined in the protocol; however, any major modifications of the primary endpoints definition and/or its analysis will also be reflected in a protocol amendment.  Additional statistical analyses other than those described in this section may be performed if deemed appropriate and included in the SAP/PKAP.  
12.2 Power 
This study is designed to make an assessment of the safety,  tolerability, and pharmacokinetics of the 
capsule formulation of IMG -7289.  The number of patient s is su fficiently powered to determine mean 
pharmacokinetic parameters.  Given that all pharmacodynamic (PD) metrics are exploratory in nature, the study is not powered to make statements about the statistical significance of any changes observed.  
12.3 Treatment Assignment and Blinding  
This is an open -label study.  The Investigators, other hospi[INVESTIGATOR_11530], patients and Sponsor wil l 
know the identity of the treatment.   
Effort will be made, as appropriate, to maintain continuity of study staff who admi nister/evaluate 
various assessments at each site (i.e., p hysical examination, morphology /fibrosis grade  review, etc.), 
in order to facilitate consistency of assessments within a patient.  
12.4 Study Endpoints  
12.4.1  Primary Endpoint s 
• The safety and tolerability of IMG -7289 will be assessed by [CONTACT_374777] (AEs), 
as well as changes in physical examinations, vital signs and laboratory values   
CCI
CCI
Imago BioSciences,  Inc.  Protocol IMG -7289- CTP -102  
IMG- 7289    23Jun 2020  
Page 69 of 97 o Changes in physical examinations, vital signs and laboratory values will also be evaluated 
and assessed  from Screening/Baseline until EoS/ET .  Information on the timing of these 
assessments is presented in the schedule of assessment.   
 
• Pharmacokinetic (PK) parameters will be determined in accordance with earlier protocol 
versions and the PKAP associated  with the study (Phase 1/2a only). 
• Reduction in spleen volume will be ass essed based on spleen volume measured by [CONTACT_9268] (or CT 
scan where applicable) from Day 0, and spleen size measured by [CONTACT_374778], to 
each visit where the variables are measured.  
Note:   In [LOCATION_013], use of computerised tomography (CT) is not permitted for patients unable to 
undergo magnetic resonance imaging (MRI).  Only MRI is permitted for study purposes.  Note:   In the [LOCATION_006], serious AEs (SAEs) will be recorded from time of consent through the EoS or 
until the Investigator and Imago Bi oSciences determine that follow -up is no longer necessary.  
CCI
CCI
CCI
CCI
Imago BioSciences,  Inc.  Protocol IMG -7289- CTP -102  
IMG- 7289    23Jun 2020  
Page 70 of 97 12.5 Safety and Tolerabi lity Data  
Demographics will be tabulated and summarized. Medical and surgical history data at Screening will 
be listed, as will Physical Examination data (including height and weight) at Screening, and at 
subsequent visits.  All characteristics at baseline such as age, weight, height  and vital signs (resting 
heart rate, semi -supi[INVESTIGATOR_119225]/diastolic blood pressure, respi[INVESTIGATOR_7146]) 
parameters will be tabulated and summarized.  
All patients receiving at least one dose of IMG -7289 will be included in the safety analysis.   
Laboratory values outside the laboratory normal ranges will be summarized and assessed for change from Day 0 and trends indicating a safety signal.   
Treatment -emergent adverse events will be coded using the Medical Dictionary for Regulatory 
Activities (MedDRA) and summarized for the number of patients reporting the AE and the number of AEs reported.  A by -patient AE data listing including (but not limited to) verbatim term, coded 
term, severity, and relationship to treatment will be provided .  
Concomitant medications will be listed by [CONTACT_374779].   Medical 
history will be listed by [CONTACT_4676].  
Descriptive statistics (ari thmetic mean, standard deviation (SD), sample size, CV (coefficient of 
variation), median, minimum, maximum, and number) will be calculated for quantitative safety data as well as for the differences to baseline, when appropriate.  In addition, a shift table describing out of normal range shifts will be provided for clinical laboratory results  and physical examination 
results.  For safety and tolerability, missing data including those not obtained because of death will be the last value carried forward.  
CCI
Imago BioSciences,  Inc.  Protocol IMG -7289- CTP -102  
IMG- 7289    23Jun 2020  
Page 71 of 97 12.6 Pharmacokinetics Data  
Pharmacokinetics data will be handled as outlined in earlier protocol versions and analys ed in 
accordance with the PKAP associated with this study (Phase 1/2a only).  
12.7 Pharmacodynamic  Data  
Measuring the activity IMG -7289 has in producing a pharmacodynamics response (PD) is a n 
exploratory objective.  There are four  PD responses of interest.  T he effect of the drug (s) on normal 
myeloid haematopoiesis, which will be measured by [CONTACT_374780] .  The PD effect on inflammatory cytokines and growth factors which will measured regularly 
before and during the treatment p eriod.  The PD effect on the mutant allele burden of the patients -
specific mutation s identified at the time of enrollment and assessed in bone marrow cells ( when 
accessible ) and in peripheral blood at the end of the treatment period.  The PD effect on the change 
in spleen volume by [CONTACT_374781].  The PD effect on the change in bone marrow fibrosis score.   
Chi-square (χ2), Fisher exact, and Kruskal- Wallis tests may be used to assess the significance of 
differences in haematologic and pharmacodynamics markers among the patients and differing doses 
of IMG -7289.  If applicable, progression free survival (PFS), event free survival (EFS), and overall 
survival (OS) will be calculated using the Kaplan -Meier method. 
[ADDRESS_469192] in a Study Reference Manual for Pro tocol IMG -7289- CTP -102  and are available from 
Imago BioSciences.  
13.1 Ethical Considerations  
This research will be carried out in accordance with the protocol, US Code of Federal Regulations, 
GCP, 21 CFR Parts 50, 56, and 312, the ethical principles set forth in the Declaration of Helsinki, and 
the ICH harmonized tripartite guideline regarding GCP (E6 Consolidated Guidance, April 1996).  
13.2 Participation Inform ation Sheet/ Consent Form  (PI[CONTACT_306741])  
A sample PI[INVESTIGATOR_374712].  No major deviation s may be made from the 
sample PI[INVESTIGATOR_374713]- or region -specific formatting or legal requirements.  Imago 
BioSciences and its advisors will review the site -specific draft PI[INVESTIGATOR_374714], and the final 
IRB/IEC/HREC -approved document  must be provided to Imago BioSciences  for regulatory purposes.  
The PI[INVESTIGATOR_374715].  A copy of the 
PI[INVESTIGATOR_374716].  If required by [CONTACT_307970] a second original of the PIS CF 
may be provided to the patient.  If applicable, it will be p rovided in a certified translation of the local 
language.  
An original signed PIS CF must remain in each patient’s study file and must be available for 
verification by [CONTACT_9534].  
Imago BioSciences,  Inc.  Protocol IMG -7289- CTP -[ADDRESS_469193] (IRB), Independent Ethics Committee  (IEC) and Human 
Research Ethics Committee (HREC)  
This protocol, the PIS CF, relevant supporting information and all types of patient recruitment or 
advertisement information must be submitted to IRB/IEC/HREC  for review and must be approved 
before the study  is initiated.  Any amendments to the protocol must also be approved, where 
necessary, by [CONTACT_1201]/IEC/HREC  prior to implementing changes in the study.  
The Investigator is responsible for keepi[INVESTIGATOR_1683]/IEC/HREC  apprised of the progress of the study 
and of  any changes made to the protocol as deemed appropriate, but in any case, at least once a year.  
The Investigator must also keep the IRB/IEC/HREC  informed of any AEs, according to the 
IRB/IEC/HREC  policy. 
13.4 Study or Site Termination  
The End -of-Trial date is considered to be the date of Database Lock.  
If Sponsor, an Investigator, or regulatory authorities discover conditions during the study that 
indicate that the study or related activities at a particular site should be terminated, this action may be taken after appropriate consultation between Sponsor and the Investigator.  Conditions that may 
warrant study or site termination include but are not limited to:  
1. The incidence or severity of AEs in this or other studies indicates a potential health hazard to patients  
2. Patient recruitment is unsatisfactory  
3. Data recording is inaccurate or incomplete  
4. Investigator(s) do not adhere to the protocol or applicable regulatory guidelines in conducting the study  
5. GCP is not being maintained or adequately followed  
6. Administrative reasons  
7. Reasons unrelated to the study.  
Study or site termination and follow -up will be performed in compliance with the conditions set forth 
in 21 Code of Federal Regulations (CFR) Section 312 and/or other national and local regulations, as appli cable, and in compliance with the principles set forth in International Conference on 
Harmonisation (ICH) Good Clinical Practices (GCPs), including ICH E6,  and ethical principles 
established by [CONTACT_44484].  
13.5 Study Monitoring Requirements  
Mon itoring and auditing procedures developed by [CONTACT_374782] (GCP) guidelines.  On -site checking of the e CRFs for 
completeness and clarity, cross checking with source documents, and clarification of administrative matters will be performed  whenever  possible .  Additionally, off -site or ‘remote’ monitoring visits may 
be conducted as needed.  Remote monitoring may consist of centralized monitoring  or remote data  
review .  Centralized monitoring is t he remote, cross -functional review and evaluation of 
accumulat ing in-house data conducted by [CONTACT_374783], central monitor associate s, medical 
Imago BioSciences,  Inc.  Protocol IMG -7289- CTP -102  
IMG- 7289    23Jun 2020  
Page 73 of 97 directors, the clinical team, and biostatisticians. The review of data within and acr oss sites 
proactively identifies missing or inconsistent data, data trends, systematic or significant errors and 
enables site performance characteristics to be analyzed. Remote data review  is intended to 
encompass as many activities performed in a routine on -site monitoring visit  as is functionally 
possible , and as permitted by [CONTACT_374784] .  The remote review of data may be actioned 
via multiple pathways, often contingent on site’s  capabilities.  Remote data review, specifically, has 
become critically important in the COVID -[ADDRESS_469194] ing patient 
safety, while also minimizing risks to trial data integrity and facilitating GCP compliance .  Any 
implementation of remote data review will be performed in accordance with the applicable  local  
regulations/regulatory guidance .  Please see Section 16.[ADDRESS_469195] facilities and records relevant to this study.  
Imago BioSciences or its designee will monitor the study.  Monitoring will be done by [CONTACT_374785] (monitors) who will review the e CRFs and source documents.  
The monitors will ensure that the investigation is conducted according to protocol design and 
regulatory requirements by [CONTACT_54665] (letter, email, telephone, and fax).  
All unused study materials are to be returned to Imago Bi oSciences or its designee after the clinical 
period of the trial has been completed, or be disposed of at the site according to institutional policies but not prior to the approval of the Sponsor and with appropriate documentation.   
13.6 Quality Assurance  
The study will be initiated and conducted under the sponsorship of Imago BioSciences.  IMG -7289 
and clinical supplies will be supplied by [CONTACT_374760].  Representatives of Imago BioSciences will monitor the study to verify study data, medical records, wor ksheets, and eCRFs are in accordance 
with current International Conference on Harmonisation (ICH) GCPs and the respective local and national government regulations and guidelines.  
The Investigator will contact [CONTACT_12559] a regu latory agency about an 
inspection at his or her center. The purpose of Sponsor audit or inspection is to systematically and independently examine all study -related activities and documents to determine whether these 
activities were conducted, and data were  recorded, analyzed, and accurately reported according to 
the protocol, ICH/GCP guidelines, and any applicable regulatory requirements.  
13.[ADDRESS_469196] parties other than those noted below is prohibited.  
The patient’s identifying information will not leave the clinical site at which they are recruited.  The patient will be identified on all study documentation using a code number and their initials (w here it 
is lawful to collect such information).  
Imago BioSciences,  Inc.  Protocol IMG -7289- CTP -[ADDRESS_469197] (HIPAA) 
and may be inspected by [CONTACT_374786], the researcher’s staff, Sponsor and its representatives, partners, advisors, affiliates, successors, and clinical research contractors and subcontractors to check, process, evalu ate, and use the information collected during the study.  The 
patient PI[CONTACT_306741] (or a separate data protection consent form if required locally)  will be used to obtain 
participant consent to authorise transfer and processing of data consistent with applicable law.  Processing, evaluation, or use of the information will be performed by a health professional for medical purposes and/or by [CONTACT_374787] a duty of confidentiality that is equivalent to that of a health professional.  Information obtained from the study will likely be used by [CONTACT_374788], including possible filing of applications with governmental authorities for marketing approval, and for other pharmaceuti cal and medical research purposes.  The study Investigator is obliged to provide Sponsor 
with complete test results and all data developed in this study.  This information may be disclosed to other physicians who are conducting similar studies and to the a pplicable regulatory authorities as 
deemed necessary by [CONTACT_374760].  Patient -specific information may be provided to other 
appropriate medical personnel only with the patient’s permission, as necessary and in accordance with other applicable privacy  laws and regulations protecting patient health information.   
To ensure compliance with the ICH GCP guidelines, data generated by [CONTACT_374789] , 
Imago BioSciences, and the IRB/IEC/ HREC  for each study site.  
The raw dataset will be available to Imago BioSciences on completion of the study.  Imago BioSciences  
will actively pursue publication of the results of the study in cooperation with the Lead Investigators subject to the terms and conditions of the clinical trial agreement between Imago BioSciences and Investigators.  The Lead/Coordinating  Investigator [INVESTIGATOR_374717].  The Lead/Coordinating  Investigator, with the agreement of 
Imago BioSciences, will coordinate the principal publication of the data arising from the study.  
Patient names and other personal data relating to an identified or identifiable patient (such as photographs, audio, videotapes, or other factors specific to physical, physiological, mental, economic, cultural, or social identity), may not be disclosed in any publication without prior written authorisation, in compliance with patient privacy law, from Imago BioSciences and the patient.  
[ADDRESS_469198] be approved by [CONTACT_374760]’s authorised representative in writing prior to seeking approval, where necessary, fr om the IRB/IEC/HREC .  Each Investigator will 
Imago BioSciences,  Inc.  Protocol IMG -7289- CTP -[ADDRESS_469199] met all protocol eligibility criteria to be 
enrol led.   
Modifications to the protocol should not be made without agreement of the Investigators and Imago BioSciences.  Changes to the protocol will require written IRB/IEC/HREC  approval / favorable 
opi[INVESTIGATOR_51703], except when the modification is needed to eliminate an immediate hazard(s) to patients.  The IRB/IEC/HREC  may provide expedited re view and approval/favorable 
opi[INVESTIGATOR_51704](s) in ongoing trials that have the approval/favorable opi[INVESTIGATOR_1100]/IEC/HREC .  The Investigator will submit all protocol modifications to the IRB/IEC/HREC in 
accordance with the governing regulation s. 
When immediate deviation from the protocol is required to eliminate an immediate hazard(s) to patients, the Investigator will contact [CONTACT_2728], if circumstances permit, to discuss the planned course of action.  Any departures from the protocol must be fully documented in the e CRF and source 
documentation.  
14.[ADDRESS_469200] maintain detailed records of all study participants who are enrolled in the 
study or who undergo screening. Source documents include patient medical records and  
Investigator’s patient study files, as well as all test results.  Information required for study purposes 
and any data recorded in the eCRF must be supported by [CONTACT_134405].  
14.[ADDRESS_469201] Access to Source Documentation  
The Investigator will ensure that the Sponsor, IRB/IEC/HREC  and regulatory authorities will have 
direct access to all trial -related sites, source data/documents, and reports for the purpose of 
monitoring and auditing (ICH[E6] 5.1.2 & 6.10).  This includes electronic source data .   
14.4 Case Report Forms  
Case report forms (or an electronic data capture system) will be provided to each investigational site 
for the collection of all study data for enrolled patients, with the exception of data that may be captured externally to the site  (i.e., central laboratory data).  Study site personnel will record the data 
in the source documentation and enter it in the eCRF within, on average, 5 business days of the study 
visit, while carefully reviewing all information recorded for accuracy and con sistency.  Any required 
data printouts should be filed in the patient’s source data, i.e., laboratory reports, etc. and 
signed/dated by [CONTACT_374790] a true copy of the original . 
A clinical study monitor will review the e CRFs a nd compare the content to the source data.  
The eCRFs for each patient must be reviewed and signed by [CONTACT_737].  This should be done as 
soon as possible after the patient has completed the study and all data queries have been resolved.   
14.[ADDRESS_469202] or 
other appropriate individual.  Drug accountability records indicating the drugs’ delivery date to the 
Imago BioSciences,  Inc.  Protocol IMG -7289- CTP -102  
IMG- 7289    23Jun 2020  
Page 76 of 97 site, inventory at the site, use by [CONTACT_6904], and return to Imago BioSciences (or dis posal of the 
drug, if approved by [CONTACT_374760]) will be maintained by [CONTACT_977].  These records will 
adequately document that the patients were provided the drugs and doses as specified in the protocol and should reconcile all study drugs received from Imago BioSciences.  Accountability records will include dates, quantities, batch/serial numbers, expi[INVESTIGATOR_31637] (if applicable), and patient numbers.  Imago BioSciences or its designee will review drug accountability at the site on an ongoing basis  
during monitoring visits.  
A Per Patient Dispensing Log must be kept current and contain the following information:  
• The identification of the patient to whom the drug was dispensed;  
• The date(s), lot numbers and quantity of the drug dispensed to the patient ; 
• The date(s), lot numbers and quantity of drug returned by [CONTACT_102]  
A “Per Lot” Inventory must be maintained, and both the Per Patient and Per Lot Logs must be available for inspection by [CONTACT_374791].   
14.6 Disposal of Study Drug  
All unused study drug will be retained at the site until inventoried by [CONTACT_374760] / designee.  
All unused or expi[INVESTIGATOR_374718], if authorised by [CONTACT_374760], will be disposed of at the study site and the disposal will be 
appropriately documented.  Records shall be maintained by [CONTACT_374792].  These records must show the identification and quantity of each unit disposed of, the method of destruction (taking into account the requirements of local law), and the person/company who disposed of the test substance.  Such records must be submitted to the sponsor and copi[INVESTIGATOR_374719]’s Site File.  All material containing stu dy drug will be treated and 
disposed of as hazardous waste in accordance with governing regulations.  
14.[ADDRESS_469203] of the study at this study site, including delegation of specified 
study responsibilities, and training of study staff.  The PI [INVESTIGATOR_374720], ICH/GCP guidelines, and regulations.  
The PI [INVESTIGATOR_17459] a record of all individuals involved in the study (medical, nursing and other staff).  He or she will ensure that appropriate training relevant to the study is given to all of these 
staff, and that any new information of relevance to the performance of this study is forwarded to the staff involved.  
14.[ADDRESS_469204].  No study records shall be destro yed without notifying Sponsor and giving Sponsor the opportunity 
to take such study records  or authorizing in writing the destruction of records after the required 
retention period.  
  
Imago BioSciences,  Inc.  Protocol IMG -7289- CTP -102  
IMG- 7289    23Jun 2020  
Page 78 of 97 15 REFERENCES  
Abdel -Wahab, O., Levine, R.L. Primary myelofibrosis: update on definition, pathogenesis, and 
treatment Ann Rev Med 2009:60:233 -245 
Adamo, A., Sese, B., Boue, S., Castano, J., Paramonov, I., Barrero, M.J., Izpi[INVESTIGATOR_374721], J.C., 2011. LSD1 
regulates the balance between self- renewal and differentiation in human embry onic stem 
cells. Nat Cell Biol 13, 652 -659.  
Arber, A.A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M.J., Le Beau, M.M., Bloomfield, C.D., Cazzola, 
M., Vardiman, J.W.  2016 . The 2016 revision to the World Health Organization classi fication 
of myeloid neoplasms and acute leukemia Blood 127(20),  2391- 2405  
Bannister, A.J., Kouzarides, T., 2011. Regulation of chromatin by [CONTACT_374793]. Cell Res 21, 
381 -395.  
Beisel, C., Paro, R., 2011. Silencing chromatin: comparing modes and mechanisms. Nat Rev Genet 12, 
[ADDRESS_469205], A. , 2002. DNA methylation patterns and epi[INVESTIGATOR_374722]. Genes Dev. 16, 6 -21 
Cervantes,  F., Dupriez, B ., Pereira, A ., Passamonti,  F., Reilly, J.T., Morra, E., Vannucchi,  A.M., Mesa,  R.A., 
Demory, J., Barosi, G., Rumi, E., Tefferi, A.  2009.  New prognostic scoring system for primary 
myelofibrosis based on a study of the International  Working Group for Myelofibrosis 
Research and Treatment.  Blood 113(13), 2895 -2901 
Chen, E. and Mullally, A. 2014 . How does JAKV617F contribute to the pathogenesis of 
myeloproliferative neoplasms? Hematology (American Society of Hematology Education) 
[ADDRESS_469206] of long -term 
ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis. Blood 
126(13):[ADDRESS_469207], K., Begum, S., Rose, S., Geddes, N., Griffiths, 
M., Standen, G., Sternberg, A., Cavenagh, J., Hunter, H., Bowen, D., Killick, S., Robinson, L., Price, 
A., Macintyre, E., Virgo, P., Burnett, A., Craddock, C., Enver, T., Jacobsen, S.E., Porcher, C., Vyas, 
P. 2011. Coexistence of LMPP -like and GMP -like leukemia stem cells in acute myeloid 
leukemia. Cancer Cell 19 , 138- 152.  
Guardiola, P., Anderson, J.E., Bandini, G., Cervantes, F ., Runde, V ., Arcese, W ., Bacigalupo, A ., 
Przepi[INVESTIGATOR_12776], D., O'Donnell, M.R ., Polchi, P ., Buzyn, A., Sutton, L ., Cazals -Hatem, D ., Sale, G ., de 
Witte, T ., Deeg, H.J ., Gluckman, E . 1999 . Allogeneic stem cell trans -plantation for agnogenic 
myeloid metaplasia: a European Group for Blood and Marrow Transplantatio n, Société 
Française de Greffe de Moelle, Gruppo Italiano per il Trapi[INVESTIGATOR_374723], and Fred 
Hutchinson Cancer Research Center collaborative study. Blood 93, 2381 -2388  
Gupta, V ., Hari, P ., Hoffman, R . Allogeneic hematopoiesis cell transplantation for myelofibrosis in the 
era of JAK inhibitors 2012 Blood 120 (7), 1367 -1279 
Harris, W.J., Huang, X., Lynch, J.T., Spencer, G.J., Hitchin, J.R., Li, Y., Ciceri, F., Blaser, J.G., Greystoke, B.F., 
Jordan, A.M., Miller, C.J., Ogilvie, D.J., Somervaille, T.C., 2012. The histone demethylase KDM1A sustains the oncogenic potential of MLL -AF9 leukemia stem cells. Cancer Cell 21 , 473 -487.  
Hultcrantz, M, , Lund, S.H., Landgren, O., Samuelsson, J., Goldin, L.R., Oddsson, A., Björkholm, M., 
Kristinsson, S.Y. 2015 . Survival in patients with familial and sporadic myeloproliferative 
neoplasms. Blood 125(23):[ADDRESS_469208] risk of 
prostate cancer recurrence. Cancer Res 66 , [ZIP_CODE] -[ZIP_CODE].  
Kerenyi, M.A., Shao, Z., Hsu, Y.J., Guo, G., Luc, S., O'Brien, K., Fujiwara, Y., Peng, C., Nguyen, M., Orkin, 
S.H., 2013. Histone demethyla se Lsd1 represses hematopoietic stem and progenitor cell 
signatures during blood cell maturation. Elife 2, e00633.  
Kiladjian, J -J., Cassinat, B., Chevret, S., Turlure,  P., Cambier, N., Roussel, M., Bellucci, S., Grandchamp, 
B., Chomienne, C., Fenaux, P. 20 08. Pegylated interferon -alfa- 2a induces complete 
hematologic and molecular responses with low toxicity in polycythemia vera. Blood 112(8), 
3065 -3072  
Klose, R.J., Kallin, E.M., Zhang, Y., 2006. JmjC -domain -containing proteins and histone demethylation. 
Nat Rev Genet 7 , 715 -727.  
Kornberg, R. D., 1974. Chromatin structure: a repeating unit of histones and DNA. Science 184, 868 –
871  
Kouzarides, T., 2007. Ch romatin modifications and their function. Cell 128: 693 - 705 
Kröger, N ., Holler, E ., Kobbe, G ., Bornhäuser, M ., Schwerdtfeger, R ., Baurmann, H ., Nagler, A ., Bethge, 
W., Stelljes, M., Uharek, L ., Wandt, H ., Burchert, A ., Corradini, P ., Schubert, J ., Kaufmann, M., 
Dreger, P ., Wulf, G.G ., Einsele, H ., Zabelina, T ., Kvasnicka, H.M., Thiele, J ., Brand, R ., Zander, 
A.R., Niederwieser, D., de Witte, T.M . Allogeneic stem cell transplantation after reduced-
intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Group of the European Group for Blood and Marrow 
Transplantation 2009 Blood 114 (26), 5264- [ADDRESS_469209] in nucleosomal 
histone 3 lysine 4 demethylation. Nature 437, 432 -435.  
Lim, S., Janzer, A., Becker, A., Zimmer, A., Schule, R., Buettner, R., Kirfel, J., 2010. Lysine -spec ific 
demethylase 1 (LSD1) is highly expressed in ER -negative breast cancers and a biomarker 
predicting aggressive biology. Carcinogenesis 31 , 512- 520.  
Lin, X.M., Zhong, W.T., Wang, C.L., Wang, S.Q., 2011. [Expression of histone demethylase lysine specific 
demethylase 1 in acute leukemia and its clinical significance]. Zhongguo Shi Yan Xue Ye Xue 
Za Zhi 19 , 1348- 1352.  
Lin, Y., Wu, Y., Li, J., Dong, C., Ye, X., Chi, Y.I., Evers, B.M., Zhou, B.P., 2010. The SNAG domain of Snail1 
functions as a molecular hook for recruiting lysine -specific demethylase 1. EMBO J 29, 1803 -
1816.  
Malak, S., Labopin, M., Saint -Martin, C., Bellanne -Chantelot, C., Najman, A.. 2012. Long term follow up 
of 93 families with myeloproliferative neoplasms: life expectancy and implications of  
JAK2V617F in the occurrence of complications. Blood Cells Mol Dis 49(3 -4):170- 176.  
Metzger, E., Wissmann, M., Yin, N., Muller, J.M., Schneider, R., Peters, A.H., Gunther, T., Buettner, R., 
Schule, R., 2005. LSD1 demethylates repressive histone marks to promote androgen -
receptor -dependent transcription. Nature 437, 436 -439.  
Imago BioSciences,  Inc.  Protocol IMG -7289- CTP -102  
IMG- 7289    23Jun 2020  
Page 80 of 97 Nangalia, J , Massie, C.E., Baxter, E.J ., Nice, F.L ., Gundem, G ., Wedge, D.C ., Avezov, E ., Li, J., Kollmann, K., 
Kent, D.G ., Aziz, A ., Godfrey, A.L ., Hinton, J ., Martincorena, I ., Van Loo, P., Jones, A.V ., 
Gug lielmelli, P ., Tarpey, P ., Harding, H.P ., Fitzpatrick, J.D., Goudie, C.T ., Ortmann, C.A ., 
Loughran, S.J ., Raine, K., Jones, D.R ., Butler, A.P ., Teague, J.W ., O'Mea ra, S ., McLaren, S ., Bianchi, 
M., Silber, Y ., Dimitropoulou, D ., Bloxham, D ., Mudie, L ., Maddison, M., Robinson, B ., Keohane, 
C., Maclean, C ., Hill, K ., Orchard, K ., Tauro, S ., Du, M.Q ., Greaves, M., Bowen, D ., Huntly, B.J ., 
Harrison, C.N ., Cross, N. C., Ron, D ., Vannucchi, A .M., Papaemmanuil, E., Campbell, P.J ., Green, 
A.R. 2013 Somatic CALR mutations in myeloproliferative neoplasms with non -mutated JAK2  
New Engl J Medicine 369 (25), 2391 -2405  
Niebel, D., Kirfel, J., Janzen, V., Holler, T., Majores, M., Gutgemann, I. 2014 . Lysine -sepcific demethylase 
1 (LSD1) in haematopoietic and lympoid neoplasms Blood 124(1):[ADDRESS_469210], A, Liu, E. Guan, Y., Durette, A., Reddy, V., Prchal J.T. 2006 . High levels of circulating 
CD34 cells, dacrocytes, clonal hematopoiesis, and JAK2 mutation differentiate myelofibrosis 
with myeloid metaplasia from secondary myelofibrosis associated with pulmonary hypertension. Blood 107(9):3486 -3488.  
Rhodes, D.R., Kalyana -Sun
 daram, S., Mahavisno, V., Varambally, R., Yu, J., Briggs, B.B., Barrette, T.R., 
Anstet, M.J., Kincead -Beal, C., Kulkarni, P., Varambally, S., Ghosh, D., Chinnaiyan, A.M., 2007. 
Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia 9 , 166- 180.  
Rumi, E ., Pi[INVESTIGATOR_374724] D., Pascuttom, C ., Guglielmellim ,P ., Martínez- Trillos, A ., Casetti, I ., Colomer, D ., Pi[INVESTIGATOR_77332], 
L., Pratcorona, M ., Rotunno , G., Sant'Antonio, E ., Bellini, M., Cavalloni, C
., Mann
arelli, C ., 
Milanesi, C ., Boveri, E., Ferretti, V ., Astori, C ., Rosti, V., Cervantes, F ., Barosi, G ., Vannucchi, A.M ., 
Cazzola, M . 2014.  Clinical effect of driver mutations of JAK2 , CALR , or MPL  in primary 
myelofi brosis Blood 124(7), [ADDRESS_469211] and LSD1. Mol Cell 
27, 562 -572.  
Schulte, J.H., Lim, S., Schramm, A., Friedrichs, N., Koster, J., Versteeg, R., Ora, I., Pajtler, K., Klein -
Hitpass, L., Kuhfittig -Kulle, S., Metzger, E., Schule, R., Eggert, A., Buettner, R., Kirfel, J., 2009. 
Lysine -specific demethylase 1 is strongly expr essed in poorly differentiated neuroblastoma: 
implications for therapy. Cancer Res 69, [ADDRESS_469212] at Twenty Immunity 36, 502 -514  
Thiele, J., Kvasnicka, H.M., Facchetti, F., Franco, V., van der Walt, J., Orazi, A. 2005 . European consensus 
on grading bone marrow fibrosis and assessment of cellularity Haematologica 90(8), 1128 -
1132  
Wang, J., Hevi, S., Kurash, J.K., Lei, H., Gay, F., Bajko, J., Su, H., Sun, W., Chang, H., Xu, G., Gaudet, F., Li, 
E., Chen, T., 2009. The lysine demethylase LSD1 (KDM1) is required for maintenance of global 
DNA methylation. Nat Genet 41 , 125 -129.  
Wang, J., Scully, K., Zhu, X., Cai, L., Zhang, J., Prefontaine, G.G., Krones, A., Ohgi, K.A., Zhu, P., Garcia -
Bassets, I., Liu, F., Taylor, H., Lozach,  J., Jayes, F.L., Korach, K.S., Glass, C.K., Fu, X.D., Rosenfeld, 
M.G., 2007. Opposing LSD1 complexes function in developmental gene activation and repression programmes. Nature 446, 882 -887.  
Whyte, W.A., Bilodeau, S., Orlando, D.A., Hoke, H.A., Frampton, G.M., Foster, C.T., Cowley, S.M., Young, 
R.A., 2012. Enhancer decommissioning by [CONTACT_356049]1 during embryonic stem cell differentiation. Nature 482, 221 -225.  
Whyte, W.A., Orlando, D.A., Hnisz, D., Abraham, B.J., Lin, C.Y., Kagey, M.H., Rahl, P.B., Lee, T.I., Youn g, 
R.A., 2013. Master transcription factors and mediator establish super- enhancers at key cell 
identity genes. Cell 153, 307- 319.  
Wouters, B.J., Lowenberg, B., Erpelinck- Verschueren, C.A., van Putten, W.L., Valk, P.J., Delwel, R., 2009. 
Double CEBPA mutati ons, but not single CEBPA mutations, define a subgroup of acute 
myeloid leukemia with a distinctive gene expression profile that is uniquely associated with 
a favorable outcome. Blood 113 , 3088 -3091.  
Yang. J., Huang, J., Dasgupta, M., Sears, N., Miyagi, M., Wang, B., Chance, M.R., Chen, X., Du, Y., Wang, Y., 
An, L., Wang, Q., Lu, T., Zhang, X., Wang, Z., Stark, G.R. 2010 Reversible methylation of 
promoter -bound STAT3 by [CONTACT_356050] -modifying enzymes Proc Nat Acad Sci 107(50), [ZIP_CODE] -
21504Zhang, W., Zecca, L., Wi lson, B., Ren, H.W., Wang, Y.J., Wang, X.M., Hong, J.S., 2013. 
Human neuromelanin: an endogenous microglial activator for dopaminergic neuron death. Front Biosci (Elite Ed) 5 , 1-11. 
Zhang, W., Zecca, L., Wilson, B., Ren, H.W., Wang, Y.J., Wang, X.M., Hong, J.S., 2013. Human 
neuromelanin: an endogenous microglial activator for dopaminergic neuron death. Front 
Biosci (Elite Ed) 5, 1 -11 
Imago BioSciences,  Inc.  Protocol IMG -7289- CTP -102  
IMG- 7289   23Jun 2020  
CCI
Imago BioSciences,  Inc.  Protocol IMG -7289- CTP -102  
Page 83 of 97 
CCI
Imago BioSciences,  Inc.  Protocol IMG -7289- CTP -102  
IMG- 7289   23Jun 2020  
Page 84 of 97 
CCI
Page 8
5 of 97 
CCI
Imago BioSciences,  Inc.  Protocol IMG -7289- CTP -102  
IMG- 7289   23Jun 2020  
Page 86 of 97 
CCI
Imago BioSciences,  Inc.  Protocol IMG -7289- CTP -102  
IMG- 7289   23Jun 2020  
Page 87 of 97 
CCI
Imago BioSciences,  Inc.  Protocol IMG -7289- CTP -102  
IMG- 7289   23Jun 2020  
Page 88 of 97 16.2 The 2016 WHO Diagnostic Criteria for Primary Myelofibrosis (PMF)  
  Primary Myelofibrosis ( PMF )¥ 
Major criteria  1 Presence of m egakaryocyt ic proliferation and atypia accompanied by [CONTACT_362259]/or collagen fibrosis  grades 2 or 3 
(see Table 16.5 ) 
 2 Not meeting WHO criteria for ET, PV, BCR -ABL1 + CML, MDS, or other myeloid neoplasm 
 [ADDRESS_469213] mutation or in the absence of these mutations, presence of another  clonal marker , † or 
absence of reactive bone marrow fibrosis‡ 
Minor criteria  1 Anaemia not attributed to no comorbid condition  
 2 Leukocytosis ≥11 x 109/L 
 3 Palpable splenomegaly  
 4 LDH increased to above upper normal limit of institutional reference range  
 5 Leukoerythroblastosis  
WHO indicates World Health Organization; PMF, primary myelofibrosis; Hgb, ha emoglobin; CML, chronic myelogenous leuk aemia; MDS, myelodysplastic syndrome; BM, 
bone marrow; Epo, erythropoietin; LDH, lactate dehydrogenase; EEC, endogenous erythroid colony.5  
¥ The diagnosis of PMF requires meeting all 3 major criteria and 2 minor criteria.  
† In the absence of any of the [ADDRESS_469214] frequent accompanying mutations (e.g., ASXL1 , EZH2 , TET2 , IDH1 /IDH2 , SRSF2 , SF3B1 ) are 
of help in determining the clonal nature of the disease.  
‡ BM fibrosis secondary to infection, autoimmune disorder, or other chronic inflammatory conditions, hairy cell leuk aemia or other lymphoid neoplasm, metastatic 
malignancy, o r toxic (chronic) myelopathies. 
16.[ADDRESS_469215] -Polycythaemia Vera Myelofibrosis (PPV- MF)  
Diagnostic Criteria for Post-Polycyt haem ia Vera Myelofibrosis  (PPV -MF)  
Required 
criteria:  1 Documentation of a previous diagnosis of polycyt haem ia vera as defined by [CONTACT_175546]  
2 Bone marrow fibrosis grade 2 –3 (on 0 –3 scale) or grade 3 –4 (on 0 –4 sc ale)*  
Additional 
criteria:  
(two are required)  1 An aemia  or sustained loss of requirement for phlebotomy in the absence of cytoreductive therapy  
2 A leukoerythroblastic peripheral blood pi[INVESTIGATOR_1103]  
 3 Increasing splenomegaly defined as either an increase in palpable splenomegaly of ≥5 cm (distance of the tip of the spleen from 
the left costal margin) or the appearance of a newly palpable splenomegaly  
 4 Development of ≥1 of three constitutional sympt oms: >10% weight loss in 6 months, night sweats, unexplained fever (>37.5 °C) 
Imago BioSciences,  Inc.  Protocol IMG -7289- CTP -[ADDRESS_469216] -Essential Thrombocythaemia Myelofibrosis (PET -MF)  
Diagnostic Criteria for Post -Essential Thrombocyt haem ia Myelofibrosis  
Required 
criteria:  1 Documentation of a previous diagnosis of essential thrombocythaem ia as defined b y the WHO criteria  
2 Bone marrow fibrosis grade 2 –3 (on 0 –3 scale) or grade 3 –4 (on 0 –4 scale) * 
Additional criteria:  
(two are required)  1 An aemia and a ≥2 g/dL decrease from baseline haem oglobin level  
2 A leukoerythroblastic peripheral blood pi[INVESTIGATOR_1103]  
3 Increasing splenomegaly defined as either an increase in palpable splenomegaly of ≥5 cm (distance of the tip of the spleen from 
the left costal margin) or the appearance of a newly palpable splenomegaly  
 4 Increased lactate dehydrogenase  
 5 Development of ≥1 of three constitutional symptoms: >10% weight loss in 6 months, night sweats, unexplained fever (>37.5 °C) 
*Grade 2 –3 according to the European classification: diffuse, often coarse fiber network with no evidence of collagenization (negative trichrome stain) 
or diffuse, coarse fiber network with areas of collagenization (positive trichrome stain). Grade 3 –[ADDRESS_469217] classification: diffuse and 
dense increase in reticulin with extensive intersections, occasionally with only focal bundles of collagen and/or focal osteosclerosis or diffuse and dense increase in reticulin with extensive intersections with coarse bundles of collagen, often associated with significant osteosc lerosis.  
16.5 Criteria for Grading Myelofibrosis  (Arber et al. , 2016)*   
Fibrosis grade  Definition  
MF-0 Scattered linear reticulin with no intersections (crossovers) corresponding to normal bone marrow  
MF-1 Loose network of reticulin with many intersections, especially in perivascular areas  
MF-2 Diffuse and dense increase in reticulin with extensive inters ections, occasionally with focal bundles of thick fibers 
mostly consistent with collagen, and/or focal osteosclerosisa  
MF-3 Diffuse and dense increase in reticulin w ith extensive intersections and coarse b undles of thick fibers consistent 
with collagen, usually  associated with osteosclerosis a  
*Slighly modified from the European Consensus Criteria  as presented in Thiele et al ., 2005 
Semiquantitative grading of BM fibrosis with minor modifications concerning collagen and osteosclerosis. Fibe r density should be assessed only in h aematopoietic areas .   
aIn grades MF -2 or MF -3 an additional tri chrome stain is recommended.   
Imago BioSciences,  Inc.  Protocol IMG -7289- CTP -102  
IMG- 7289   23Jun 2020  
Page 90 of 97 16.6 Eastern Cooperative Group Performance Status  
Grade  ECOG Performan ce Status  
0 Fully active, able to carry on all pre- disease performance without restriction  
1 Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, 
office work  
2 Ambulatory and capable of all self -care but unable to carry out any work activities; up and about more than 50% of waking hours  
3 Capable of only limited self -care; confined to bed or chair more than 50% of waking hours  
4 Completely disabled; cannot carry on any self -care; totally confined to bed or chair  
[ADDRESS_469218] Response Criteria for MF  
Response categories  Required criteria (for all response categories, benefit must last for ≥12 weeks to qualify as a response)  
CR Bone marrow:* Age- adjusted normocellularity; < 5% blasts; ≤grade 1 MF† and 
Peripheral blood: Haem oglobin ≥100 g/L and < UNL; neutrophil count ≥ 1 x  109/L and < UNL;  Platelet count ≥100  x 109/L 
and <UNL; <2% immature myeloid cells‡ and  
Clinical: Resolution of disease symptoms; spleen and liver not palpable; no evidence of EMH  
PR Peripheral blood: Haem oglobin ≥100 g/L and < UNL; neutrophil count ≥1 x  109/L and < UNL; platelet count ≥100 x 109/L 
and <UNL; <2% immature myeloid cells‡ and 
Clinical: Resolution of disease symptoms; spleen and liver not palpable; no evidence of EMH or  
Bone marrow:* Age- adjusted normocellularity; < 5% blasts; ≤grade 1 MF†, and peripheral blood: Haem oglobin ≥85 but 
<100 g/L and < UNL; neutrophil count ≥1 x  109/L and < UNL; platelet count ≥50, but <100 x  109/L and < UNL; <2% immature 
myeloid cells‡ and 
Clinical: Resolution of disease symptoms; spleen and liver not palpable; no evidence of EMH  
Clinical 
improvement (CI)  The achievement of an aemia , spleen or symptoms response without progressive disease or increase in severity  of an aemia, 
thrombocytopenia , or neutropenia§ 
Anaemia response  Trans fusion -independent patients: a ≥ 20 g/L increase in haem oglobin level¶ 
Transfusion- dependent patients: bec oming transfusion -independent{ 
Imago BioSciences,  Inc.  Protocol IMG -7289- CTP -102  
IMG- 7289   23Jun 2020  
Page 91 of 97 Response categories  Required criteria (for all response categories, benefit must last for ≥12 weeks to qualify as a response)  
Spleen response  A baseline splenomegaly that is palpable at 5 -10 cm, below the LCM, becomes not palpable**  or 
A baseline sp lenomegaly that is palpable at > 10 cm, be low the LCM, decreases by ≥50%**  
A baseline splenomegaly that is palpable at <5 cm, below the LCM, is not eligible for spleen response  
A spleen response requires confirmation by [CONTACT_374794] ≥ 35% spleen volume reduction  
Symptoms response  A ≥50% reduction in the MPN -SAF TSS††  
Progressive 
disease‡‡  Appearance of a new splenomegaly that is palpable at least 5 cm below the LCM or  
A ≥100% increase in palpable distance, below LCM, for baseline splenomegaly of 5 -10 cm or  
A 50% increase in palpable distance, below LCM , for baseline splenomegaly of > [ADDRESS_469219] count of ≥20% or  
A peripheral blood blast content of ≥20% associated with an absolute blast count of ≥1 x 109/L that lasts for at least [ADDRESS_469220] 1 month  
EMH, extramedullary haematopoiesis (no evidence of EMH implies the absence of pathology - or imaging study- proven non -hepatosplenic EMH); LCM, left costal margin; 
UNL, upper normal limit.  
*Baseline and post -treatment bone marrow slides are to be interpreted at one sitting by a central review process.  
†Grading of MF is according to the European classification Thiele et al . European consensus on grading bone marrow fibrosis and assessment of cellularity.  It is 
underscored that the consensus definition of a CR bone marrow is to be used only in those patients in which all other criteri a are met, including resolution of 
leukoerythroblastosis.   
‡Immature myeloid cells constitute blasts + promyelocytes + myelocytes + metamyelocytes + nucleated red blood cells.  In splenectomized patients, <5% immature 
myeloid cells are allowed.  
§See above for definitions of an aemia response, spleen response, and progressive disease. Increase in severity of an aemia constitutes the occurrence of new transfusion 
dependency or a ≥20 g/L decrease in haemoglobin level from pretreatment baseline that lasts for at least 12 weeks.  Increase in severity of thrombocytopenia or neutropenia is defined as a 2 -grade decline, from pretreatment baseline, in platelet or absolute neutrophil count, according to the Common Terminology Criteria for 
Adverse Events (CTCAE) version 4.0.  In addition, assignment to CI requires a minimum platelet count of ≥[ZIP_CODE] x 10
9/L and absolute neutrophil count of ≥0 .5 x 109/L.  
¶Applicable only to patients with baseline haem oglobin of <100 g/L.  
{Transfusion dependency before study enrollment is defined as transfusions of at least 6 units of packed red blood cells (PRBC ), in the 12 weeks prior to study  
enrollment, for a ha emoglobin level of < 85 g/L, in the absence of bleeding or treatment-induced an aemia. In addition, the most recent transfusion epi[INVESTIGATOR_374725] 28 days prior to study enrollment. Response in transfusion -dependent patien ts requires absence of any PRBC transfusions during any consecutive 
“rolling” 12 -week  interval during the treatment phase, capped by a ha emoglobin level of ≥ 85 g/L.  
Imago BioSciences,  Inc.  Protocol IMG -7289- CTP -102  
IMG- 7289   23Jun 2020  
Page 92 of 97 **Spleen response must be confirmed by [CONTACT_320885] a ≥35% reduction in spleen volume, as assessed by [CONTACT_68454], is required. Furthermore, a ≥35% volume 
reduction in the spleen, by [CONTACT_68454], constitutes a response regardless of what is reported with physical examination.  
††Symptoms are evaluated by [CONTACT_91635] -SAF TSS.  The MPN -SAF TSS i s assessed by [CONTACT_362246], concentration, early satiety, inactivity, 
night sweats, itching, bone pain, abdominal discomfort, weight loss, and fevers.  Scoring is from 0 (absent/as good as it can  be) to 10 (worst imaginable/ as bad as it can 
be) for each item.  The MPN -SAF TSS is the summation of all the individual scores (0 -100 scale). Symptoms response requires ≥50% reduction in the MPN -SAF TSS.  
‡‡Progressive disease assignment for splenomegaly requires confirmation by [CONTACT_374794] a ≥25% increase in spleen volume from baseline. 
Baseline values for both physical examination and imaging studies refer to pretreatment baseline and not to post- treatment measurements. 
Imago BioSciences,  Inc.  Protocol IMG -7289- CTP -102  
IMG- 7289   23Jun 2020  
Page 93 of 97 16.8 Myeloproliferative Neoplasm  Symptom Assessment Form Total Symptom Score  
(MPN -SAF  TSS ) – 24-Hour Recall 
 
  
 

Imago BioSciences,  Inc.  Protocol IMG -7289- CTP -102  
IMG- 7289   23Jun 2020  
Page 94 of 97 16.9 Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score  
(MPN -SAF TSS)  – 7-Day Recall  
 
 
  

Imago BioSciences,  Inc.  Protocol IMG -7289- CTP -[ADDRESS_469221] and there is 
no government guidance to the contrary in individual countries . 
16.10.2  Security Measures  
Monitors  are only permitted  to undertake remote  data  review  through  the processes detailed  
below  in Sections  [IP_ADDRESS] and [IP_ADDRESS]  (EMR  access  or video  call/conferencing ) where  the 
following  security  measures  are in place: 
• Location  of Monitor: remote  data  review  activities may  be performed in locations that  do 
not allow access/viewing  by [CONTACT_374795]:  
o Acceptable locations  include: closed  room  in an IQVIA/IQVIA  Biotech  office,  at home  
in private  area for home -based  staff.  
o Examples  of prohibited  locations  include: Open  plan  desk space  in IQVIA/IQVIA  
Biotech  offices,  on public  transportation,  in airport lo unge  or other  public  areas.  
• Internet  connection:  remote  data  revi ew is permi tted  only through  a secure  internet  
connection  i.e. IQVIA/IQVIA  Biotech  office  internet  or secure  personal internet  after  logging  
into  IQVIA  Biotech  virtual private  network  (VPN).  Use of a public  internet,  hot spot  or hotel  
internet  is prohibited.  
• Device:  remote  data  review  is permitted  only throug h IQVIA/IQVIA  Biotech  registered  
device  (e.g., laptop,  iPad)  or through  a device  provided by [CONTACT_779].  
• While  the EMR  system is accessed  or video  call/conference are ongoing,  the computer  must  
be locked  if left unattended.  
16.10.[ADDRESS_469222] ing patient safety, while also minimizing risks to trial data 
integrity and facilitating GCP compliance .  The remote review of data may be actioned via  mul tiple 
pathways, often contingent on site’s capabilities.  Examples includ e: 
Imago BioSciences,  Inc.  Protocol IMG -7289- CTP -102  
IMG- 7289   23Jun 2020  
Page 96 of 97 • Remote Source Data Review  (via Electronic Medical Records (EMR))  
• Remote Source Data Review  (via video call/conferencing)  
• Remote Data Verification (using redacted source documents)  
Additionally, to facilitate continued interaction with and support of the site, phone monitoring visits 
may also periodically be conducted . Remote review of data will not occur during phone visits . 
[IP_ADDRESS]  Direct,  Controlled  Remote  Access  to the Systems  Used by [CONTACT_374796]/ Source  Data 
For data review  whereby [CONTACT_374797] , the following criteria are 
required to be met before this process can be implemented for any subject:  
• An audit trail  is available in the Electronic  Medical Records  (EMR) system.  
• There  is unique  password  access to the EMR  system  assigned  to each  member  of site staff.  
• There  is unique  password,  read -only access to the EMR  system assigned  to the Monit or. 
• EMR access  has been  granted  only to trial  subjects’  records and other patient  data  is not 
accessible  to the Monitor  (unless  a procedure is in place  to monitor  the Monitor’s  activity  
following  each  session ).    
• US sites only:  written  procedure is in place  for the use of EMR system.  
• US sites  only:  If the EMR system is certified  by [CONTACT_374798]  (ONC)  at the Department  of Health  and Human  Services,  it is 
sufficient  to confirm this on the COVID -19 Remote  Source  Data  Monitoring  Site Agreement.  
[IP_ADDRESS]  For Passive  Access  to Original  Documents/ Original  Data via Live I mage  
Transmission  
The following controls will be applied for remote data review  by [CONTACT_31688]/conferencing:  
• The video  call/conference  may  only occur  using an IQVIA  Biotech  approved  information  and 
communication  technology.  
• Video  review  of documentation  only is permitted.  
• No recording of the interaction  is permitted.  
• No document  upload  is permitted.  
• No Document  storage  is permitted.  
• Usage  must  comply  with  applicable  local  regulations/ regulatory guidance.  
• During  remote  data  review  by [CONTACT_374799]/conferencing  care will be taken  to avoid  inadvertent  
viewing  of individuals  who  should  not be part  of the interaction.  
[IP_ADDRESS]  Passing on Re dacted  Copi[INVESTIGATOR_374726]: 
Imago BioSciences,  Inc.  Protocol IMG -7289- CTP -102  
IMG- 7289   23Jun 2020  
Page 97 of 97 • Process must be  allowed by [CONTACT_374800] 
• Principal Investigator [INVESTIGATOR_374727]  
• Site staff who will provide source documents to Monitor for remote data review will be  
train ed on the role, responsibility, and process for providing pseudonymized Certified 
Copi[INVESTIGATOR_374728]  
• Certified Copi[INVESTIGATOR_374729] d ocuments  will be prepared  
Certified Copy: A copy (irrespective of the type of media used) of the original record that has been verified (i.e., by a dated signature [INVESTIGATOR_4388] [CONTACT_97214] a validated process) to have the same information, including data that describe the context, content, and  structure, as the 
original. (International Council for Harmonization (ICH) Guideline for Good Clinical Practice (GCP) Revision 2). 
Note: A copy is certified by [CONTACT_374801] a statement “certified copy” and adding a note on the fir st page that the certified copy package consists of # pages.  
Each page must be numbered so that, in total, the pages match the full # of pages documented on the first page of the package.  
• All subject  direct identifiers (e.g. name, social security/national identification number, 
medical record number, initials, full date of birth, home address etc.) will be  redacted/ 
obscured  (i.e. pseudonymized) on the copi[INVESTIGATOR_374730].  
• A quality check of the redacted Certified Copi[INVESTIGATOR_374731] a  second site staff 
member to confirm all subject directly identifiable information has been redacted and the 
correct subject identification code added.  
o The quality check will be documented by [CONTACT_374802]’s initials,  
dating  of the first page of the package and add ition of the statement “QC’d/Checked”  
• A transmittal form will be completed each tim e Pseudonymized Certified Copi[INVESTIGATOR_374732] .  
• The prepared source document package, including transmittal form, will be provided  by [CONTACT_374803]:   
o Overnight Courier  
o Secure Fax Transmission  
o Scanned images via secure email ( encrypted email or password protected email 
attachment. If the latter, the password will be provided to Monitor via telephone)  
o A secure  platform for document exchange  
• A set of the prepared source document package, including transmittal form , will be retained 
in the Investigator’s Site File.  